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ABSTRACT 
KWUN WAH WEN: CHARACTERIZATION OF THE K1 PROTEIN OF KAPOSI 
SARCOMA-ASSOCIATED HERPESVIRUS AND DEVELOPMENT OF A NOVEL 
VACCINE FOR PROTECTION AGAINST RHADINOVIRUS INFECTION 
(Under the direction of Blossom Damania, PhD)  
 
 
Kaposi sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi 
sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). 
KS is the most common malignancy in HIV/AIDS patients worldwide and can lead to 
significant mortality. There is no cure or vaccine for KSHV infection. KSHV encodes several 
oncogenic/transforming proteins that are implicated in KSHV-associated malignancies.  
Our work is directed towards understanding the functional role of the KSHV K1 
protein, which has been shown to activate signaling in B lymphocytes as well as to transform 
cells. We used tandem affinity purification (TAP) to identify the cellular interacting proteins 
of K1 and study the mechanisms by which K1 activates signal transduction pathways, 
inhibits apoptosis, and induces cellular transformation. The functional consequences of the 
interactions of K1 with its cellular binding partners were investigated with respect to the 
regulation of K1 expression and its anti-apoptotic function, using pharmacological inhibitors 
and RNA interference (RNAi). This study thus identified cellular targets essential for K1 
function and may also aid in the identification of therapeutic targets that can be used in the 
treatment of KSHV-associated cancers. 
In addition, we examined the role of K1 in the viral lifecycle. We took advantage of a 
highly related virus, rhesus rhadinovirus (RRV), which is the simian relative of KSHV. 
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Unlike KSHV, RRV grows to high titers in vitro making it a good model to study lytic 
replication and viral spread. RRV encodes a gene named R1, which is functionally 
homologous to the KSHV K1 gene. We constructed a RRV∆R1/GFPcc recombinant virus to 
analyze the contribution of R1 during de novo infection, latency, and reactivation of RRV.  
Furthermore, we attempted to develop a novel vaccine for protection against 
rhadinovirus infection in primates using the RRV model system. The latency-associated 
nuclear antigen (LANA) is critical for the establishment and maintenance of both KSHV and 
RRV latency. We generated a recombinant virus deleted for RRV LANA, named 
RRVΔLANA/GFP, and found that this virus was highly lytic and unable to establish latency. 
A future goal of this aim will be to evaluate the RRVΔLANA/GFP as a vaccine candidate in 
rhesus macaques. 
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CHAPTER 1 
KSHV: MOLECULAR BIOLOGY AND ONCOGENESIS 
 
 
Kwun Wah Wen and Blossom Damania 
 
A portion of this chapter was published as a review article. 
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Introduction  
The members of the herpesviridae family are well represented in nature and can be 
found in many different species across the animal kingdom. They are also highly adapted to 
their hosts and are thought to have coevolved with their hosts for millions of years. Typically, 
herpesviruses have a double-stranded DNA genome (124-230 kb) enclosed in an icosahedral 
capsid (~125 nm in diameter) composed of 162 capsomeres. The capsid structure is 
surrounded by an amorphous tegument layer that separates it from the outer, glycoprotein-
decorated, envelope. Common to all human herpesviruses is their ability to adapt very well to 
the cellular milieu of the infected host and their ability to evade host immune responses to 
establish life-long latent infection. Based on their biological properties including host range, 
replication cycle and cell tropism, these viruses are classified into the alpha-, beta-, and 
gammaherpesvirinae subfamilies (181) (Fig. 1).  
There are eight known human herpesviruses (HHV). Most of the human population is 
infected with one or more of these viruses, and they rarely cause severe disease in the host 
unless the host immune system is compromised. Human herpesviruses belonging to the alpha 
subfamily include herpes simplex viruses (HSV) 1 and 2 (HHV-1 and HHV-2), and varicella-
zoster virus (VZV; HHV-3). Members of the human betaherpesvirinae include 
cytomegalovirus (CMV; HHV-5), HHV-6 variants A and B, and HHV-7. Human 
gammaherpesvirinae include Epstein-Barr virus (EBV; HHV-4) and Kaposi sarcoma-
associated herpesvirus (KSHV; HHV-8). Strikingly the members of gammaherpesvirinae are 
strongly associated with neoplastic disease. For example, EBV is the etiological agent of 
Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, T and natural killer cells 
lymphoma, and post-transplant lymphoma (47, 99, 172, 242). KSHV is the etiological agent 
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of several human cancers including Kaposi sarcoma (KS) (36, 147), primary effusion 
lymphoma (PEL) (33), and the plasmablastic variant of multicentric Castleman’s disease 
(MCD) (75, 200). Additionally, there have also been reports of KSHV-associated solid 
lymphomas of HIV-positive and negative individuals (30) as well as KSHV-associated 
lymphomas in patients with primary immunodeficiencies such as common variable 
immunodeficiency (233). 
 
 
Figure 1. Phylogenetic depiction of the alpha, beta, and gamma subfamilies of 
herpesviruses. The phylogram is unrooted and was constructed by parsimony analysis 
using the viral DNA polymerase gene and the neighbor-joining method. (Taken from 
Damania and Jung (45).) 
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The gammaherpesviruses have evolved to possess a plethora of viral gene products 
that intricately subvert normal cellular pathways. The dysregulated signaling pathways 
include those involved in cell cycle progression, apoptosis, immune surveillance, and 
antiviral responses. Gammaherpesviruses are masters of altering these pathways in favor of 
their survival. They are known to establish persistent viral infection, and to evade viral 
clearance by actively suppressing apoptosis and escaping immune detection. The survival 
mechanisms used by these viruses are thought to inadvertently contribute to host cell 
transformation and the development of neoplasia, which is most frequently seen in the setting 
of immunodeficiency. In this chapter, we will focus on KSHV in terms of its associated 
clinical diseases and current therapies, as well as viral genes implicated in tumorigenesis and 
oncogenesis. 
Clinical diseases associated with KSHV infection 
Kaposi sarcoma. Kaposi sarcoma was named by Dr. Moritz Kaposi, a prominent Hungarian 
dermatologist, who first described the rare classical form of KS as “idiopathic multiple 
pigmented sarcoma of the skin” in 1872 (95). Since the 1950s, an infectious agent was 
suspected to cause KS. The discovery of the causative agent of KS, however, was not 
intensively pursued until the early 1980s, when the incidence of KS dramatically increased in 
homosexual and bisexual HIV-positive individuals during the AIDS epidemic. The sudden 
surge of KS incidence among HIV-infected individuals strongly suggested an infectious 
agent was involved in the development of KS. In 1994, Chang and Moore used 
representational difference analysis to characterize DNA fragments obtained from KS 
biopsies and established an association of a novel human gammaherpesvirus with KS (36). 
This newly identified virus was named KSHV. KS is a highly vascular tumor of endothelial 
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lymphatic origin (14, 223). Histologically, the signature KSHV-infected cells are spindle-
shaped, poorly differentiated, and highly proliferative (60). KS is also characterized by 
extravasation of erythrocytes, infiltration of inflammatory cells (macrophages, lymphocytes 
and plasma cells) and neo-angiogenesis (74). Clinically, KS is characterized by 
dermatological lesions that are red, brown, or purple in pigmentation. These lesions can be 
found cutaneously, mucosally, or viscerally. KS can be staged by six overlapping 
clinicopathologic forms: patch, plaque, nodular, lymphadenopathic, infiltrative, and florid 
(104, 213). It is important to note that greater than 95% of KS lesions contain KSHV viral 
DNA. Based on epidemiological and clinical outcomes, KS can be classified into 4 different 
clinical subtypes. These are classic/sporadic, endemic/African, epidemic/AIDS-associated, 
and iatrogenic/post-transplant. Classic KS is the form described by Dr. Kaposi. The 
presentation of classic KS typically occurs with an indolent course in Mediterranean and 
Eastern European elderly men over 50 years of age. The lesions are generally localized in the 
upper and/or lower extremities without much involvement with, or spreading to, the lymph 
nodes and internal organs. Patients diagnosed with classic KS may progress to other 
secondary malignancies, primarily non-Hodgkin lymphomas (NHL) (71, 89). African 
endemic KS is commonly seen in Eastern and central African countries such as Uganda, 
Malawi, and Kenya. Endemic KS may be indolent or aggressive, with more lymph node 
involvement than classic KS. The aggressive form (also known as lymphadenopathic form) 
of endemic KS is more commonly found in children at pre-puberty ages, with high fatality 
rates (62). AIDS-associated KS is the most common and aggressive variant, with the most 
lymph node/visceral spreading amongst all KS subtypes (17, 20). During the HIV/AIDS 
epidemic, the incidence of KS concurrently peaked with HIV diagnoses. Due to its strong 
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association with AIDS, KS was identified as an AIDS-defining illness and served as a marker 
for HIV disease in the mid-eighties (134). Indeed,  KS is the most common malignancy 
associated with HIV infection and can lead to significant mortality (18). KS is the most 
common tumor in African men (63, 159, 221). This epidemiologic form of KS is found with 
increased frequency in homosexual AIDS patients who are relatively young. With the advent 
of highly active antiretroviral therapy (HAART) in the 1990s, the incidence and mortality of 
AIDS-associated KS have dramatically dropped (65, 212). However, KS continues to remain 
the most common AIDS-associated cancer in developed nations and in developing countries 
(32). Another form of KS, known as iatrogenic/post-transplant KS, is associated with 
immune suppression after long-term immunosuppressive therapy used to prevent rejection of 
solid allografts (164). Renal transplant patients are the most likely group to develop this form 
of KS. Interestingly, the KSHV-infected endothelial cells or lymphocytes found in KS 
lesions in these patients can originate from donor tissues (12). Reduction or withdrawal of 
immunosuppressive therapy has been shown to be effective in resolving iatrogenic KS. 
However, this also increases the likelihood of allograft rejection.  
 
Primary effusion lymphoma. In addition to KS, primary effusion lymphoma (PEL), 
sometimes referred to as body cavity-based lymphoma (BCBL), has been strongly associated 
with KSHV (33). PEL is a unique form of NHL found more commonly in 
immunocompromised AIDS patients. Unlike KS, PEL is derived from clonally expanded 
malignant B cells and presents as a lymphomatous effusion tumor contained in various body 
cavities such as the pericardium, pleurum, and peritoneum. There are, however, reports of 
PEL as a solid mass in lymph nodes and other organs (8). PEL is aggressive and rapidly 
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progressing, and can cause high fatality. The mean survival time for patients with PEL is 
approximately two to six months (101). Histologically, PEL cells are larger than normal 
lymphocytes and erythrocytes, and contain features of both large cell immunoblastic 
lymphoma and anaplastic large cell lymphoma. PEL cells express CD45, activation-
associated antigens, clonal immunoglobulin rearrangements but usually lack B cell-
associated antigens (144). PEL cells can be KSHV single-positive or KSHV/EBV double-
positive. KSHV genomes are found in PEL cells at a high copy number (50-150 viral 
genomes per infected cell) (33, 179, 206).  
 
Multicentric Castleman’s disease. The plasmablastic variant of multicentric Castleman’s 
disease (MCD) is also highly associated with KSHV; however, the other form of MCD, 
namely, the hyaline variant of MCD, is not. MCD is a reactive lymphadenopathy that is 
considered non-neoplastic as polyclonal B-cell populations are usually found in the lesion. 
However, monoclonal B cell expansion has also been reported for plasmablastic MCD (86, 
173). Plasmablastic MCD can have an aggressive and rapid progression leading to high 
fatality. Histologically, germinal center expansion and vascular endothelial proliferation 
occur within the involved lymph nodes of MCD. Dysregulated IL-6 levels, likely contributed 
in part by virally encoded IL-6 (vIL-6) (161), may account for the clinico-pathophysiology of 
MCD. Like KS and PEL, KSHV genomes are detectable in almost all HIV-positive MCD 
cases and about fifty percent of HIV-negative MCD cases (60, 200). Additionally, KSHV has 
been shown to be associated with a plasmablastic variant of MCD. 
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The KSHV genome  
KSHV has a double-stranded DNA genome and its size ranges from 165-170 kb (146, 
180). The long unique region (LUR), which is about 138 to 140.5 kb in length and contains 
all of the KSHV ORFs, is flanked by terminal repeat (TR) sequences at both ends of the 
linear viral genome. Each TR is 801 bp in length and is highly GC-rich. The number of TRs 
varies among KSHV isolates, ranging from 16 to 75 (61), which accounts for the variation in 
the genome sizes of KSHV isolates. The KSHV genome exhibits very high degree of 
similarity to retroperitoneal fibromatosis-associated herpesvirus (RFHV) and rhesus monkey 
rhadinovirus (RRV) in the rhadinovirus subfamily of gammaherpesvirinae. RFHV appears to 
be more closely related to KSHV. Although many of the KSHV ORFs are conserved in 
alpha- and beta-herpesviruses, the virus does contain a significant number of unique ORFs 
not found in other herpesviruses (Table 1). These KSHV-specific ORFs are designated K1 to 
K15, based on their relative locations (from left to right) in the KSHV genome (Fig. 2). 
Moreover, KSHV also contains several viral genes that have been pirated from the host 
genome and are homologs of cellular genes (210). 
 Many viral genes are involved in signal transduction (e.g. K1, K15), cell cycle 
regulation (e.g. vCyclin, LANA), inhibition of programmed cell death (e.g. K1, vFLIP, vBcl-
2) and immune modulation (e.g. viral chemokine receptors, vIRFs, K3, K5). Additionally, a 
number of KSHV genes are expressed by alternative splicing (reviewed in (191)), by the use 
of alternative transcriptional start sites, or internal ribosome entry sites (IRES) (121, 126). 
Very recently, a total of 12 microRNAs have been discovered in the KSHV genome (28, 163, 
165, 188). Ten of these microRNAs were found in the non-coding region between 
K12/Kaposin and K13/Orf71/vFLIP, and two were located within the K12 ORF (Fig. 2). All 
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of the KSHV microRNAs were expressed during latency (27, 143, 163, 189), with a sub-set 
of these microRNAs being upregulated during the lytic cycle. Recent evidence has identified 
cellular and viral targets of these microRNAs, as well as their roles in KSHV pathogenesis 
(77, 133, 143, 189, 198). Besides microRNAs, KSHV also produces a non-coding RNA 
transcript that is 1077 bp in size, polyadenylated and exclusively nuclear (PAN) (41, 42, 208, 
245). PAN RNA is made during the lytic cycle and has been shown to retain RNA in the 
nucleus and block the assembly of an export-competent mRNP.  
 
Figure 2. The KSHV genomic open reading frames (ORFs). The arrows represent 
individuals ORFs and the dots represent the KSHV-encoded microRNAs. ORFs unique to 
KSHV are labeled K1 through K15 and are indicated by black arrows. Alternative names 
for some of these unique KSHV genes are in parentheses. Additional ORFs discussed in 
this chapter are also labeled. The ORFs common to rhadinoviruses are indicated by dark 
gray arrows, ORFs common to other gammaherpesviruses (e.g. EBV) are indicated by 
light gray arrows, and ORFs common to most herpesviruses are indicated by white 
arrows. TR denotes terminal repeats. The numbers on demarcated lines specify the 
approximate genome positions in Kb.  
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Table 1. Unique ORFs encoded by KSHV 
ORF Alternative 
name 
Functions 
K1 * VIP Transformation; B cell activation; inhibition of apoptosis; 
downregulation of surface B cell receptor (BCR); activation of 
PI3K/Akt/mTOR kinases 
K2 * vIL-6 IL-6 homolog; B cell proliferation; autocrine/paracrine signaling 
K3 MIR1 E3 ubiquitin ligase; immune evasion; inhibition of MHC class I 
and T cell killing 
K4 vMIP-II; vMIP-
1b; vCCL-2 
MIP-I homolog; angiogenesis; CCR3 and CCR8 binding; 
chemoattraction of TH2 cells and monocytes (immune modulation)
K4.1 vMIP-III; vBCK; 
vCCL3 
TARC/eotaxin homolog; induction of VEGF-A and angiogenesis; 
CCR4 binding; chemoattraction of TH2 cells (immune 
modulation) 
K5 MIR2 E3 ubiquitin ligase; immune evasion; inhibition of MHC class I, 
B7, and ICAM expression 
K6 vMIP-I; vMIP-1a; 
vCCL-1 
MIP-I homolog; angiogenesis; CCR5 and CCR8 binding; 
chemoattraction of TH2 cells and monocytes 
K7 Survivin; vIAP Inhibitor of apoptosis protein (IAP) homolog; inhibition of vGPCR 
expression and function 
K8 K-bZIP An immediate-early gene that represses RTA transactivation 
activity and Rta induction of KSHV lytic cycle 
K8.1  Viral glycoprotein (structural protein) 
K9* vIRF-1 IRF homolog; Inhibition of type I interferon, p300, p53, and TGF-
β; transformation 
K10 vIRF-4 IRF homolog 
K10.1 
K10.5 
K10.6 
LANA-2 (K10.5); 
vIRF-3 
IRF homolog; inhibition of type I interferon production and 
apoptosis (PKR-and caspase-3 mediated); inhibition of p53 and 
NFκB; inhibition of Fas-mediated apoptosis via inhibition of 
CD95L surface expression 
K11 
K11.1 
K11.5 
vIRF-2 (K11.5) IRF homolog; inhibition of type I interferon and NFκB; inhibition 
of Fas-mediated apoptosis via inhibition of CD95L surface 
expression 
K12* Kaposin Transformation (Kaposin A); cytokine and AU-rich mRNA 
stabilization by induction of p38 or MK2 signaling (Kaposin B) 
K13* vFLIP FLIP homolog; transactivator of NF-κB; anti-apoptotic function; 
transformation 
K14 vOx-2 Ox-2 (CD200) homolog; downregulation of myeloid cell 
activation; regulation of inflammatory cytokine production such as 
IL-1β, TNF-α, IL-8, IFN-γ and IL-6  
K15 LAMP Activation of the intracellular signaling pathways (Ras/MAPK, 
NF-κB, and JNK/SAPK), leading to IL-6, IL-8, and Cox-2 
induction. A chimeric protein consisting of the CD8 extracellular 
domain of CD8 and the K15 cytoplasmic domain could inhibit 
BCR signaling  
Note: Only KSHV unique genes marked with an asterisk are discussed in more detail in the 
text. 
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The viral lifecycle 
Like other herpesviruses, KSHV displays two different phases of its viral lifecycle. 
Latent KSHV is characterized by a circularized, extra-chromosomal viral genome (episome) 
and the expression of a very small subset of latent transcripts in the infected cells; no 
functional or infectious viral particles are produced during latency. In latently infected cells, 
in all three KSHV-associated malignancies, the expression of OrfK12/Kaposin, 
K13/Orf71/vFLIP, Orf72/vCyclin, and Orf73/LANA has been detected. In PEL and MCD 
cells, OrfK10.5/LANA-2/vIRF3 expression was also detected (160). The lytic cycle is 
characterized by the replication of linear viral genomes, and the expression of more than 80 
transcripts in a highly orchestrated temporal order of immediate-early (α), early (β), and late 
(γ) categories. These categories are defined by sensitivity to cycloheximide and 
phosphonoacetic acid (PAA) treatment after chemical induction of viral reactivation (57, 66, 
92, 162). Unlike early and late genes, immediately-early (IE) genes are not sensitive to the 
protein synthesis inhibitor cycloheximide, as the expression of IE genes does not rely on viral 
protein synthesis. IE genes are important for regulating the subsequent transcriptional 
cascade. KSHV encoded Rta is an IE lytic master switch protein that has been shown to be 
required and sufficient for initiating the lytic replication cycle to completion. The IE gene 
K8/K-bZIP appears to antagonize Rta transactivation activity (90, 183). The third IE gene, 
Orf45, is important for the suppression of interferon induction by lytic viral infection or 
reactivation (247). In contrast to IE genes, early and late genes are sensitive to cycloheximide, 
and are distinguished by their dependence on DNA replication. The expression of early genes 
is independent of viral DNA synthesis and is not inhibited by PAA treatment, whereas the 
expression of late genes is dependent on the replication of viral genomes and therefore 
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sensitive to PAA inhibition. To model KSHV lytic replication in vitro, chemical induction 
using n-butyrate and 12-O-tetradecanoylphorbol-13-acetate (TPA) to reactivate PEL cells has 
been reported. TPA treatment can lead to reactivation in about 20-30% of PEL cells (138, 
180). The general function of early and late genes is to facilitate the replication of viral 
genomes, viral assembly and egress.  
Rta. Rta (replication and transcription activator) is an immediate-early (IE) gene encoded by 
KSHV Orf50. As an IE gene, Rta can be expressed in the presence of the protein synthesis 
inhibitor, cycloheximide. The Rta transcript consists of two exons separated by an intron. 
Such an arrangement is conserved in all other gamma-2-herpesviruses (205). The Rta 
transcript is tricistronic, containing Orf50, OrfK8, and OrfK8.1 (246). The major Rta 
message is spliced out for expression; it is induced in PEL cells within 4 hours of n-butyrate 
treatment (128, 129, 203). Rta is necessary and sufficient to trigger and complete the KSHV 
lytic cycle. KSHV reactivation has been demonstrated in PEL cells when  Rta was 
ectopically expressed (78, 209). Similar to the HSV-1 IE transactivator protein VP16, Rta 
protein is virion-associated (13). The Rta protein consists of 691 amino acids and is nuclear 
(127). Rta is highly phosphorylated and contains an N-terminal DNA binding domain (127) 
and a C-terminal transactivation domain (228) that are conserved in gammaherpesviruses. 
When the C-terminal domain was deleted, Rta mutant could no longer function to 
transactivate other lytic genes. This truncated Rta multimerized with the wild-type Rta and 
inhibited their activity in a dominant-negative fashion (128). Another line of evidence 
supporting Rta as the key lytic switch protein was that an Rta deletion virus exhibited defects 
in reactivation and viral DNA replication upon chemical induction. When Rta was provided 
in trans, such a defect was corrected in cells infected with the Rta deletion virus (235). 
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The transactivation activity of Rta is mediated by Rta binding to Rta responsive 
elements (RREs) on the promoters of target genes. An RRE and a TATA box were 
discovered in the ori-Lyt (223, 225), providing strong evidence for the importance of Rta on 
the lytic cycle in terms of DNA replication and transcription activation. RREs have been 
found in various viral promoters including PAN, Orf57/MTA, vIL-6, Kaposin, and Rta itself  
(205). The RREs of different viral transcripts do not share sequence homology, raising the 
question of how a viral protein could associate with such a diversity of DNA sequences. As a 
rare exception, the promoters of Orf57 and K-bZIP share the same 12-bp palindromic RRE 
sequence (127). Strikingly, Rta associates with several cellular proteins that are known 
transcriptional regulators. These cellular proteins include: recombination signal sequence-
binding protein Jκ (RBP-Jκ), C/EBP-α, Ap-1, Sp1, Sp3, and Oct-1 (40, 118, 186, 229-231, 
243). Among these cellular binding candidates of Rta, RBP-Jκ is particularly noteworthy. Rta 
recruitment of RBP-Jκ could convert this cellular protein from a transcriptional repressor into 
a transactivator on a number of lytic viral promoters (e.g. PAN, MTA, vIL-6, Kaposin 
aforementioned) as well as ori-Lyt. This gives rise to a mechanistic understanding of Rta 
transactivation function on a variety of viral genes. Interestingly, Rta has been shown to 
upregulate its own expression (Fig. 3). The binding of RBP-Jκ, Oct-1, Sp1, Sp3 and C/EBP-α 
appears to be responsible for Rta auto-activation (40, 78, 186, 230, 243). Interestingly, 
Orf57/MTA, the KSHV homolog of HSV-1 ICP27 and EBV SM, binds and synergizes with 
Rta to promote the lytic transcriptional cascade (130, 157).  
The default lifecycle of KSHV is predominantly latent. Thus, transactivation activity 
of Rta needs to be dampened by the virus in order to switch back to latency after a primary 
lytic infection. During early infection, LANA expression is induced by Rta-mediated RBP-Jκ 
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binding to the LANA promoter (110) (Fig. 3). As a negative feedback loop of the lytic cycle, 
LANA has been shown to downregulate Rta promoter activity as well as physically associate 
with Rta (109). LANA-1 inhibits Rta expression by recruiting RBP-Jκ to close proximity of 
Rta promoter. (108) (Fig. 3). In addition to LANA, other viral proteins (e.g. K-bZIP (90, 183), 
K-RBP (238), and vFLIP (240, 244)) and cellular proteins (e.g. CREB binding protein, 
histone deacetylases (84), poly(ADP-ribose) polymerase 1 (PARP-1), Ste20-like kinase 
hKFC (85), HEY1 (236)) may also repress lytic Rta activity. To counteract the inhibitory 
effects of these proteins, Rta is able to promote the proteasomal degradation of some of these 
proteins (239). This demonstrates that KSHV proteins finely tune various viral and cellular 
pathways to achieve an intricate balance between the lytic and latent cycles.  
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Putative viral genes involved in KSHV transformation and oncogenesis 
Transformation is a key event in the multistep process of oncogenesis. It involves 
changes in cellular signaling pathways and cell morphology, leading to a state of 
uncontrolled proliferation. In KSHV, transformation of endothelial cells can lead to 
chromosome instability (158), alteration of cellular gene expression profiles (167), 
acquisition of telomerase activity and anchorage-independent growth (69), increase in cell 
invasiveness (171) as well as long-term proliferation and survival of these cells (69, 224). A 
number of KSHV-encoded proteins are believed to have transforming and oncogenic 
properties. They include both latent and lytic proteins: the latent proteins are likely to 
enhance the survival and proliferation of the infected cells, whereas the lytic viral proteins 
 
 
Figure 3. Feedback loops of LANA and Rta to control the switch between latency 
and lytic replication. Depiction of the regulation of LANA and Rta via positive and 
negative feedback loops. Both Rta and LANA transactivate their own promoters while Rta 
also induces LANA expression through interactions with RBP-Jκ. LANA can repress Rta-
mediated transactivation through binding of Rta. Rta encodes ubiquitin E3 ligase activity 
and regulates its own expression through self-ubiquitination and also targets IRF-7 for 
degradation by the proteasome. (Taken from Dillon and Damania (53)) 
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are believed to mediate paracrine secretion of growth and angiogenic factors essential for 
tumor growth and development. This is postulated based partially on the observation that the 
latent genes (especially those encoded on the latency-associated cassettes) are detectable in 
situ in the majority of KS, PEL, and MCD samples, whereas the lytic genes (e.g. K1, vIL-6, 
vGPCR) are detectable in only small sub-sets of tumor samples. These oncogenic viral 
products are described below. 
LANA. The latency-associated nuclear antigen (LANA) is required for the maintenance of 
latency (reviewed in (54, 175, 217)). LANA maintains the episomal KSHV genome in 
latently infected cells and allows for the co-segregation of viral and host genomes into the 
daughter cells during mitosis. LANA is able to perform this function by tethering the KSHV 
episome to the host chromatin (11, 86, 192, 219). When homodimerized, the N-terminus of 
LANA binds to the nucleosome via interaction with histone H1 and heterochromatin protein 
1 (86), while the C-terminus of LANA-1 binds to the terminal repeats of the viral genome 
(192). LANA is also involved in the replication of the latent viral genome (79) and can 
autoregulate its expression by binding to its own promoter (93). Furthermore, LANA has 
been described to interact with multiple cellular proteins including the mSin3A corepressor 
complex, the DNA methyltransferase Dnmt3a, RBP-Jκ, and cAMP response element-binding 
protein which results in the transcription repression of several viral and cellular genes (84, 
103, 119, 176, 195, 223). Of particular importance is the demonstrated antagonistic effect of 
LANA on the KSHV Rta promoter (165) (Fig. 3). LANA has been shown to recruit RBP-Jκ 
to the Rta promoter resulting in chromatin silencing of Rta expression. Furthermore, LANA 
can also inhibit Rta transactivation through a direct physical interaction (223). 
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LANA can perturb a plethora of cellular pathways to contribute to tumorigenesis. For 
example, LANA can physically associate with p53 and inhibit p53-mediated transcription 
activity and apoptosis (70). LANA can also inactivate the tumor suppressor retinoblastoma 
(Rb) gene and release E2F transactivator which induces cell to transit through the G1/S cell 
cycle checkpoint (174). To promote G1/S transition, LANA interacts with the bromodomain-
containing protein RING3/Brd2 (48, 83, 166, 220), and can sequester glycogen synthase 
kinase (GSK)-3β in the nucleus, which prevents GSK-3β from complexing with, and 
degrading, β-catenin in the cytoplasm. The stabilized β-catenin can translocate into the 
nucleus, where it complexes with the transcription factors lymphoid enhancing factor (LEF) 
and T-cell factor (TCF) to transactivate responsive genes including CCND1 and Myc, which 
have been implicated in cell cycle regulation and oncogenesis (23, 72). LANA can cooperate 
with the oncogene H-Ras to transform primary rat embryo fibroblasts and render them 
tumorigenic (174). LANA was also shown to upregulate human telomerase reverse 
transcriptase (hTERT) gene expression and to immortalize primary HUVEC and increase 
their proliferation (232). Finally, transgenic mice expressing LANA under the endogenous 
LANA promoter developed splenic follicular hyperplasia with increased germinal centers as 
well as lymphomas (67). Based on these findings, LANA appears to at least set the initial 
stage for sarcomagenesis and lymphomagenesis. 
 
K13/vFLIP. The viral FLICE (Fas-associated death-domain like IL-1 beta-convertase 
enzyme) inhibitory protein (vFLIP) is also known as K13, and is encoded by Orf71 (55, 66, 
92). Latent expression of vFLIP occurs via splicing of the LANA transcript from the 
tricistronic messenger RNA, and via the use of the IRES in vCyclin coding sequences (19, 80, 
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126). Similar to cellular FLIPs, vFLIP inhibits death receptor signaling by specifically 
abrogating the interaction between Fas-associated death domain (FADD) and caspase-8 (15). 
The inhibition of this pathway blocks Fas-mediated apoptosis, thus providing a survival 
advantage for KSHV-infected cells (59). In addition to blocking the extrinsic apoptotic 
pathway, vFLIP also associates with the IKK complex and the heat shock protein 90 (hsp90) 
to induce NF-κB survival signaling (25, 39, 68, 125). The induced NF-κB signaling is 
significant in at least two aspects: viral latency and oncogenesis. First, NF-κB activation by 
vFLIP is critical for vFLIP inhibition of lytic replication via the AP-1 pathway (240, 244). 
Second, the enhanced NF-κB signaling may be important for the transforming and oncogenic 
potential of vFLIP as demonstrated in Rat-1 fibroblast assays and tumors in nude mice (207). 
In primary dermal microvascular endothelial cells, vFLIP expression was shown to induce 
anoikis (detachment induced apoptosis), but not apoptosis, due to growth factor depletion 
suggestive of its role in paracrine factor secretion and KS development (64).  
 
vCyclin. This gene is encoded by Orf72, located immediately downstream of the LANA 
ORF in the latency-associated cassette (55, 211). Expression of vCyclin occurs via splicing 
of the LANA transcript from the tricistronic messenger RNA. vCyclin is the viral homolog of 
cellular cyclin D1. Cellular cyclin D1 associates with cyclin-dependent kinases such as 
CDK6 and CDK4, to form a complex that phosphorylates the retinoblastoma (Rb) protein. 
Phosphorylated Rb can no longer antagonize E2F’s transactivation of S-phase cell cycle 
genes. vCyclin was shown to complex with CDK6 and inhibit Rb sequestration  of E2F from 
the nucleus; however, vCyclin, unlike its cellular homolog, is insensitive to CDK inhibitors 
such as p16/INK4a, p21/CIP1 and p27/KIP1 (37, 76, 150, 210). It is believed that vCyclin 
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has a proliferative effect on latently infected cells and thus promotes their transition into 
tumor cells. The oncogenic potential  of vCyclin was demonstrated in mice lacking 
functional p53 (218, 219), providing evidence that vCyclin has an auxiliary role in 
oncogenesis. 
 
Kaposin. The Kaposin transcripts represent the most abundantly expressed viral transcripts 
during KSHV latency. Kaposin A is encoded by OrfK12, while Kaposins B and C initiate 
upstream of OrfK12 at two repeat regions (termed DR1 and DR2), and their transcripts 
extend into OrfK12 (185). Kaposin A has oncogenic potential as demonstrated by focus 
formation assay in transfected Rat-3 cells. This morphological change is mediated through 
interaction with cytohesin-1 (100). Cytohesin-1 is a guanine nucleotide exchange factor for 
the GTPase ARF as well a regulator of cell adhesion. When injected into athymic mice, the 
transformed Rat-3 cell lines containing Kaposin sequences produced high-grade, highly 
vascular, undifferentiated sarcomas (142). In contrast to the undetectable protein level of 
Kaposin A in virus-infected cells, Kaposin B was shown to be the most abundant Kaposin 
protein in the PEL cell line BCBL-1 (185). Kaposin B functions to stabilize cytokine 
expression such as IL-6 and GM-CSF by inhibiting degradation of their messages. The 
inhibition was achieved via Kaposin B binding and activation of MK2 kinase, which inhibits 
degradation of mRNA containing AU-rich elements (e.g. cytokines) (135). The mRNA 
stabilization activity is dependent on the direct repeat (DR1 and DR2) elements of Kaposin B 
(136). 
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K1. K1 is a 46-kDa type I membrane glycoprotein encoded by the first open-reading frame 
(106). K1 is also designated VIP (variable ITAM-containing protein) as it contains an 
immunoreceptor tyrosine-based activation motif (ITAM) (115). The K1 genomic location is 
equivalent to those of the transforming proteins STP of herpesvirus saimiri (HVS) and LMP-
1 of EBV. K1 is expressed at low levels during latency and is upregulated during lytic 
infection where it demonstrates early kinetics (24, 35). K1 expression has been detected in 
KS, PEL, and MCD (92, 106, 114, 225). K1 has been shown to transform Rat-1 rodent 
fibroblasts by inducing morphological changes and foci formation (116), and can 
functionally substitute for STP in the context of HVS infection of common marmoset to 
immortalize T lymphocytes to IL-2-independent growth as well as induce lymphomas (116). 
Transgenic mice expressing the K1 gene showed constitutive activation of NF-κB and Oct-2, 
increased Lyn tyrosine kinase phosphorylation and activity, as well as increased basic 
fibroblast growth factor (bFGF) expression (169). Some of these mice developed tumors with 
features resembling the spindle-cell sarcomatoid tumor and malignant plasmablastic 
lymphoma (169). Structurally, K1 contains a long N-terminal extracellular domain, a 
transmembrane domain, and a short C-terminal cytoplasmic tail. The N-terminal domain has 
a very high sequence variability in different geographical regions and can be glycosylated for 
multimerization (87, 96, 248). The C-terminus of K1 is well conserved and contains an 
ITAM that is normally important for lymphocyte activation signaling (115). Upon ligand 
binding, the ITAM of lymphocyte receptors functions to transduce the extracellular signal to 
downstream SH2-containing molecules. This subsequently induces calcium mobilization and 
tyrosine phosphorylation events leading to cellular activation. The ITAM-based signaling of 
K1, however, appears to be constitutively active, independent of ligand binding (116). In B 
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cells, K1 has been shown to activate PI3K (p85 subunit), Akt, Vav, and Syk kinases, and to 
induce NFAT and NF-κB transcriptional activities for cell survival (107, 115, 215) (Fig. 4 & 
5). In addition, K1 can prevent death receptor-mediated apoptosis of B lymphocytes by 
inhibiting the induction of FasL expression and activating the PI3K/Akt pathway (215) (Fig. 
4 & 5). Another striking feature of K1 is the induced downregulation of surface B cell 
receptor by endoplasmic reticular sequestration (113). This may inhibit apoptosis as a 
consequence of BCR signaling. K1 signaling activity in B-cells has been linked to K1 
internalization and since K1 also co-internalizes with BCR, it suggests a possible mechanism 
of BCR downregulation from the cell surface (214). In epithelial and endothelial cells, K1 
expression induced the secretion of angiogenic factors, including vascular endothelial growth 
factor (VEGF) and matrix metalloproteinase-9 (227). K1 also activated the PI3K/Akt/mTOR 
pathway in endothelial cells (225) (Fig. 5). In endothelial cells, K1 has been shown to 
immortalize and extend the life span of primary human umbilical vein endothelial cells 
(HUVEC) in culture (225). K1 ITAM expression also activates both the VEGF/VEGFR-2 
and the PI3K/Akt signaling pathways in HUVEC (225). In C33A epithelial cells, K1 
expression also contributes to increased angiogenesis (225). Cumulatively, these data suggest 
a paracrine model in which K1-mediated secretion of cytokines is involved in the 
development of KSHV-associated diseases (227). Thus K1 appears to be important in 
KSHV-associated tumorigenesis and angiogenesis. 
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Figure. 5. K1 activates the PI3K/Akt/mTOR signaling pathway in endothelial and B 
cells. 
 
 
 
Figure. 4. KSHV K1 modulates cellular signaling events. K1 can mobilize calcium 
and activate SYK, VAV, p85 and AKT kinase leading to B-cell activation through the 
induction of the cellular transcription factors NFAT and NF-κB. K1 can also protect 
cells from Fas-induced apoptosis by preventing the induction of expression of the Fas 
ligand (Taken from Damania (43)) 
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vGPCR. Viral G-protein-coupled receptor is encoded by Orf74 of KSHV (7, 81). It is 
expressed early during the lytic cycle and is a viral homolog of the cellular angiogenic IL-8 
receptor (34). vGPCR possesses seven transmembrane domains that are universally found in 
cellular GPCRs (34). The expression of vGPCR can be found in only a small fraction of KS, 
PEL, and MCD samples (199). This protein has potent oncogenic activities, as evidenced by 
its ability to transform and form foci in murine NIH3T3 cells as well as to produce tumors 
when injected into nude mice (9). Like K1, vGPCR can immortalize HUVEC and protect 
these cells from apoptosis induced by serum starvation (10, 141). A sub-set of vGPCR 
transgenic mice developed KS-like angioproliferative lesions with surface markers and 
cytokine profiles resembling those of KS (82, 140, 237). Similar to the situation in KSHV-
associated malignancies, the expression of vGPCR was detected in only a small population of 
cells in the transgenic tumors and in a few other tissues, suggesting that vGPCR-mediated 
tumor formation is driven by spontaneous lytic reactivation in the background of latently 
infected cells. To support this argument, endothelial cells with vGPCR expression were 
demonstrated to cooperate with latent genes to mediate tumorigenesis (140). VEGF secretion, 
which was linked to angiogenesis (9, 10, 199), was increased in these vGPCR-induced 
tumors (82). Unlike its cellular homologs, vGPCR signaling is constitutive and independent 
of ligand binding (182). vGPCR can activate mitogen-activated protein kinases (MAPKs) 
(199), PLC (10), PI3K (10), and Akt (141) in endothelial cells. These data implicate that like 
KSHV K1, autocrine/paracrine signaling of vGPCR might contribute to KSHV-associated 
oncogenesis and angiogenesis. More recently, vGPCR has been shown to increase the 
expression and secretion of the pro-angiogenic molecule angiopoietin-2 in KSHV infected 
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lymphatic endothelial cells, the precursor cells of KS spindle cells (216). In PEL cells, 
vGPCR can activate ERK-2 and p38 pathways, induce the secretion of VEGF and vIL-6, as 
well as increase the transcription of Rta and Mta (29). Thus, besides its roles in 
transformation, vGPCR is also involved in promoting the KSHV lytic cycle. 
 
vIL-6. Viral interleukin-6 (vIL-6) encoded by OrfK2 is a homolog of cellular IL-6 (24.6% 
amino acid sequence identity). Viral IL-6 expression can be detected in KS, PEL, MCD 
samples to different extents (MCD>PEL>>KS) (160, 203). Interestingly, IL-6 
overexpression was suspected to be important in KS and MCD pathogenesis, prior to the 
identification of this viral homolog (137, 241). Similar to cellular IL-6, vIL-6 signaling 
triggers the JAK/STAT (Jansus tyrosine kinases signal transducers and activators of 
transcription) (139), MAPK, and H7-sensitive pathways (156). The JAK/STAT pathway 
induced by vIL-6 results in increased VEGF expression and signaling in an 
autocrine/paracrine fashion (124). Unlike its cellular IL-6 homolog, whose signaling depends 
upon both gp80 (IL-6Rα)  and gp130, vIL-6 signaling can be achieved through gp130 alone 
in BAF cells (139). Therefore, vIL-6 seems to bypass the normal negative feedback loop on 
gp80. Because of this, vIL-6 signaling is able to evade the interferon response by blocking 
IFNα signaling induced by viral infection. This could promote cell cycle progression and the 
proliferation of the infected cells (38), setting the stage for further transformation and 
tumorigenesis events. Injection of NIH3T3 cells stably expressing vIL-6 into athymic mice 
resulted in tumor formation, hematopoiesis, and plasmacytosis compared to the control mice. 
The vIL-6-expressing tumors were also more vascularized, which correlated with an elevated 
level of VEGF secretion (5). Human PEL cell lines such as BC-1, BCP-1, and BCBL-1 were 
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also shown to produce elevated levels of VEGF as a result of vIL-6 signaling. When PEL 
cells were inoculated into nude mice, almost all of them developed PEL-like tumors; 
however, no tumor formation occurred when PEL-innoculated mice were treated with the 
neutralizing anti-human VEGF antibody (6), these data suggest that VEGF induction by vIL-
6 may contribute to progression of KSHV-associated malignancies. As an alternative 
mechanism for Kaposi sarcomagenesis, vIL-6 can also induce the expression of angiopoietin-
2 in lymphatic endothelial cells infected with KSHV (216). 
 
vIRF-1. The viral interferon regulatory factor-1 is encoded by KSHV OrfK9 (117, 184). In 
contrast to the other three KSHV-encoded IRFs, the vIRF-1 transcript is unspliced. In PEL 
cells, the expression of vIRF-1 is low during latency but can be induced to high levels during 
lytic infection (168). The most apparent function of vIRF-1 is to suppress both type I and 
type II interferon responses (26, 73, 117). vIRF-1 can compete with cellular IRF3 to interact 
with the transcriptional coactivator CBP and p300. This interferes with the formation of the 
IRF3/CBP/p300 complexes (26, 120). In addition to suppressing the host anti-viral response, 
vIRF-1 can block apoptosis induced by tumor necrosis factor α (TNFα) and p53, respectively 
(26, 194). Viral IRF-1 can physically associate with p53 and repress its transactivation and 
apoptotic functions through inhibition of p53 phosphorylation and acetylation (145, 194). 
Viral IRF-1 is a potential oncogene, as NIH3T3 cells stably expressing vIRF-1 can grow 
under conditions of serum deprivation. These cells exhibit loss of contact inhibition in soft 
agar and can form tumors in nude mice (73). Transformation of vIRF-1 expressing NIH3T3 
cells was found to be mediated by the induction of Myc proto-oncogene through vIRF-1 
activation of the plasmacytoma repressor factor (PRF) element (91). 
26 
 
In addition to their transforming/oncogenic properties in overexpression systems (in 
isolation), most of the putative oncogenic KSHV gene products (e.g. LANA, vCyclin, vFLIP, 
vIL-6, Kaposin B, K1, vGPCR, vIRF-1) can be detected in KS, PEL, and MCD specimens, 
albeit with differential contribution (Table 2). This further corroborates their important roles 
in the initiation and/or maintenance of KSHV-associated malignancies. Very generally 
speaking, predominantly latent proteins are expressed in KS and PEL cells, but both latent 
and lytic proteins are expressed in MCD. Intriguingly, processivity factor-8 (PF-8)/Orf59 and 
vIRF-1 can be detected in PEL cell line but not in PEL primary tissues (98, 160). 
Furthermore, PEL cell lines require chemical induction to express vIL-6 while primary PEL 
tumor cells express vIL-6 without the dependence of lytic reactivation (97, 160, 203). 
However, a recent report by Chandriani and Ganem found using a very sensitive, limiting 
dilution-based assay that transcripts of vIL-6 and K1 were present at low levels in latently 
infected cells in some contexts (35). The discrepancies could also be due to the loss of tumor 
microenvironment in cell lines or adaptation of PEL cells during passages.  
Although we have not described the functions of all the unique genes encoded by 
KSHV, a brief description of these genes is listed in Table 1. 
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Table 2. In situ detection of KSHV gene products in KS, PEL, and MCD 
 KS PEL MCD 
LANA RNA & protein RNA & protein RNA & protein 
vCyclin RNA RNA RNA 
vFLIP RNA RNA RNA 
Kaposin B RNA RNA & protein ? 
vIRF-3/LANA-2 - RNA & protein RNA & protein* 
vIL-6 RNA & protein RNA & protein RNA & protein* 
K1 RNA & protein RNA & protein RNA & protein 
vGPCR RNA RNA RNA 
Rta/Orf50 RNA RNA ? 
PF-8/Orf59 RNA & protein* RNA & protein* RNA & protein* 
vIRF-1 RNA RNA RNA 
Note: * represents a viral gene whose protein levels can be detected in only a small 
percentage of tumor cells.  
 
Treatment of KS, PEL, and MCD 
Treatment options for KS are based on disease severity, the KS subtype, and immune 
status. For relatively mild and limited KS, local treatment options such as topical alitretrinoin, 
surgical excision, radiation therapy, and intralesional chemotherapy (e.g. vinblastine) can be 
used to treat the symptoms. These local therapies do not prevent new KS lesions from 
developing. For more severe and aggressive KS, systemic chemotherapy with agents such as 
liposomal anthracyclines (doxorubicin and daunorubicin; first-line) and paclitaxel (second-
line) is usually the mainstay of treatment. Other chemotherapeutics include vinorelbine, 
interferon-α, and interleukin-12. Although the approaches mentioned above have some 
beneficial effects to the patients, they are not very effective, as they do not target specifically 
the agent causing the tumor. The mTOR inhibitor, rapamycin (Sirolimus) was tested against 
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iatrogenic KS and was highly successful (201, 202). In AIDS-KS patients, HAART is 
recommended to reduce the extent and size of KS lesions. HAART might also reduce the 
incidence of new KS in HIV-positive individuals. These beneficial effects are likely due to 
immune reconstitution. In addition to HAART, the tyrosine kinase inhibitor imatinib, and IL-
12 also demonstrate some activities against AIDS-KS (102, 123).  
PEL patients have very poor prognosis and have a median survival of only two to 
three months after diagnosis. As in the case of KS, a patient co-infected with HIV is likely to 
benefit from HAART (152). Complete remission of PEL with HAART is seen occasionally 
(88, 152, 196). On the other hand, conventional CHOP-like regimens (cyclophosphamide, 
doxorubicin, vincristine, and prednisone) did not improve survival compared to other HIV-
associated NHL (196). For HIV-negative cases of PEL, patients may be given liposomal 
anthracycline with or without bortezomib (proteasome inhibitor) and prednisone. Bortezomib 
was reported to be efficacious in treating PEL cell lines when it was used alone or in 
combination with doxorubicin and Taxol (4). Rapamycin has also shown promise in treating 
PEL cells in culture and in a xenograft model (197). Although radiation therapy is rarely 
performed to treat PEL, it may be an option for patients who do not tolerate the above 
treatment options.  
Treatment options for MCD include surgical excision, cytoreduction chemotherapy 
(CHOP or CVAD), radiation therapy, immune modulators such as steroids and interferon-α, 
thalidomide, monoclonal antibodies against IL-6 (atlizumab) and CD20 surface marker 
(rituximab), and inhibitors of KSHV viral replication (reviewed in (31, 32)). The patient 
responses to these therapeutic options are mixed and therefore, the establishment of treatment 
regimens requires more epidemiological data. As a general rule of thumb, chemotherapy is 
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preferred for MCD with severe systemic symptoms; the viral replication inhibitors 
(especially ganciclovir), interferon-α, and anti-IL-6 and anti-CD20 monoclonal antibodies 
appear to be the more specific and promising candidates for treating MCD (31). 
In conclusion, the current treatment strategies for KS, PEL, and MCD are still sub-
optimal. While our understanding of KSHV biology and tumorigenesis has been increasing 
since the discovery of the virus, we are just beginning to translate knowledge from basic 
science research into more effective clinical management and therapies. We believe that the 
use of antiviral agents and small molecules that specifically target the signaling pathways of 
these tumor cells are potentially more efficacious and have fewer side effects than 
conventional chemotherapy regimens. More case reports and randomized clinical trials are 
needed to advance and standardize treatments for KSHV-associated malignancies. 
 
Rhesus rhadinovirus as a model to study KSHV pathogenesis  
A detailed understanding of KSHV replication and pathogenesis is important for 
understanding the biology of the diseases that are associated with this virus. However, in vivo 
studies of KSHV are limited due to the inability of KSHV to persistently infect mice or 
rhesus macaques (56, 178). Furthermore, difficulties are encountered when trying to study 
KSHV replication in vitro (177). Endothelial cells were previously proposed to study the de 
novo lytic replication and replication of KSHV because they were natural targets of in vivo 
KSHV infection. Nevertheless, cell lines derived from KS lesions rapidly lose the viral 
genome after serial passage in vitro (2, 3, 16, 204, 208). Although several groups have 
described the use of immortalized human umbilical vein endothelial cells (HUVEC) and 
microvascular endothelial cells (TIME) to investigate de novo KSHV replication (52, 105, 
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177, 187), the virus replicates lytically only for a limited number of rounds before entering 
latency in these cells. Hence viral titers of KSHV are quite low in endothelial cells and 
plaques are rarely observed. Another system to generate lytic virus involves the treatment of 
KSHV-infected PEL cell lines with chemicals (TPA or n-butyrate) (138, 180) or etopic 
expression of Orf50 (128). Here the problem is that only a small subset (25-30%) of latently 
infected PEL lymphocytes can be artificially reactivated with TPA (138, 180). Although 
without chemical induction, KSHV- positive PEL cell lines are mostly latent, about 2-5% of 
these cells still undergo spontaneous lytic reactivation (180). Thus, the heterogeneous nature 
of the lytically and latently infected cell populations hampers the dissection of the function of 
individual viral genes in the context of the whole virus.  
We have used rhesus monkey rhadinovirus (RRV) to model KSHV pathogenesis in 
rhesus fibroblasts (RhF) (149). RRV was first identified by Desrosiers et al. in 1997 at the 
New England Primate Research Center (NEPRC) as a γ2-herpesvirus of rhesus macaques 
(Macaca mulatta) (49). This isolate was designated H26-95. Additionally, Wong et al. at the 
Oregon Regional Primate Research Center isolated a different strain of RRV (designated 
17577) from SIV-infected macaques (234). Sequence analysis revealed that the two RRV 
isolates are homologous to each other, though not identical (49, 234). Importantly, both 
genomes exhibit co-linearity with the KSHV genome (1, 193) and all RRV genes have 
homologs in KSHV (1, 193) (Fig. 6). Wong et al. showed that in SIV-infected macaques, 
RRV induced B-cell hyperplasia resembling KSHV MCD (234) as well as non-Hodgkin 
lymphoma (154, 155). Mansfield et al. reported that RRV also caused an arteriopathy in SIV-
infected macaques (131).  
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RRV presents several advantages for studying lytic replication. First, the RRV 
lifecycle can be modeled in vivo, in rhesus macaques. Second, rhesus fibroblasts (RhF) 
support one hundred percent lytic replication of RRV and allows for the production of high 
titers of virus (approximately 106 plaque forming units per ml) without the need to 
concentrate virus by ultra-centrifugation (148). Our group has demonstrated that the 
transcription program of RRV is similar to that of KSHV (50, 58). Several laboratories have 
used the RRV model to study viral gene products, including the viral interleukin-6 (vIL-6) 
homolog (94, 153), Rta/Orf50, R8/RAP, R8.1 (50, 122), R1 (44, 46), R15 (112, 170), RK15 
(226), RRV Orf4 (132), glycoproteins (gB, gH, gL) (22, 111), RCP (151), and the RRV-
encoded microRNAs (190, 222). We previously reported the kinetics of gene expression with 
regard to immediate-early, early, and late genes during RRV lytic infection and have reported 
they are similar to those seen during KSHV reactivation (50, 58). We also generated a RRV-
GFP recombinant virus and devised plaque assays and quantitative real time QPCR assays 
for the determination of viral titers (51). In this dissertation, we generated and analyzed the 
replicative properties of recombinant viruses deleted for R1 (Chapter 3) and LANA (Chapter 
4) in RRV, to gain insights into their roles in KSHV biology in the context of the whole virus.  
 
Objectives 
 
 Expression of the K1 transcript and protein has been detected in KS, PEL, and MCD. 
The K1 protein has been shown to activate the PI3/Akt/mTOR signaling pathway in B 
lymphocytes and endothelial cells, inhibit apoptosis in B lymphocytes and epithelial cells, as 
well as to transform rodent fibrobloasts. This suggests that K1 plays an important role in 
KSHV infection and transformation.  The goal of our study was to identify the cellular 
proteins that interact with K1 and study the mechanisms by which K1 activates signal 
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transduction pathways, inhibits apoptosis, and contributes to oncogenesis. Using RRV as a 
model, we also dissected the role of KSHV K1 in the viral lifecycle. RRV encodes a gene 
named R1, which is functionally homologous to the KSHV K1 gene. We constructed a 
RRV∆R1/GFPcc recombinant virus to analyze the contribution of R1 during de novo 
infection, latency, and reactivation of RRV.  
The second objective of our study was to develop a novel vaccine for protection 
against rhadinovirus infection in primates using the RRV model system. The latency-
associated nuclear antigen (LANA) is critical for the establishment and maintenance of both 
KSHV and RRV latency. We generated a recombinant virus deleted for RRV LANA, named 
RRVΔLANA/GFP, by a homologous recombination approach. We analyzed its biological 
properties in vitro with respect to viral latency and lytic replication. 
The objectives of this dissertation are described in further detail below: 
1) To identify the cellular binding partners of KSHV K1 and explore the 
consequences of the interactions of K1 and cellular proteins for K1 signaling and function.  
Using tandem affinity purification, we identified the molecular chaperones, Hsp90 
and ER-associated Hsp40/Erdj3, as the cellular interacting partners of K1. We showed that 
Hsp90 and Hsp40/Erdj3 modulated the protein expression and anti-apoptotic function of K1. 
We also showed that the interaction of K1 with Hsp90 and Hsp40/Erdj3 is relevant in 
KSHV-associated tumorigenesis by demonstrating co-localization of these proteins in a PEL 
cell line and their expression in mouse xenograft sections. This study has identified Hsp90 
and Hsp40/Erdj3 as being essential for K1 expression and function. These cellular proteins 
may serve as targets for future therapies for KSHV-associated cancers. This wok has been 
published in Oncogene in 2010. 
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2) To elucidate the role of KSHV K1 in the viral lifecycle using RRV R1 as a model system. 
RRV R1 is the homolog of KSHV K1 (45). Using a cosmid system for RRV (21), the 
R1 ORF, was disrupted by insertion of a GFP expression cassette. We analyzed the effects of 
R1 deletion on de novo lytic viral replication, reactivation, and the establishment and 
maintenance of viral latency. This work has led to a detailed understanding of the 
contribution of K1 to the KSHV lifecycle. A manuscript has been submitted to the Journal of 
Virology. 
 
3) To develop a novel vaccine for protection against rhadinovirus infection. 
 
The LANA proteins of both KSHV and RRV play key roles in the establishment and 
maintenance of these herpesviruses. We have constructed a RRVΔLANA/GFP in which the 
RRV LANA open reading frame has been disrupted with a GFP expression cassette 
generated by homologous recombination. The RRVΔLANA/GFP recombinant virus 
exhibited significantly elevated lytic replicative properties and failed to establish latency. We 
also observed significant differences in global viral gene expression between 
RRVΔLANA/GFP and the wild-type viruses. Several cellular genes that are known to be 
repressed by KSHV LANA were de-repressed during de novo lytic infection with the 
RRVΔLANA/GFP virus compared to RRV-GFP. This work has been published in the 
Journal of Virology in 2009. 
A future goal is to evaluate the RRVΔLANA/GFP as a vaccine candidate in rhesus 
macaques in collaboration with Dr. Ronald Desrosiers at Harvard Medical School. 
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ABSTRACT 
Kaposi sarcoma-associated herpesvirus (KSHV) is a member of the 
gammaherpesvirus family. It is the etiological agent of three different human cancers, Kaposi 
sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease 
(MCD). The far left-end of the KSHV genome encodes a unique transmembrane 
glycoprotein called K1. K1 possesses the ability to transform rodent fibroblasts and block 
apoptosis. K1 has also been shown to activate the PI3K/Akt/mTOR pathway in different cells. 
Using tandem affinity purification (TAP), we identified heat shock protein 90β 
(Hsp90β) and endoplasmic reticulum (ER)-associated Hsp40 (Erdj3/DnaJB11), as cellular 
binding partners of K1. Interactions of K1 with Hsp90β and Hsp40 were confirmed by co-
immunoprecipitation in both directions. Furthermore, K1 also interacted with the 
Hsp90α isoform. We report that siRNAs directed against Hsp90 and Erdj3, as well as 
pharmacological inhibitors of Hsp90 dramatically reduced K1 expression, suggesting that K1 
is a client protein of these chaperones. Additionally, both Hsp90 and Erdj3 were essential for 
K1’s anti-apoptotic function. Finally, we report that the Hsp90 inhibitors, 17-AAG and 17-
DMAG, can suppress the proliferation of KSHV-positive PEL cell lines and exhibited IC50 
values of 50 nM and below. 
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INTRODUCTION 
Kaposi sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8, is a 
gammaherpesviruses. This virus has been implicated as the etiological agent of Kaposi 
sarcoma (KS) (7) and lymphoproliferative diseases of B cell origin, namely, primary effusion 
lymphoma (PEL) (6) and the plasmablastic variant of multicentric Castleman disease (MCD) 
(13, 48). 
The first open-reading frame (ORF) of KSHV encodes a viral glycoprotein named K1 
(20). K1 is the positional homolog of the saimiri transformation protein (STP) of herpesvirus 
saimiri (HVS) (31) and the R1 oncogene of rhesus monkey rhadinovirus (9). K1 expression 
has been detected in KS, PEL, and MCD (3, 18, 20, 25). We, and others, have shown that K1 
is a transforming protein of KSHV capable of transforming rodent fibroblasts. Injection of 
these cells into nude mice resulted in the development of large, multifocal, disseminated 
tumors (9, 40). Additionally, K1 could functionally substitute for the HVS STP oncogene in 
the context of a virus to transform immortalize peripheral blood mononuclear cells to IL-2 
independent growth as well as induce lymphomas (27). Expression of the K1 gene in 
transgenic mice resulted in constitutive NF-κB activation in both T and B lymphocytes, and 
tyrosine phosphorylation of the Lyn protein kinase (40). These K1-transgenic mice 
developed tumors with features resembling spindle-cell sarcomas and malignant 
plasmablastic lymphoma (40).  
K1 is a 46 kDa type I transmembrane glycoprotein, which structurally and 
functionally resembles a B cell receptor (BCR). The extracellular N-terminal domain of K1 
exhibits homology to the variable region of the immunoglobulin λ light chain (26), and K1 
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appears to interact with the BCR μ chain to inhibit the intracellular transport of BCR and 
downregulate surface BCR expression (24). In its cytoplasmic tail, K1 contains an 
immunoreceptor tyrosine-based activation motif (ITAM) that is also found in many 
immunoglobulin receptors e.g. BCR. The  K1 ITAM is comprised of two appropriately 
spaced Src-homology 2 (SH2) binding motifs (22, 26, 27) and is required for BCR activation 
events (22, 26). We and others have shown that K1 is capable of activating B lymphocyte 
signal transduction and interacting with Syk (8, 22, 26). Like BCR, K1 can induce tyrosine 
phosphorylation of cellular proteins, intracellular mobilization of calcium, and activation of 
transcription factors (21, 22, 26, 40).  However, unlike BCR, K1 signaling appears to be 
constitutively active and independent of ligand binding (27). K1 signaling activity in B cells 
has been linked to K1 internalization (49), and K1 also co-internalizes with the BCR (49) 
resulting in the downregulation of BCR surface expression (24).  
We previously reported that K1 activates the phosphatidyl-inositol-3’-OH-kinase 
(PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway in both B cells and 
endothelial cells (50, 52). In addition, we and other have shown that K1 can prevent Fas-
mediated apoptosis (1, 50, 54) through activation of the PI3K/Akt pathway (50). In epithelial 
and endothelial cells, K1 expression induced the secretion of angiogenic factors, including 
vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) (53). 
Cumulatively, these data suggest a paracrine model in which K1-mediated secretion of 
cytokines is involved in the development of KSHV-associated tumorigenesis and 
angiogenesis (53).  
Molecular chaperones are involved in various cellular processes including and 
maturation, DNA replication and transcription, protein translocation, and cell signaling. For 
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example, both heat shock protein (Hsp) 90 and the Hsp40/Hsp70 system act to enhance the 
Akt pathway which is important for cell survival (12, 19). Hsp40, Hsp70, and Hsp90 are 
important for the assembly of signaling receptor complexes (32, 38, 47).  Hsp90 and the 
Hsp40/Hsp70 system have been shown to suppress tumor necrosis factor (TNF)- and Fas-
induced apoptosis (28, 34). Additionally, Hsp90 overexpression has been detected in a 
variety of cancers (reviewed in (42)). The KSHV K1 protein targets similar signaling 
pathways as Hsp90 e.g. the PI3K/Akt pathway, and hinders apoptosis by modulating this pro-
survival pathway. Hence the functions of Hsp90, Hsp40, and K1 appear to be concordant.  
Using tandem affinity purification, we identified Hsp90β and the ER-associated 
Hsp40 (Erdj3/DnajB11) as cellular binding partners of K1. We confirmed this finding by 
performing co-immunoprecipitation in both directions. We also found that K1 interacts with 
Hsp90α by co-immunoprecipitation. Pharmacological inhibition of Hsp90 function reduced 
expression of the K1 protein. This suggests that K1 protein expression is dependent on 
Hsp90 activity. Additionally, when Hsp90β or Erdj3 was knocked down by specific siRNAs, 
the level of K1 protein as well as the total and phosphorylated levels of Akt were reduced, 
implicating that Hsp90β and Erdj3 are important for K1 protein expressing and downstream 
Akt signaling. Knockdown of these chaperones also prevented K1 from promoting cell 
survival and inhibiting apoptosis. Hence, these molecular chaperones are critical for the 
expression and function of oncogenic K1. Finally, we report that the Hsp90 inhibitors, 17-
AAG and 17-DMAG, were very effective in inhibiting the proliferation of KSHV-positive 
PEL cell lines.  
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MATERIALS AND METHODS 
Cell culture 
293-K1 and 293-Vec stable cells were established and maintained in 1 mg/ml G418 selection 
in DMEM medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL 
streptomycin in 5% CO2. BCP-1, JSC-1, and BCBL-1 cell lines were cultured in RPMI 1640 
medium supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM 
L-glutamate, 0.05 mM 2-mercaptoethanol, and 0.075% sodium bicarbonate in 5% CO2. 
Antibodies  
Rabbit anti-K1 antibody was a kind gift from Dr. Jae Jung. Anti-Hsp90 (ab1429) and anti-
Hsp70 antibodies (ab2787) were purchased from Abcam. Anti-Hsp90α and Hsp90β 
antibodies were purchased from Stressgen (SPS-771 and SPA-843). Anti-Hsp40 (DNAJB11) 
antibody was obtained from Sigma (HPA010814). Anti-Akt and anti-phospho-Akt (S473) 
were purchased from Cell Signaling, while anti-actin antibody was purchased from Santa 
Cruz (C16). EZview Anti-FLAG M2 resin was obtained from Sigma for 
immunoprecipitation of K1. Normal mouse IgG (sc-2025), normal rabbit IgG (sc-2027), and 
protein A/G PLUS-Agarose (sc-2003) were purchased from Santa Cruz. HRP-conjugated 
anti-ECS antibody used for FLAG immunoblotting was purchased from Bethyl (A190-101P). 
Immunoblotting detection was performed by using the ECL Plus kit (Amersham).  
Inhibitors and small-interfering RNAs (siRNAs) 
Geldanamycin, 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-
Dimethylamino-ethylamino-17-demethoxygeldanamycin (17-DMAG) were purchased from 
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Invivogen. Stealth siRNAs targeting Hsp90β and Erdj3 were purchased from Invitrogen. 
Anti-Luc siRNA-1, Accell non-targeting siRNA pool, and GFP siRNA duplex were 
purchased from Thermo Scientific. The siRNAs directed against K1 
(CCACAACAATTGCAGGATT-UU and CCATGCAACCACACATAAA-UU) were 
designed by Dharmacon siDESIGN® Center Custom siRNA Design Tool and Invitrogen 
BLOCK-iT™ RNAi Designer and purchased from Dharmacon. 
Tandem affinity purification 
We generated the FLAG HA tandem tagged K1 construct (TAP-K1) by QuikChange site-
directed mutagenesis. A FLAG-tagged K1 construct previously published (50) was used as 
the PCR template for mutagenesis. The oligonucleotides 5'-
ACGACGACAAGGGTACCTACCCATACGACGTCCCAGACTACGCTCTTTATGTGCT
ATCGTC-3' and 5'-
GACGATAGCACATAAAGAGCGTAGTCTGGGACGTCGTATGGGTAGGTACCCTTG
TCGTCGT-3' were used to introduce the HA epitope sequence between FLAG and K1 at the 
N-terminus. pcDNA3-K1 and empty pcDNA3 vector were transfected into 293 cells using 
FuGENE 6 reagent (Roche) and selected with 1 mg/ml G418 to establish 293-K1 and 293-
Vec stable cells, respectively. Forty confluent flasks (T175) of each cell line were harvested 
and washed twice in cold PBS. Cells were pelleted and stored at -80oC. 293-K1 and 293-Vec 
stable cell pellets were thawed and lysed in NP40 buffer supplemented with PMSF, EDTA-
free protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1 & 2 (Sigma). 
The lysates were pelleted and the supernatants (20 mg/ml) were subjected to TAP using the 
FLAG HA Tandem Affinity Purification Kit (Sigma) according to the manufacturer’s 
instructions. After TAP, the samples were eluted in 2X Laemmli sample buffer and resolved 
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on a 12% NuPAGE Novex Bis-Tris Mini Gel (Invitrogen) with MOPS SDS Running Buffer 
(Invitrogen). The gel was Coomassie-stained and submitted to the UNC Proteomics Center 
for mass spectroscopy. Protein bands unique to K1 expressing cells were excised, trypsin-
digested, and subjected to Matrix Assisted Laser Desorption/Ionization-Time Of Flight 
(MALDI-TOF) mass spectroscopy (MS) analysis. 
Immunoprecipitation  
For each immunoprecipitation reaction, confluent cells in a 10-cm dish were harvested, 
washed twice in ice cold PBS, and lysed in RIPA buffer supplemented with PMSF, EDTA-
free protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktails 1 & 2 (Sigma). 
Cell lysates were freeze-thawed twice and centrifuged at 13,000 rpm for 10 min at 4oC. The 
extract was subjected to pre-clearing with Protein A/G PLUS-Agarose and 1 µg of normal 
mouse Ig or normal rabbit IgG for 30 min at 4oC with gentle rocking. For FLAG 
immunoprecipitation, pre-cleared extract was incubated with FLAG resin at 4oC overnight, 
with gentle rocking. The beads were washed three to four times with RIPA buffer and 
immunoprecipitated protein complexes were subjected to competitive elution with 3X FLAG 
peptide. For all other immunoprecipitation reactions, pre-cleared extract was incubated with 
1 µg of primary antibody at 4oC for 4 h. 20 µl of Protein A/G PLUS-Agarose was added to 
the lysate and incubated at 4oC overnight, with gentle rocking. After binding, the resins were 
washed three to four times with RIPA buffer. Immunoprecipitated protein complexes were 
eluted in 2X Laemmli sample buffer.  
MTS assay 
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The number of metabolically active cells was assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)–based colorimetric 
assay. Cells were incubated for 4 days with indicated amounts of drug at a seeding density of 
1 x 105 cells/ml in triplicate. The amount of MTS, which is converted to a formazan product 
represents the number of viable cells. The degree of the conversion was determined by 
measuring the absorbance at a wavelength of 490 nm. 
Caspase-3 assay 
For Fas-mediated apoptosis, 293-K1 and 293-Vec stable cells were transfected with siRNAs 
using Superfect (Qiagen). At 36 h posttransfection, the transfected cells were stimulated with 
anti-Fas cross-linking antibody (clone CH11, Millipore) at 0.2 µg/ml in 1% fetal bovine 
serum, and cells were harvested 12 h later (50). Apoptosis was analyzed by using an 
ApoAlert caspase-3 fluorimetric assay kit from Clontech. Absorbance was read on a 
FLUOstar Optima fluorometric plate reader with a 400-nm excitation and 505-nm emission 
filter. 
Cell-cycle analysis 
Cells fixed in 70% ethanol were resuspended in PBS with 20 µg/mL propidium iodide and 
200 µg/mL RNaseA. Flow cytometric analysis was performed with a Becton Dickinson 
FACScan and ModFitLT V3.2.1 program. 
Immunohistochemistry 
Tumors from SCID mice injected with BC-1 cells as previously described (2, 46) were 
excised and mixed in 10% neutral buffered formalin. Tumors were paraffin-embedded and 5-
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µm sections were prepared on slides. Slides were deparaffinized using Histochoice Clearing 
Agent (Sigma) and re-hydrated using graded ethanol, followed by extensive washing with 
water. Endogenous peroxidase activity was quenched with 3% H2O2 in 10% methanol 
solution, and antigens were exposed by heating sections for 10 minutes in 1 mM EDTA (pH 
8.0), and cooled to room temperature. Non-specific antigens were blocked using a blocking 
buffer (10% normal horse serum [Vector Labs], 5% BSA, and 0.3% TritonX-100) for 1 h at 
room temperature, followed by overnight incubation at 4oC in blocking buffer containing 
anti-K1 antibody (1:100 dilution), a kind gift from Dr. Jae Jung,  or anti-Hsp90 (1: 10 
dilution) (Abcam). Sections incubated in blocking buffer lacking primary antibody were used 
as negative controls. Sections were washed in PBS, incubated with biotinylated goat 
secondary antibody (anti-rabbit for K1 and anti-mouse for Hsp90), followed by 1 h 
incubation in pre-formed Avidin DH- biotinylated horseradish peroxidase H complexes 
(Vectastain ABC kit, Vector Labs), after which sections were stained with Vector NovaRed 
substrate or NovaDab substrate, and washed. Sections were counterstained with hematoxylin 
(Invitrogen), dehydrated using graded alcohols, and mounted using Cytoseal XYL (Richard-
Allan Scientific). Dried slides were imaged using a LEICA DM LA histology microscope 
and LEICA Firecam software. 
Confocal immunofluorescence microscopy 
BCBL-1 cells were air-dried on slides, fixed in 1% paraformaldehyde and permeabilized 
with 0.1% Triton X-100. The cells were then blocked with 1:10 goat sera and 1% BSA in 
PBS, and then incubated overnight with primary antibodies in PBS with 1% BSA. Slides 
incubated in PBS with 1% BSA lacking primary antibody were used as negative controls. 
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After several washes in PBS with 1% BSA, the cells were incubated with species-specific 
fluorophore-conjugated secondary antibodies for 30 min, followed by counterstained with 
0.1X DAPI. Slides were mounted with Vetashield (Zymed Labs), coverslipped, and imaged 
using ZEN 2009 program with the Olympus BX61 confocal microscope. 
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RESULTS 
Tandem affinity purification identifies Hsp90β and Hsp40 (Erdj3) as cellular binding 
partners of K1.  
In order to identify cellular binding partners of K1 in the context of mammalian cells, 
we performed tandem affinity purification (TAP) (41) since it preserves the endogenous 
milieu of cellular proteins, and the two sequential column purification steps provide high 
stringency. We cloned the FLAG and HA epitopes in tandem right after the signal peptide 
sequence in the N-terminus of K1 using PCR. The double-tagged K1 gene was expressed by 
the pcDNA3 vector. Stable 293 cells expressing FLAG HA tadem tagged K1 (293-K1) or 
empty vector (293-Vec) were generated by transfection using FuGENE 6 reagent (Roche) 
and selection with 1 mg/ml G418 for two weeks. The stable cells were maintained under 1 
mg/ml G418 selection. Robust expression of K1 and successful detection of the FLAG and 
HA epitopes were verified by Western blots.  
For tandem affinity purification, forty confluent T175 flasks per stable cell line were 
harvested and lysed in Nonidet P-40 (NP40) buffer (Invitrogen) supplemented with protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktails (Sigma). The protein lysates 
(20 mg/ml) were centrifuged and the supernatants were subjected to tandem affinity 
purification at 4oC as follows. The protein lysates were incubated with anti-FLAG resin 
overnight with gentle rocking and then transferred to a Spin column. Non-specific, unbound 
proteins were removing by washing the anti-FLAG resin three times with NP40 
supplemented with protease and phosphatase inhibitors. After washing, protein complexes 
were eluted twice with 150 ng/µl 3X FLAG peptide and then pooled. The elutions were then 
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subjected to binding to anti-HA resin in a Spin column overnight with gentle rocking. 
Unbound proteins were removing by washing the anti-HA resin three times with NP40 
supplemented with protease and phosphatase inhibitors. Proteins bound to the anti-HA resin 
were eluted in 2X Laemmli Sample Buffer (LSB) (Sigma) and resolved on a 12% NuPAGE 
Novex Bis-Tris Mini Gel (Invitrogen) with MOPS SDS Running Buffer (Invitrogen). The gel 
was Coomassie-stained; protein bands unique to K1 expressing cells were excised, trypsin-
digested, and subjected to MALDI-TOF Mass spectrometry analysis (Fig. 1A). 
Mass spectrometry identified Hsp90β and the ER-associated Hsp40 (Erdj3) as cellular 
binding partners of K1 (Fig. 1A). Importantly, the specific protein bands for both Hsp90β 
and Hsp40 were only visible in the K1 lanes, but not in the empty vector (pcDNA3) lanes 
(Fig. 1A). Furthermore, the digested peptides fully matched the peptide sequences of Hsp90β 
and Hsp40 (Erdj3) and achieved very high ion scores (Fig. 1B). 
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Figure 1. TAP identified Hsp90β and ER-associated Hsp40 as cellular binding 
partners of K1. A. A Coomassie-stained gel of the K1 cellular partners identified by TAP 
is shown. After TAP, eluted proteins were resolved by SDS-PAGE and visualized by 
Coomassie staining. Protein bands unique to K1 expressing cells were excised and 
subjected to MALDI-TOF mass spectrometry (MS). M denotes marker. B. MS/MS data 
for the protein identities of Hsp90β and ER-associated Hsp40 are shown.  
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the TAP results, equivalent micrograms of 293-K1 and 293-Vec lysates 
were precleared with normal mouse immunoglobulin (Santa Cruz) and protein A/G beads 
(Santa Cruz) and then used to perform immunoprecipitation with anti-FLAG agarose beads 
(Sigma) overnight. (Figs. 2A and 2C).  The immunoprecipitates were subjected to Western 
blot analysis with anti-Hsp90β (Fig. 2A) or anti-Erdj3 antibody (Fig. 2C). Interactions of K1 
 
Figure 2. K1 interacts with endogenous Hsp90β and ER-associated Hsp40.  
A. Protein lysates from stable 293 cells expressing empty control vector (left 
lanes) or FLAG-K1 (right lanes) were immunoprecipitated with anti-FLAG 
antibody. Immunoprecipitation reactions were subjected to SDS-PAGE followed 
by Western blotting with an anti-Hsp90β antibody. Input lysates showed the 
presence of Hsp90β in all cell lysates, and K1 protein in the 293-K1 cell lysate. B. 
Reverse co-immunoprecipitations were also performed. Lysates from 293-Vec or 
293-K1 stable cells were immunoprecipitated with an anti-Hsp90β antibody. 
Immunoprecipitations were subjected to SDS-PAGE and WB analysis with an 
anti-FLAG antibody to detect K1 protein expression. Input lysates showed the 
presence of Hsp90β in all cell lysates, and K1 protein in the 293-K1 cell lysate. 
These data are representative of at least three independent experiments.  C. & D. 
Identical co-immunoprecipitations were performed as indicated in panels A and 
B, respectively, except that anti-Hsp40 antibody was used instead of Hsp90β 
antibody. 
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with endogenous Hsp90β and Erdj3 were confirmed by reverse co-immunoprecipitation 
using anti-Hsp90β (Fig. 2B) or anti-Erdj3/Hsp40 (Fig. 2D), followed by immunoblotting 
with an anti-FLAG antibody to detect K1 expression. Immunoprecipitation assays performed 
in both directions strongly corroborated the TAP results, and demonstrated that K1 
physically associates with Hsp90β and Erdj3/ER-associated Hsp40. To confirm specificity, 
we repeated the K1 immunoprecipitation assay with a normal mouse IgG antibody as a 
negative control. We found that immunoprecipitatons using an anti-FLAG antibody to pull 
down K1 co-immunoprecipitated Hsp90 and Hsp40, while immunoprecipitation with the 
control normal mouse IgG antibody did not pull down K1, Hsp90 or Hsp40 (Fig. 3). 
 
Figure 3. K1 interacts with endogenous Hsp90β and ER-associated Hsp40/Erdj3. 
Protein lysates from stable 293 cells expressing empty pcDNA3 vector (left 2 lanes) or 
FLAG-K1 (right 2 lanes) were immunoprecipitated with anti-FLAG antibody or anti-
normal mouse IgG. Immunoprecipitates and inputs were subjected to SDS-PAGE 
followed by Western blots for Hsp90β, Hsp40 or K1. Input lysates show the presence of 
Hsp90β and Hsp40 in all cell lysates, and K1 protein in the 293-K1 cell lysate only. 
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Since Hsp90α and Hsp90β show >80% identity and each isoform possesses 
chaperoning activity (37), we also investigated whether K1 could interact with Hsp90α. 
Hsp90β is the constitutive form, whereas Hsp90α is more inducible and has been found in the 
medium and on the cell surface (37). We immunoprecipitated K1 using anti-FLAG resin 
beads from pre-cleared 293-K1 and 293-Vec lysates, and performed Western blot analysis 
using anti-Hsp90α antibody. We found that K1 associated with Hsp90α (Fig. 4), indicating 
that K1 can interact with both α and β isoforms of Hsp90.  
 
 We next investigated whether K1 interacts with heat shock proteins other than Hsp40 
and Hsp90. We immunoprecipitated K1 from 293-K1 stable cells with an anti-FLAG 
antibody. The immunoprecipitates were subjected to Western blot analysis with an anti-
Hsp70 antibody (Fig. 5A). We found that K1 failed to interact with Hsp70 suggesting that K1 
specifically interacts with Hsp90 and Erdj3/Hsp40.  
 
Figure 4. K1 interacts with 
endogenous Hsp90α. Protein 
lysates from 293 cells expressing 
empty control vector (left lane) or 
FLAG-K1 (right lane) were 
immunoprecipitated with anti-
FLAG antibody. 
Immunoprecipitation reactions 
were subjected to SDS-PAGE 
followed by Western blots for 
Hsp90α or K1. Input lysates 
showed the presence of Hsp90α 
in all cell lysates, and K1 protein 
in the 293-K1 cell lysate only. 
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Hsp90 possesses intrinsic ATPase activity critical for its chaperoning function (35). 
Apyrase catalyzes the breakdown of ATP and ADP into AMP and inorganic phosphate 
thereby depleting the ATP content in cells (36, 58). We investigated whether K1’s interaction 
with Hsp90β was dependent on the presence of ATP. We incubated 293-K1 or 293-Vec 
stable cell lysates with 20 units/ml of apyrase for 30 min, in order to deplete ATP from the 
samples (36). The ATP-depleted extracts were used to immunoprecipitate K1 and the 
  
 
Figure 5. K1 interacts with Hsp90β and Erdj3/Hsp40 in both 293 and BJAB cells. 
A. Protein lysates from stable 293 cells expressing empty pcDNA3 control vector or 
FLAG-K1 were immunoprecipitated with anti-FLAG or control anti-normal mouse Ig 
antibody. Immunoprecipitation reactions were subjected to SDS-PAGE followed by 
Western blotting with an anti-Hsp70 antibody. Input lanes show the presence of Hsp70 
in all protein lysates and K1 protein in the 293-K1 lysate only. B. Protein lysates from 
stable 293-Vec or 293-K1 cells after treatment with vehicle or apyrase were 
immunoprecipitated with anti-FLAG antibody. Immunoprecipitation reactions were 
subjected to SDS-PAGE followed by Western blotting with an anti-Hsp90β antibody. 
C. Identical co-immunoprecipitations were performed as described in Fig. 2A, except 
that protein lysates from BJAB B cells transfected with pcDNA3 vector or K1 
expression plasmid were immunoprecipitated with anti-FLAG antibody. 
Immunoprecipitates were subjected to SDS-PAGE followed by Western blotting with 
an anti-Hsp90β antibody. Input lysates showed the presence of Hsp90β in all cell 
lysates, and K1 protein in the 293-K1 cell lysate.  Immunoprecipitation was also 
performed with species-matched normal IgG antibody as a negative control.  
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immunoprecipitates were subjected to immunoblotting with an anti-Hsp90β (Fig. 5B) or anti-
Erdj3/Hsp40 antibody. Notably, ATP depletion by apyrase resulted in less Hsp90β protein 
being immunoprecipitated with K1 (Fig. 5B), suggesting that ATP levels (and possibly 
Hsp90 hydrolysis of ATP) modulate K1’s interaction with Hsp90β. Interestingly, apyrase 
treatment did not alter the interaction of K1 with Erdj3/Hsp40, which lacks ATPase activity 
(data not shown). 
Given that K1 expression can be detected in B cells and that K1 perturbs B cell 
signaling and function, we examined if K1 could interact with Hsp90β and Erdj3/Hsp40 in B 
cells. Lysates from BJAB cells transfected with FLAG-tagged K1 or pcDNA3 vector 
plasmids were subjected to immunoprecipitation using an anti-FLAG antibody to pull down 
K1 or normal mouse IgG as a negative control (Fig. 5C). The K1 immunoprecipitates as well 
as the input lysates were subjected to Western blot analysis to detect K1, Hsp90β, or 
Erdj3/Hsp40 (Fig. 5C). Similar to the situation in 293 epithelial cells, we detected specific 
interactions of Hsp90β with K1 and Erdj3 with K1 in B cells which suggests that these 
interactions might be relevant in KSHV-associated B lymphoproliferative diseases such as 
PEL and MCD.  
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To corroborate the above findings, we also performed co-localization assays for K1 
and Hsp90 or Erdj3 in KSHV-positive BCBL-1 cells. Briefly, BCBL-1 were fixed, 
permeabilized, and then stained with anti-K1 antibody and anti-Hsp90/anti-Erdj3 antibody 
and examined by confocal microscopy. We found that K1 colocalizes with Hsp90 and 
Erdj3/Hsp40 (Fig. 6). Additionally, we performed immunohistochemistry on PEL tumor 
sections (Fig. 7). We found that both K1 and Hsp90 proteins were detected by 
immunohistochemical staining of tumor sections  (Fig. 7). 
 
Figure 6. Co-localization of endogenous K1 and Hsp90 or Hsp40/Erdj3 in BCBL-1 
cells. BCBL-1 cells were fixed, permeabilized, and subjected to labeling with (i) anti-K1 
antibody followed by anti-rabbit IgG-TRITC (ii) anti-Hsp90 antibody followed by anti-
mouse IgG-FITC or (iii) anti-Hsp40/Erdj3 followed by anti-goat IgG-FITC. Nuclei were 
counterstained with DAPI and slides were mounted in Vectashield. Images were taken at 
126X and analyzed by confocal microscopy using ZEN 2009 program. For each set, the 
upper left quadrant shows DAPI (blue); upper right quadrant shows Hsp90 or Hsp40 
(green); lower left quadrant shows K1 (red); lower right quadrant shows the merged 
image. Cells were also stained with no primary antibody and only secondary antibody as 
a negative control (not shown). 
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Hsp90β and Erdj3/Hsp40 associate with the N-terminal domain of K1. 
To gain insight into the function and topology of the interaction, we used a panel of 
FLAG-tagged K1 domain deletion constructs ((ΔC, C-terminal deletion; ΔTM, 
transmembrane deletion; ΔN, N-terminal deletion)) to determine the K1 domain that 
interacted with Hsp90β and the ER-associated Hsp40. These constructs were derived from 
the previously described FLAG-tagged pcDNA3-K1 plasmid (53). In brief, a restriction site 
was added to both ends of a domain to be deleted by QuikChange site-directed mutagenesis 
(QIAGEN). The domain deletion mutants were created by restriction digestion and re-
 
 
Figure 7. Detection of K1 and Hsp90 in PEL tumors. BC-1 tumors grown in 
xenografted mice were sectioned and stained with antibodies against K1 or Hsp90. BC-1 
tumor sections were stained with Hsp90 antibody followed by NovaDAB secondary 
antibody (brown stain; panel B) and with K1 antibody followed by NovaRed secondary 
antibody (red; panel D).  Sections that were stained with only secondary antibodies but 
no primary antibodies for either Hsp90 (Panel A) or K1 (panel C) showed no positive 
staining. The tissue sections in all four panels were counterstained with hematoxylin 
(blue). 
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ligation. Expression plasmids for the K1 deletion mutants, the FLAG-tagged wild-type K1, 
and the control pcDNA3 vector, were transiently transfected into 293 cells. Protein lysates 
were harvested 48 h post-transfection. Co-immunoprecipitations for K1 with Hsp90β and 
Hsp40 were performed as described above for Fig. 2. FLAG-tagged K1 was 
immunoprecipitated with anti-FLAG beads, followed by immunoblotting with anti-Hsp90β 
(Fig. 8A) or anti-Hsp40/Erdj3 antibody (Fig. 8C). Hsp90β and Hsp40 were detected in all of 
the samples expressing K1 except for the sample expressing the K1ΔN mutant. Additionally, 
the reverse immunoprecipitation of Hsp90β (Fig. 8B) or Hsp40 (Fig. 8D) followed by 
Western blot analysis with anti-FLAG antibody also suggested that the K1ΔN mutant protein 
does not interact with Hsp90β or Hsp40. Collectively, our data suggest that the N-terminal 
domain of K1 interacts with the Hsp90β and Hsp40/Erdj3 molecular chaperones.  
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Figure 8. K1 interacts with endogenous Hsp90β and ER-associated Hsp40 through its 
N-terminus. A. Co-immunoprecipitation of a panel of K1 constructs with endogenous 
Hsp90β. 293 cells were transfected with the empty vector or a panel of FLAG-K1 domain 
deletion mutants (ΔC: C-terminal deletion; ΔTM: transmembrane deletion; ΔN: N-
terminal deletion), or the full-length FLAG-K1. Lysates were immunoprecipitated with 
anti-FLAG resin. Immunoprecipitation reactions were subjected to SDS-PAGE and 
Western blotting with an anti-Hsp90β antibody. Input lysates showed the presence of 
Hsp90β in all cell lysates and the presence of K1 mutants in the K1 mutant transfected 
cells. B. Reverse co-immunoprecipitations were also performed. Lysates from cells 
transfected with the vector control or the K1 panel of mutants were immunoprecipitated 
with an anti-Hsp90β antibody. Immunoprecipitation reactions were subjected to Western 
blot analysis with an anti-FLAG antibody to detect K1 protein expression. Input lysates 
showed the presence of Hsp90β in all cell lysates and the presence of K1 mutants in the 
K1 mutant transfected cells. These data are representative of at least three independent 
experiments. C. & D. Identical co-immunoprecipitations were performed as indicated in 
panels A and B, respectively, except that anti-Hsp40 antibody was used instead of Hsp90β 
antibody. In panels A-D, arrows indicate the N-terminal deletion mutant of K1. 
  
80 
 
K1 protein expression is dependent on Hsp90 activity.  
As heat shock proteins are molecular chaperones that confer protein stability to their 
client proteins, we next tested whether the chaperoning activity of Hsp90 affected K1 protein 
expression. The ansamycin antibiotic, geldanamycin (GA), was used to inhibit the ATPase 
activity of Hsp90, an activity that is essential for its chaperoning function. Thus, GA prevents 
the transfer of client proteins to Hsp90. GA inhibits all isoforms of Hsp90, but not Hsp40. 
After GA treatment, client proteins of Hsp90 are degraded by the proteasomal machinery (55, 
57). We treated stable 293-K1 or 293-Vec cells with 1 µM GA, or the vehicle DMSO, for 6 h 
under serum-starving. Lysates were harvested and subjected to immunoblotting. We found 
that pharmacological inhibition of Hsp90 with 1µM GA in 293-K1 cells dramatically 
decreased K1 protein level when compared to DMSO treatment (Fig. 9A). Expectedly, the 
protein level of phosphorylated Akt (S473), a known client protein of Hsp90 (57), was also 
diminished in the presence of GA.  
We previously reported that K1 can activate and phosphorylate Akt in B and 
endothelial cells (50, 52). Here we observed the same phenomenon in epithelial cells, where 
293-K1 cells showed increased p-Akt (S473) levels compared to 293-Vec samples (Fig. 9A). 
We next tested whether K1 had any effect on the endogenous levels of Hsp90β and ER-
associated Hsp40. Western blot analysis of 293-K1 and 293-Vec cell lysates did not show an 
appreciable difference in Hsp90β and Hsp40 protein abundance, albeit the total Akt and p-
Akt (S473) levels were increased in K1-expressing 293 cells (Fig. 9B). 
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siRNA-mediated depletion of Hsp90β or ER-associated Hsp40/Erdj3 reduces K1 
protein expression.  
To confirm the results obtained with pharmacological inhibition of Hsp90, and to rule 
out any off-target effects of GA that may lead to decreased K1 protein levels, we performed 
genetic knockdown of Hsp90β or Erdj3/ER-associated Hsp40 using siRNAs. Briefly, 293-K1 
cells were transfected ) using Superfect reagent (QIAGEN) with 200pmol of pooled Stealth 
Hsp90β-targeting siRNAs (Invitrogen) or a control luciferase-targeting siRNA (siLUC) 
(Thermo Scientific). Cells were harvested 48 h post-transfection and the protein lysates were 
subjected to Western blot analysis. The Hsp90β siRNAs (siHsp90β-1 or siHsp90β-1&2) 
robustly depleted the endogenous level of Hsp90β without affecting endogenous actin levels 
(Fig. 9C). Similar to GA treatment, Hsp90β siRNA expression resulted in a reduction of K1 
protein expression compared to control luciferase siRNA (Fig. 9C). Hsp90β siRNA 
knockdown also led to reduced total Akt and p-Akt (S473) levels.  
We also tested if K1 protein level is dependent upon ER-associated Hsp40/Erdj3 
expression. Using Superfect transfection reagent (QIAGEN), 293-K1 cells were transfected 
with a pool of three different siRNAs directed against Hsp40/Erdj3 (siHsp40 in Fig. 9D) 
(Invitrogen) or the irrelevant siLUC (Thermo Scientific) for 48 h. The protein lysates were 
then subjected to immunoblotting. As shown in Fig. 9D, the pooled siHsp40 siRNAs 
effectively reduced the endogenous level of Hsp40/Erdj3 compared to the siLUC transfected 
sample, but did not alter endogenous actin levels. We found that siRNA knockdown of 
Hsp40/Erdj3 also inhibited K1 protein expression and was accompanied by a slight reduction 
of the total Akt and p-Akt (S473) levels (Fig. 9D). Taken together, these data suggest that 
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Hsp90 and Erdj3 are required for the protein stability of K1, and that K1 is a client protein of 
Hsp90 and the Hsp40/Hsp70 chaperone system.  
 
Interaction with Hsp90β and Erdj3 regulates K1 anti-apoptotic function.  
We next interrogated whether Hsp90β and Erdj3’s association with K1 can modulate 
its function. In order to examine the impact of Hsp90β or Erdj3 knockdown on K1 function, 
 
 
Figure 9. K1 protein expression is dependent on Hsp90 activity and the endogenous 
levels of Hsp90β and ER-associated Hsp40. A. Stable 293-Vec cells expressing empty 
control vector (pcDNA3) or 293-K1 cells expressing FLAG-K1 were treated with 1 µM of 
the Hsp90 inhibitor, geldanamycin (GA), or DMSO (vehicle), for 6 h in the absence of 
serum. Cell lysates were harvested and resolved by SDS-PAGE and immunoblotting. 
Western blots were probed with the indicated antibodies. Arrows indicate monomeric and 
multimeric forms of the K1 protein. B. K1 does not affect the endogenous levels of 
Hsp90β and Hsp40. Stable 293-K1 or 293-Vec cell lysates were subjected to SDS-PAGE 
and Western blot analysis using the indicated antibodies. Each panel is representative of at 
least three independent experiments. C. 293-K1 cells were subjected to siRNA targeting 
luciferase (siLUC; control), or Hsp90β (siHsp90β-1 or siHsp90β-1&2) for 48 h. Cell 
lysates were harvested and subjected to SDS-PAGE and Western blot analysis. D. 293-K1 
cells were subjected to siRNA targeting luciferase (siLUC; control) or a pool of siRNAs 
targeting ER-associated Hsp40 (siHsp40) for 48 h. Cell lysates were harvested and 
subjected to SDS-PAGE and Western blot analysis.
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we tested the ability of K1 to prevent Fas-mediated apoptosis (1, 50, 54) in the presence of 
Hsp90β and/or Erdj3 siRNAs (Invitrogen) described above. 293-K1 or 293-Vec cells were 
transfected with 200 pmol of siRNAs targeting Erdj3 and/or Hsp90β, or K1. To control for 
any undesirable effect of siRNA transfection on apoptosis, non-targeting siRNA, as well as a 
GFP-targeting siRNA were used for comparison. Thirty-six hours post-siRNA transfection, 
the cells were subjected to Fas-receptor antibody stimulation for 12 h to stimulate Fas-
receptor dependent apoptosis. Equivalent number of cells (1 x 106) were trypsinized and 
centrifuged. The pellets were lysed and subjected to a fluorescence-based assay that 
measures caspase-3 activity as a readout of apoptosis (50). Absorbance was read by the 
FLUOstar OPTIMA fluorometric plate reader with a 400-nm excitation and 505-nm emission 
filter. Caspase-3 activity in the antibody stimulated 293-K1 cells was calculated as a percent 
of the caspase-3 activity in the antibody stimulated 293-Vec control cells. Fig. 10A shows the 
percent of activated caspase-3 detected in the Fas antibody-stimulated 293-K1 cells 
compared to the stimulated 293-Vec cells with the same siRNA transfection. Overall, the 
293-K1 cells displayed a fifty percent decrease in caspase-3 activation compared to the 293-
Vec cells, after Fas-receptor stimulation. This is in concordance with what we and others 
have previously reported (1, 50, 54). Transfection of either Hsp90β siRNA, Hsp40/Erdj3 
siRNA, GFP siRNA, or non-targeting siRNA into the 293-K1 cells, followed by anti-Fas-
receptor antibody stimulation, yielded similar levels of caspase-3 activity in these cells (Fig. 
10A) indicating that single knockdown of either the Hsp90β or Hsp40 chaperone did not alter 
K1’s ability to prevent Fas-mediated apoptosis. However, when both Hsp90β siRNAs and 
Hsp40/Erdj3 siRNAs were co-transfected into 293-K1 and 293-Vec cells, the 293-K1 cells 
now displayed similar levels of caspase-3 activity as the 293-Vec cells (Fig. 10A), suggesting 
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that both Hsp90β and Erdj3 are required for K1 to exert its anti-apoptotic function, and that 
knockdown of both chaperones increases the sensitivity of K1-expressing cells to Fas-
mediated apoptosis.  
In order to look at the role of Hsp90β and Hsp40/Erdj3 on K1’s ability to prevent cell 
death, we repeated the experiment with Fas antibody stimulation but extended the incubation 
time with the antibody to 18 h (instead of 12 h) to analyze cell death of 293-K1 versus 293-
Vec cells transfected with the indicated siRNAs (Fig .10B). Cells were stained with trypan 
blue and the numbers of viable and dead cells were counted under microscopy in four 
different fields. Cell death in the Fas antibody stimulated 293-K1 cells was calculated as a 
percentage of cell death seen in 293-Vec cells stimulated with the same antibody. Overall, 
the trend in Fig. 10B recapitulates that in Fig. 10A. As a control, a Western blot of K1 
expression in 293-K1 cells transfected with siLUC versus K1 siRNA is depicted in Fig. 10C 
to show effective knockdown of K1 protein levels in the K1 siRNA transfected cells. 
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Figure 10. K1 anti-apoptotic function is dependent on the endogenous levels of Hsp90β 
and ER-associated Hsp40. A. 293-K1 and 293-Vec stable cells were transfected with the 
indicated panel of siRNAs. At 36 h post-transfection, anti-Fas antibody was added for 12 h 
to simulate Fas-receptor-dependent apoptosis. Cells were harvested and subjected to a 
fluorescence-based caspase-3 assay. Caspase-3 activity was measured using the caspase-3 
fluorescent substrate, DEVD-AMC. Percent caspase-3 activity in 293-K1 cells compared to 
293-Vec cells is plotted on the y-axis, and the siRNA transfected samples are depicted on 
the x-axis. Error bars represent standard deviations from the mean. The graphs are 
representative of three independent experiments. B. The experimental setup was identical to 
that in panel A, except Fas-antibody induction time was increased to 18 h. Cells were then 
stained with Trypan blue and counted using a hemocytometer. Each sample was performed 
in quadruplicate.  Cell death in 293-K1 cells was plotted as a percentage of cell death in 
293-Vec cells. Error bars represent standard deviations from the mean. C. 293-K1 cells 
were transfected with K1 siRNA or control siLUC for 48 h. Protein lysates were subjected 
to SDS-PAGE and Western blot analysis using an anti-FLAG or actin antibody.  
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Hsp90 inhibitors decrease the proliferation of KSHV-positive PEL-derived B cell lines 
in vitro.  
Because Hsp90 and the ER-associated Hsp40 regulate the protein expression and 
anti-apoptotic function of K1, we wanted to determine if Hsp90 inhibitors can block 
proliferation of KSHV-positive PEL cells. PEL cells have previously been shown to express 
K1 transcripts and protein at low levels (4, 25). We treated PEL cells with DMSO (vehicle 
control) or 50 nM of the GA-derived Hsp90 inhibitors, 17-AAG and 17-DMAG, that are 
currently in clinical trials (14, 17) for 0, 24, 48, 72, and 96 hours. We found that both 
inhibitors suppressed the growth of KSHV-harboring PEL cell lines, BCP-1, BCBL-1, and 
JSC-1, in a MTS-based cell proliferation assay (Fig. 11A). We also determined the half-
maximal inhibitory concentration (IC50) of 17-AAG and 17-DMAG in BCP-1, BCBL-1, and 
JSC-1 cell lines 72 h post-treatment. The IC50 of 17-AAG and 17-DMAG were ~50 nM and 
~10 nM, respectively, in all three cell lines (Fig. 11B and 11C). These IC50 values are 
consistent with other tumor cell lines that are dependent on Hsp90 (15). Hence, 17-AAG and 
17-DMAG can effectively inhibit KSHV-infected primary effusion lymphoma cell lines in 
vitro. We also investigated the effects of 17-DMAG on 293-K1 cells compared to 293-Vec 
cells.  1x106 293-K1 and 293-Vec cells were incubated with 100 nM of 17-DMAG and a 
Trypan blue exclusion assay was performed at 24, 48 and 72 hours post-treatment. We found 
that at all three time points tested, there were more live cells present in the 293-K1 cells 
compared to the 293-Vec cells. This suggests that K1 confers a survival advantage to 293 
cells upon Hsp90 inhibition (Fig. 12) and that higher concentrations of drug are required to 
inhibit K1-expressing 293 cells compared to 293 cells that do not express the K1 protein.  
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Figure 11. The Hsp90 inhibitors, 17-AAG and 17-DMAG, inhibit the proliferation 
of KSHV-positive PEL cell lines. A. BCP-1, JSC-1, and BCBL-1 were incubated with 
50 nM of 17-AAG or 17-DMAG and subjected to a MTS assay over a period of four 
days. The absorbance at 490 nm in the presence of 50 nM of 17-AAG or 17-DMAG, or 
equivalent volume of vehicle control (DMSO) is shown on the vertical axis, and time in 
days after addition of the drugs is shown on the horizontal axis. Error bars represent 
standard deviation from the mean. B. IC50 values of 17-AAG on BCP-1, JSC-1, and 
BCBL-1 were determined after 72 h incubation with 17-AAG. A range of concentrations 
of 17-AAG was used: 0, 1, 10, 100, 1000, or 10000 nM. A nonlinear fit, sigmoidal curve 
was generated by plotting percent growth inhibition against the log concentration of 17-
AAG. Error bars represent SEM. C. IC50 values of 17-DMAG on BCP-1, JSC-1, and 
BCBL-1 were determined by MTS assays after 72 h incubation with 17-DMAG. 
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To address whether the decrease in proliferation of 50 nM 17-AAG and 17-DMAG is 
due to the induction of cell death, we treated the same three PEL lines above with 50 nM or 
500 nM of each inhibitor, or DMSO, for 0, 24, 48, 72, and 96 h and assessed cell viability by 
a Trypan blue exclusion assay. We found that 500 nM of 17-AAG and 17-DMAG induced an 
increase in cell death of PEL cells over time (Fig. 13A). In agreement with this observation, 
we have found that the LC50 values of 17-AAG and 17-DMAG in BCP-1 are 464.4 nM and 
523.5 nM, respectively (Fig. 13B & 13C) at 72 hours post-treatment. We also confirmed that 
similar to GA treatment (Fig. 9A), treatment of 293-K1 cells with 500 nM of 17-DMAG 
inhibited K1 protein expression compared to 293-K1 cells treated with vehicle (DMSO) (Fig. 
13D).  
 
 
Figure 12. 293-Vec cells are more sensitive to Hsp90 inhibition than 293-K1 cells. 
293-K1 or 293-Vec cells were incubated with 17-DMAG for the indicated time-points. 
Cells were trypsinized, stained with Trypan blue and counted using a hematocytometer. 
The percentage of lives cells was plotted on the y-axis and the incubation time-points are 
depicted on the x-axis. Error bars represent standard deviations from the mean. 
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Figure 13. The Hsp90 inhibitors, 17-AAG and 17-DMAG, induce cell death of 
KSHV-positive PEL cell lines. A. BCP-1, JSC-1, and BCBL-1 were incubated with 500 
nM of 17-AAG, 17-DMAG, or the equivalent volume of DMSO, and subjected to a 
Trypan blue exclusion assay over a period of four days. The cells were stained with 
Trypan blue and counted at the indicated timepoints. Live cells were plotted as a 
percentage of total cells on the y-axis and the time periods of incubation with 17-AAG or 
17-DMAG is depicted on the x-axis. Error bars represent standard deviation from the 
mean. B. LC50 value of 17-AAG on BCP-1was determined after 72 h incubation with 17-
AAG. A range of concentrations of 17-AAG was used: 0, 1, 10, 100, 1000, or 10000 nM. 
A nonlinear fit, sigmoidal curve was generated by plotting percent growth inhibition 
against the log concentration of 17-AAG. Error bars represent SEM. C. LC50 value of 17-
DMAG on BCP-1 was determined in the same manner as in panel B, except that 17-
DMAG was used instead of 17-AAG. D. 293-K1 cells were treated with 500 nM of 17-
DMAG or DMSO vehicle for 72 h. Protein lysates were subjected to SDS-PAGE and 
Western blot analysis using an anti-FLAG antibody to detect K1 protein levels. An anti-
tubulin blot is shown as a control. 
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 On the basis of the inhibitory effect of 17-AAG/17-DMAG on PEL cell proliferation, 
we speculated that both Hsp90 inhibitors may alter the cell cycle of PEL. We performed cell 
cycle analysis to address this possibility. JSC-1 and BCBL-1 were treated with 50 nM 17-
AAG and 17-DMAG for 48 h, and then subjected to propidium staining and flow cytometry. 
Both PEL cell lines displayed significant G0/G1 arrest and suppressed DNA synthesis upon 
Hsp90 inhibition (Fig. 14). 17-DMAG was a stronger inhibitor of the cell cycle than 17-AAG 
(Fig. 14). Thus, the cell cycle arrest phenotype seen in the presence of 17-AAG and 17-
DMAG corroborates the inhibition of cell proliferation we observed in the MTS assay for the 
different PEL cell lines (Fig. 11). 
 
 
Figure 14. 17-AAG and 17-DMAG induce G0/G1 arrest of KSHV-positive PEL cell 
lines. 1 x 106 live JSC-1 (A-C) and BCBL-1 (D-F) were incubated with 50 nM of 17-
AAG (B & E), 17-DMAG, (C & F) or equivalent volume of DMSO (A & D) for 48 h. 
The cells were washed with 1X PBS, fixed in 70% ethanol, and stained with propidium 
iodide and subjected to cell cycle analysis using flow cytometry. The percentages of cells 
at different stages in the cell cycle (G0/G1, S, G2/M) are shown. 
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DISCUSSION 
KSHV K1 is a viral oncoprotein that has been shown to transform cells, induce tumor 
formation (9, 40), as well as inhibit apoptosis (1, 50, 54). Furthermore, the K1 protein 
activates the PI3K/Akt signaling pathway in endothelial cells and B cells (50, 52). Despite 
the known signal transduction pathway and functions of K1, relatively little is known about 
how K1 protein expression and function are modulated. Using tandem affinity purification, 
we identified Hsp90β and the ER-associated Hsp40/Erdj3 protein as cellular partners of K1. 
This was corroborated by co-immunoprecipitations that confirmed these protein-protein 
interactions. Importantly, we have shown that K1’s interaction with Hsp90β (but not 
Hsp40/Erdj3) is dependent on the presence of ATP. We also found that K1 can interact with 
the Hsp90α isoform. The K1-Hsp90 interaction is relevant, as both Hsp90 and K1 have 
individually been shown to modulate the phosphorylation or function of several important 
signaling molecules such as VEGF receptor (23, 52, 53), Akt (19, 50, 52), Lyn (39, 40, 51, 
56), PDK1 (30, 52), BCR (24, 44, 49), and mTOR (33, 52).  
In KSHV, as well as other herpesviruses, Hsp90 also regulates subcellular trafficking 
and function of viral proteins (5, 11, 16). A novel finding of this report is that K1 appears to 
be a viral client protein of Hsp90 and the ER-associated Hsp40/Hsp70 system. This is 
particularly intriguing as it suggests that the protein expression of the K1 viral oncogene can 
be manipulated with existing Hsp90 inhibitors as well as siRNA/small hairpin RNA targeting 
against Hsp90 and/or Hsp40/Erdj3 chaperones. In addition, we have shown that K1 interacts 
and colocalizes with Hsp90 and Hsp40/Erdj3 in B cells. K1 and Hsp90 expression can also 
be detected in PEL tumors. Thus, our data validate Hsp90 as an important therapeutic target 
for treating KSHV-associated lymphomas. 
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Using the Hsp90 inhibitor GA, we showed that Hsp90 ATPase activity and 
chaperoning function are required for optimal expression of K1. GA inhibits all the known 
Hsp90 homologs, including cytosolic/extracellular Hsp90α and Hsp90β, as well as 
Grp94/Gp96 (ER-associated Hsp90), and Trap1 (mitochondria-associated Hsp90). Thus, it is 
possible that Hsp90 homologs other than Hsp90α and Hsp90β may also associate with K1 
and modulate its expression and function. Similar to GA treatment, genetic knockdown of 
either Hsp90β or Hsp40/Erdj3 using siRNA also dramatically reduced K1 protein expression. 
We found that depletion of both endogenous Hsp90β and ER-associated Hsp40 
negated the ability of K1 to prevent Fas-mediated apoptosis. However, depletion of only 
Hsp90β or Hsp40 by itself had no effect. One explanation is that knockdown of both Hsp90β 
and Hsp40 reduced K1 expression levels more robustly than single knockdowns of these 
proteins. A second possibility is that there are two different pools of K1 whose expression 
and/or function are regulated by Hsp90β and Hsp40. K1 has been shown to be expressed on 
the plasma membrane as well as in the ER (24). Since Hsp90β is predominantly cytosolic 
and Hsp40/Erdj3 is ER-associated, one may speculate that these different pools of K1 are 
topologically distinct. Hence, knockdown of the ER-restricted chaperone may reduce K1 
levels in the ER, but not affect cytosolic or cell surface levels of K1, and vice versa. Thus, 
single knockdowns of either Hsp90β or Hsp40/Erdj3 may not have reduced K1 protein levels 
in all cellular compartments to the same extent as double knockdowns of both these 
chaperones.  
Our finding that the N-terminal domain of K1 interacts with Hsp90β and Hsp40 also 
added an extra layer of complexity to the interaction. Besides being cytosolic, Hsp90α (10, 
29) and Hsp90β (45) have been found on the cell surface i.e. extracellularly. Thus, the N-
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terminal domain of K1 may co-internalize with extracellular Hsp90. Since K1 internalization 
has been linked to its signaling function (49), Hsp90 likely plays a role in chaperoning K1 as 
it is endocytosed. Additionally, since the N-terminal domain of K1 interacts with Hsp90β, it 
is also possible that Hsp90β interacts with the K1 N-terminus during de novo biogenesis of 
K1 protein when the growing peptide is transiting from the cytoplasm to the ER. Indeed, 
Hsp90β has been shown to be involved in the protein translation of the BCR (44). 
Furthermore, since the ER-associated Hsp40/Erdj3 functions as a co-chaperone with 
Hsp70/BiP for unfolded/nascent proteins, including the unassembled immunoglobulin heavy 
chain (43), Hsp40/Erdj3 may also participate in the folding of newly synthesized/unfolded or 
misfolded K1 within the ER.  
Our data show that Hsp90 inhibition by 17-AAG and 17-DMAG at low 
concentrations results in decreased cell proliferation and G0/G1 arrest, albeit at higher 
concentrations, 17-AAG and 17-DMAG can also induce cell death of KSHV-positive PEL 
cells. A potential mechanism for these observations is that Hsp90 inhibition leads to a 
decrease in K1 protein expression, and this has a two pronged effect on the PI3K/Akt/mTOR 
pathway. This is because Hsp90 inhibition suppresses activation of the PI3K/Akt/mTOR 
pathway that is normally activated by the K1 viral oncoprotein, and indirectly by Hsp90 
through stabilization of and maintenance of Akt kinase activity. Because PI3K, Akt, and 
mTOR are cell survival kinases, inhibition of Hsp90 destabilizes K1 protein and suppresses 
its ability to enhance PEL cell proliferation and cell survival through this pathway. This 
model would predict that Hsp90 inhibition would lead to decreased proliferation of cells that 
do not express K1 compared to proliferation of cells that do express K1. Indeed, we observed 
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that more 293-K1 cells survived in the presence of Hsp90 inhibitor compared to 293-Vec 
cells (Fig. 12).  
We also speculate that there are several other KSHV proteins that utilize molecular 
chaperones to modulate their expression and function. Field et al. previously reported that the 
KSHV latent viral FLICE inhibitory protein (vFLIP) requires Hsp90 to complex with IκB 
kinase (IKK) and activate the NF-κB pathway (11). Here we report that both Hsp90 and 
Hsp40 chaperones were needed for K1 protein expression and its anti-apoptotic function. 
Taken together, our studies provide additional rationale for using Hsp90 inhibitors to treat 
PEL and other KSHV-related malignancies. 
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ABSTRACT 
 Rhesus monkey rhadinovirus (RRV) serves as an in vitro and an in vivo model for 
Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8). At the far left end of the RRV 
genome is a distinct open-reading frame (ORF) designated R1 whose position is 
equivalent to that of the saimiri transforming protein (STP) of herpesvirus saimiri (HVS) 
and the K1 protein of KSHV. Similar to K1, the R1 cytoplasmic tail contains motifs 
capable of binding to the SH2 domains of protein kinases, and R1 has previously been 
shown to be capable of activating B lymphocyte signaling and interacting with the major 
B cell kinase, Syk. We disrupted the R1 ORF in the RRV genome by inserting a green 
fluorescence protein (GFP) expression cassette. We compared the replication kinetics of 
the wild-type virus, a R1-deleted recombinant virus, and a revertant virus by plaque 
assays and real-time QPCR-based genome quantification assays. We found that deletion 
of R1 from the RRV genome did not affect viral replication on rhesus fibroblasts. We 
also examined the ability of the R1-deleted recombinant virus to establish latency in B 
cells. We found that the R1-deleted recombinant virus was able to establish latency in B 
cells more efficiently than the wild-type virus and that the R1-deletion mutant underwent 
less spontaneous reactivation from infected B cells than wild-type RRV.  
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INTRODUCTION 
Kaposi sarcoma-associated herpesvirus (KSHV) is associated with Kaposi 
sarcoma (KS), primary effusion lymphoma (PEL), and the plasmablastic variant of 
multicentric Castleman disease (MCD) (5, 7, 33). Rhesus monkey rhadinovirus (RRV) is 
a close simian relative of KSHV and was isolated from rhesus macaques at the New 
England Primate Research Center (NEPRC), from RRV strain H26-95 (12). An 
additional RRV isolate, termed RRV 17577, was identified by the Oregon Regional 
Primate Research Center (ORPRC) (32). Analysis of the KSHV and RRV genomic 
sequences revealed that they are highly homologous and co-linear, with the majority of 
the open-reading frames (ORFs) in the same genomic locations and orientation. All RRV 
genes have homologs in KSHV (1, 32).  
RRV serves as both an in vitro and in vivo model for KSHV. Studies of many of 
the RRV ORFs have shown that they function similarly to their KSHV homologs. The 
availability of a genetic system to make recombinant viruses and the ability of RRV to 
replicate lytically on rhesus fibroblasts (RhF) and establish latency in B cells enables one 
to dissect the contribution of individual ORFs to the viral lifecycle. Additionally, the 
availability of rhesus macaques as an animal model makes RRV an attractive system to 
study KSHV pathogenesis. Experimental infection of rhesus macaques with RRV results 
in a lymphadenopathy similar to MCD (27) as well as non-Hodgkin lymphoma (28). In 
the context of a dual infection with simian immunodeficiency virus (SIV), the animals 
developed lymphoproliferative disorders and B-cell hyperplasia (39). Mansfield et al. 
reported that RRV also caused an arteriopathy in SIV-infected macaques (27).  
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The first open-reading frame (ORF) of KSHV encodes the K1 transforming 
protein (18). K1 is expressed at low levels during latency and is upregulated during lytic 
infection where it demonstrates early kinetics (6, 9, 21, 22, 31). K1 contains an 
immunoreceptor tyrosine-based activation motif (ITAM), which is comprised of two 
appropriately spaced Src Homology 2 (SH2) binding motifs (24, 26). K1 can interact 
with multiple SH2 domain-containing cellular proteins, including Lyn, Syk, p85 subunit 
of PI3K, PLC2, RasGAP, Vav and Grb2 (40). In B cells, K1 can activate PI3K (p85 
subunit), Akt, Vav, and Syk kinases, and induce NFAT and NF-κB transcriptional 
activities for cell survival and protection from Fas-mediated apoptosis (3, 24, 26, 30, 34). 
K1 co-internalizes with the BCR (2) and inhibits intracellular BCR transport via ER 
sequestration resulting in the downregulation of BCR surface expression. Recently, K1 
has been shown to interact with the molecular chaperones Hsp90 and ER-associated 
Hsp40 in B cells as well as epithelial cells (36). 
The first ORF of RRV encodes for R1, a homolog of KSHV K1 (10). Similar to 
K1, R1 can transform rodent fibroblasts and functionally substitute for the saimiri 
transforming protein (STP) of herpesvirus saimiri (HVS) to immortalize common 
marmoset peripheral blood mononuclear cells to IL-2-independent growth in vitro (11). 
When R1-expressing rodent fibroblasts were injected into nude mice, these mice 
developed multifocal and disseminated tumors (11). The C-terminal cytoplasmic tail of 
R1 is significantly longer than that of K1 but similar to K1, contains several putative SH2 
binding motifs and an ITAM (8). Like K1, R1 is capable of activating B lymphocyte 
signal transduction as evidenced by tyrosine phosphorylation of cellular proteins, calcium 
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mobilization from intracellular storage, and activation of the transcription factor NFAT 
(8). 
 In Chapter Four, we will demonstrate and discuss the conventional virology 
technique of homologous recombination in mammalian cells to perform reverse genetics. 
This approach enabled us to disrupt the LANA ORF in order to study its replicative 
properties in RRV and explore its vaccine potential against gammaherpesviral infection 
and persistence. In this chapter, we utilized a relatively less laborious approach to 
genetically manipulating RRV. When performing homologous recombination, one needs 
to isolate the recombinant virus away from the “contaminating” wild-type or parental 
virus. Here we introduce the overlapping cosmid system to functionally disrupt the R1 
ORF. This system was generated by Bilello et al. (4). In brief, overlapping cosmid clones 
were engineered to encompass the entire genome of RRV H26-95 (~130 kb), including 
the terminal repeat (TR) regions that are necessary for viral replication. Importantly, 
RRV particles resulting from co-transfection of these overlapping cosmids spanning the 
entire RRV H26-95 genome replicated with similar kinetics and titers to the parental, 
genetically unaltered RRV H26-95 (4). When developing the cosmid set Bilello et al. 
found that the RRV cosmids were too large (>46 kb including terminal repeat regions) for 
routine genetic manipulation. To that end, they generated a sub-cosmid clone by 
truncation of the existing ah28 cosmid, allowing for insertion of a reporter gene upstream 
of the R1 promoter.  
We used the same overlapping cosmid system (4) to disrupt the R1 ORF. Using 
this system, we genetically inserted a GFP expression cassette in the beginning of the R1 
ORF to create a R1 deletion virus named RRVR1/GFPcc. We also generated a rescue 
107 
virus designated Revertant, and compared the replicative properties of recombinant 
RRVR1/GFPcc and Revertant with the wild-type viruses, RRV-J and RRV-GFPcc, in 
rhesus fibroblasts (RhF) at twodifferent multiplicities of infection (MOI) (1 and 5) using 
traditional plaque assays as well as real-time PCR-based genome quantification assays. 
All four viruses exhibited similar replication kinetics during de novo infection of rhesus 
fibroblasts. However, we found that RRVR1/GFPcc established latency more efficiently 
than the wild-type virus RRV-GFPcc in B cells. RRVR1/GFPcc also exhibited less 
spontaneous reactivation compared to RRV-GFPcc.  
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MATERIALS AND METHODS 
Cell culture 
Immortalized RhF have been previously described (14). RhF, 293, and 293T cells 
were maintained at 37°C and 5% CO2 in Dulbecco’s modified eagle medium (DMEM) H 
plus Gluta-max supplemented with 10% fetal bovine serum (FBS). BJAB cells were 
maintained in RPMI 1640 supplemented with 10% FBS.  
 
RRV infection of RhF and BJAB B cells 
Approximately 3 × 105 RhF were infected with 1 ml of diluted viral stock in 
DMEM supplemented with 2% FBS as previously described (37). After two hours of 
incubation, the virus inoculum was aspirated and the cells were cultured in 1.5 ml of 
DMEM supplemented with 2% FBS. 2 × 105 BJAB cells were spinoculated in flat-
bottom 12-well plates with 1.5 ml of diluted viral stock in complete RPMI medium in the 
presence of 4 µg/ml of polybrene as previously described (37, 38). The cells were washed 
once with complete RPMI medium and then allowed to grow and expand in complete 
RPMI medium.  
Plaque assays and quantitative real-time PCR were performed as previously 
described (37). 
 
Cosmid system and generation of recombinant viruses 
Construction of the RRV H26-95 cosmid library has been previously described 
(4). To generate the recombinant RRVR1/GFPcc virus, a portion of the R1 ORF was 
amplified from the ah28A/H cosmid with primers 5’-
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CAGCTGGGATCCACTAGTAGTAACACATAGT ATTTC-3’ and 5'-
CAGCTGGAATTCATTTAAATGATTGTACTCATTGTG-3'. The amplicon was 
restriction digested with BamHI and EcoRI and then ligated into pSP72 vector at the 
same sites (R1-RRV pSP72). Site-directed mutagenesis was performed to create a new 
SmaI site in the R1 ORF using primers 5'-CACCACATCCCGGGGATACCTACTTGC-
3' and 5'-GCAAGTAGGTATCCCCGGGATGTGGTG-3' by QuikChange site-directed 
mutagenesis kit (Stratagene) as directed bythe manufacturer. Mutation was verified by 
DNA sequencing (R1-SpeI-SmaI pSP72). An EGFP expression cassette was inserted into 
the newly generated SmaI site by amplifying the CMV promoter, EGFP and polyA region 
from EGFP-N1 vector (Clontech) using primers 5'-
GGATATCGTAATCAATTACGGGGTCAT-3' and 5'-
TGGATATCACCACAACTAGAATGCAGTG-3' (R1/GFP pSP72). R1/GFP pSP72 
was then digested with SpeI and SwaI and ligated into the same sites in cosmid 
ah28A/H to generate ah28A/H-R1-GFP.  
For construction of the recombinant virus RRVR1/GFPcc, cosmids were 
digested overnight with the I-CeuI homing endonuclease in order to remove the RRV 
H26-95 sequence from the pSuperCos-1 backbone vector. 293T cells (4.5 x 105 cells/well 
in six-well plates) were transfected with a combination of digested overlapping cosmids 
(ah28A/H-R1-GFP, #15A, #1, #37, and ah34) (0.4 g of each cosmid) using 
Transfectin reagent (Bio-Rad Laboratories, Hercules, CA) (Fig. 1). Five days post-
transfection, medium was harvested and centrifuged at 2, 000 rpm for 10 minutes to 
remove debris. The supernatants from the three identical cosmid transfection reactions 
were combined and stored at 4oC.  
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To amplify recombinant virus stocks generated in 293T cells, RhF were split and 
24 hours later were inoculated with the entire culture supernatant from the transfected 
293T cells. Seven days later, the infected cells were split 1:3 and monitored daily for the 
appearance of GFP-positive viral plaques. Cultures were maintained for 2 weeks before 
clarified culture medium was harvested. Fresh RhF were inoculated with supernatant 
from the first passage described above, and maintained without splitting until complete 
lysis of the RhF monolayer. 
To generate a marker rescue virus, cosmid ah28A/H was digested overnight with 
I-CeuI. Approximately 0.5g DNA was nucleofected into RhF using the Amaxa 
Nucleofection system as described by the manufacturer (program U-23). Following 
transfection, cells were allowed to recover in complete medium for 24 h. 
RRVR1/GFPcc recombinant virus was used to infect the transfected RhF at an MOI > 
1. Upon complete CPE, clarified supernatants were harvested and used to infect fresh 
RhF monolayers. GFP-negative virus was subjected to at least three rounds of plaque-
purification. Seventeen different supernatants were harvested and viral DNA purified 
using DNeasy kit (QIAGEN, Valencia, CA). 
 Construction of RRV-GFPcc and RRV-J recombinant viruses has been previously 
described (4). 
 
Analysis of viral integrity 
Virus was harvested from virus-infected RhF by centrifugation at 17, 000 rpm for 
3 h. The virus pellet was resuspended in PBS, treated with sarkosyl and subsequently 
with proteinase K at 60°C for 1 h. Viral DNA was extracted by phenol-chloroform 
111 
method. Viral DNA was subjected to diagnostic PCR analysis with the following 
primers: R1 flanking primers: 5'-CCGTTGTGGTTACAATACACCTG-3' and 5'-
TGAACCACCGCACGG AGC-3'; R1 internal primers: 5'-
GGGGGTACCCTTCAACCTGTATCGGTGGAGC-3' and 5'-
TTGATGATTCAGAGTTCTCGTTGC-3'; GFP internal primers: 5'-CCTGG 
TCGAGCTGGACGG-3' and 5'-GATCGCGCTTCTCGTTGGG-3'. 
For Southern blot analysis, viral DNA was digested with NotI. Digestions were 
electrophoresed through 1% low-melt agarose (NuSieve) in 1X TBE and then transferred 
to a nylon membrane (Hybond N+) by capillary action. Following UV cross-linking, 
membranes were pre-hybridized in QuikHyb solution (Stratagene) at 65°C for 15 min. 
Probes were generated from RRV-DHFR and GFP by random prime method using 32P-
dCTP (Roche). Probes were denatured at 95°C for 3 min and added to pre-hybridization 
solution. Hybridization was carried out for 16 h at 65°C. Probe solution was removed and 
membranes were washed twice for 15 min with 2X SSC 0.1% SDS at room temperature 
and once for 30 min at 60°C with 0.1X SSC 0.1% SDS. Membranes were exposed and 
signals detected on a Phosphor Imager Scanner (Molecular Dynamics).  
 
Plaque assays 
2x105 RhF were plated in 12-well plates. Ten-fold serial dilutions of virus-
infected cell supernates were made in DMEM-H supplemented with 2% FBS. Each 
sample dilution was performed in triplicate. Two hundred microliters of each dilution 
were overlaid on each well of 12-well dishes and incubated at 37°C for 1 h with 
redistribution of inoculum every 15 min. Inoculum was removed and cells were overlaid 
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with 1.5 ml of DMEM with 1.5% methyl cellulose (Sigma M0512), and 2% FBS. Plaque 
assays were incubated 10 days at 37°C and 5% CO2. Overlaying medium was aspirated 
and staining solution (0.8% crystal violet (Sigma C3886), 50% ethanol) was added to 
each well for 1 h. Plaques were counted under 10X magnification. 
 
Quantitative real-time PCR 
For each sample, 10 μg of salmon sperm carrier DNA was added to 200 μl of 
clarified supernate from infected cells and was processed through the DNeasy Kit 
(QIAGEN, Valencia, CA) as per the manufacturer’s protocol. To quantify viral DNA, 
SYBR® Green Real-time PCR in 384-well format was performed using the ABI 
PRISM® 7900 Sequence Detection System (Applied Biosystems Inc., Foster City, CA). 
To generate a standard curve for cycle thresholds versus genomic copy numbers, the 
plasmid containing RRV Orf50, rhesus -tubulin, or human GAPDH was serially diluted 
to known concentrations in the range of 101 to 106 plasmid molecules/μl. Each PCR 
mixture (15 μl) contained 4 μl of viral or standard DNA, 1 μl of Orf50, rhesus -tubulin, 
or human GAPDH primer set (final working concentration at 3.33 μM), 7.5 μl of SYBR 
Green 2X PCR mix (Applied Biosystems), and 2.5 μl of DNase- and RNase- free water 
(Sigma) in a total volume of 15 μl. Primers for amplification of an 81-bp amplicon 
internal to the RRV Orf50 sequence were 5′-GTGGAAAGCGGTGTCACAGA-3′ and 5′-
TGCGGCGGCCAAAAT-3′. Primers for amplification of an 61-bp amplicon internal to 
the rhesus -tubulin sequence were 5’-CCCTTCCCACGCCTCC-3’ and 5’-
GGCTTCCACGGCTGGTG-3’. Primers for amplifying human GAPDH were 5’-GAA 
GGT GAA GGT CGG AGT-3’ and 5’-GAA GAT GGT GAT GGG ATT TC-3’. PCR 
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conditions were as follows: 95°C for 15 min, followed by 95°C for 15 sec, 60°C for 1 
min repeated for 40 cycles.  
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RESULTS 
Construction of RRVR1/GFPcc recombinant virus. 
In order to examine the role of R1 in the lifecycle of RRV, we disrupted the R1 
ORF from the RRV H26-95 genome using a cosmid-derived genetic system (4). Using 
cosmid ah28A/H, a GFP expression cassette driven under a CMV promoter was 
inserted into the R1 ORF at a newly generated SmaI site, located approximately 100 bp 
downstream from the R1 start site, to interrupt the R1 ORF (Fig. 1A). This new cosmid, 
designated ah28A/H-R1-GFP, was co-transfected with cosmids #15A, #1, #37, and 
ah34 (Fig. 1B) into 293T cells and amplified in RhF as described in the methods section. 
 
Construction of a revertant virus of RRVR1/GFPcc. 
 A revertant virus was made as a control for the inadvertent introduction of any 
mutations during the construction or isolation of RRVR1/GFPcc. The cosmid 
ah28A/H was linearized with I-CeuI homing endonuclease overnight and precipitated as 
described above and transfected into RhF. Twenty-four hours post-transfection, RhF were 
infected with RRVR1/GFPcc. Virus progeny were screened for GFP-negative isolates. 
In our diagnostic PCR analysis, two revertant viruses, designated rRRV-2.3.1 and rRRV-
4.1.1, appeared to be identical to H26-95 (Fig. 2B). The isolate rRRV-2.3.1 (designated 
“Revertant” from here on) was further analyzed by restriction digest and Southern blot 
and was included in our subsequent viral replication assays. 
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Figure 1. Construction of RRVR1/GFPcc. A) A schematic representation of the 
cosmids (ah28A/H-R1/GFP , #15A, #1, #37, and ah34) used to make 
RRVR1/GFPcc. The black bars indicate the extent and location of each cosmid 
insert relative to the parental RRV H26-95 genome (top white bar). Each cosmid 
insert was cloned into the pSuperCos 1 vector following the addition of an I-CeuI 
homing endonuclease linker. TR denotes terminal repeats. The numbers on 
demarcated lines specify the approximate genome positions in Kb. B) Insertion of 
GFP expression cassettes into the RRV ah28A/H cosmid. A SmaI site was 
introduced in the N-terminus of the R1 ORF within the ah28A/H cosmid by site-
directed mutagenesis. A 1619-bp EGFP expression cassette driven by a CMV 
promoter was inserted into the new SmaI site of R1 within cosmid ah28A/H to 
disrupt the R1 ORF to generate ah28A/H-R1/GFP. TR denotes terminal repeats. 
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Analysis of the genomic integrity of the RRVR1/GFPcc and revertant viruses.  
Viral DNA purified from RRVR1/GFPcc and wild-type H26-95 were subject to 
PCR analysis to ensure proper insertion of the GFP cassette. Primers were designed to 
amplify regions within the GFP ORF, within the R1 ORF, or flanking the R1 ORF. The 
ah28A/H-R1-GFP cosmid and the ah28A/H parental cosmid were used as positive 
and negative controls for GFP insertion, respectively. In Figure 2, lanes 2 and 6 show 
amplification of the GFP region with a band of 517 bp, when RRVR1/GFPcc and 
ah28A/H-R1-GFP were used as templates, respectively. The R1 internal primers 
amplified a band of 2322 bp for RRVR1/GFPcc or ah28A/H-R1-GFP (lanes 2 and 
6), and a band of 712 bp for RRV H26-95, the two revertant viruses, Revertant (rRRV-
2.3.1) and rRRV-4.1.1, and the ah28A/H cosmid (lanes 3-7). R1 flanking primers 
amplified a band of 3415 bp for RRVR1/GFPcc or ah28A/H- R1-GFP and a band of 
1786 bp for RRV H26-95, Revertant (rRRV-2.3.1), rRRV-4.1.1, and ah28A/H cosmid 
(lanes 3-7). 
 Following PCR analysis, viral genomic DNA of RRVR1/GFPcc, RRV H26-95, 
or the revertant virus was subjected to restriction digest. 10 g of each viral genomic 
DNA was digested with NotI (Fig. 3A and 3B) at 37oC for 3 h. Digested DNA was 
separated by electrophoresis and stained with ethidium bromide. Restriction digestion of 
RRVR1/GFPcc DNA with NotI resulted in two bands of altered mobility (6498 bp and 
2003 bp), as compared to the wild-type RRV H26-95, due to the NotI site contained in 
the 3’ end of the inserted GFP ORF (Fig. 3A and 3B). RRV H26-95 has no such site. 
Restriction digest of RRV H26-95 with NotI resulted in an expected band of 7757 bp.  
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 To verify that R1 was disrupted by the GFP cassette insertion into the R1 ORF 
and the rescue virus (Revertant) had the same genetic arrangement as the parental virus 
RRV H26-95, we performed Southern blot analysis. Viral genomic DNA of 
RRVR1/GFPcc, RRV H26-95, or Revertant was digested with NotI restriction enzyme, 
resolved on 1% agarose by electrophoresis, and then transferred to a nylon membrane 
(Fig. 3A and 3B). Probe A, a fragment complementary to the RRV DHFR ORF, was 
generated. As expected the DHFR probe hybridized to the 6498 bp fragment of 
RRVR1/GFPcc and to the 7757 bp fragment of RRV H26-95 or Revertant. Probe B is 
complimentary to the GFP ORF. Figure 3B depicts the Southern blot performed on the 
samples using Probe B and shows that the GFP cassette was inserted into the 
RRVR1/GFPcc recombinant virus in the correct site and, as expected, was absent in 
RRV H26-95 or the revertant virus genome.  
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Figure 2. PCR analysis of recombinant viruses. A) A schematic representation of 
the location of priming sites for templates containing GFP expression cassette (top) 
and those that do not (bottom). B) PCR amplification was performed using 
oligonucleotides that prime within the GFP cassette (GFP internal), within the R1 
ORF (R1 internal) or flanking the R1 ORF (R1 flank). Templates used are as follows: 
lane 1: non-template control (NTC); lane 2: RRVR1/GFPcc DNA; lane 3: RRV 
H26-95 DNA; lane 4: rRRV-2.3.1 (Revertant) DNA; lane 5: rRRV-4.1.1 DNA; lane 6: 
ah28A/H-R1/GFP cosmid; lane 7: ah28A/H cosmid. M denotes maker. 
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Figure 3. Restriction digest and Southern blot analysis of recombinant viruses. A) 
Diagram of the 5’ region of RRV R1/GFPCC (top) and H26-95 genomes, depicting NotI 
restriction sites and location of probe hybridization sites. B) NotI digest (left panel) and 
Southern blots of RRV R1/GFPcc (lane 1), RRV H26-95 (lane 2) and rescue rRRV-
2.3.1 (Revertant; lane 3) genomes hybridized with the RRV DHFR probe (Probe A; 
middle panel) or the GFP probe (probe B; right panel).  
120 
Disruption of the R1 gene from RRV does not impact RRV lytic replication in 
rhesus fibroblasts. 
We next determined if the disruption of R1 affected the replication kinetics of 
RRV. Four viruses, RRVR1/GFPcc, Revertant, RRV-GFPcc (a wild-type cosmid-
derived RRV H26-95 virus with a GFP expression cassette inserted far upstream of the 
R1 ORF (4)), and RRV-J (a cosmid-derived wild-type RRV H26-95 (4)) were used in 
this assay. Two days post-seeding, rhesus fibroblasts were infected with 
RRVR1/GFPcc, RRV-J, RRV-GFPcc, or Revertant at an MOI of 1 or 5 (Figs. 4 and 5, 
respectively). 
After an inoculation period of two hours for optimal adsorption, the supernatants 
from the infected cells were aspirated and replaced with DMEM containing 2% FBS to 
allow infections to proceed. At 0, 24, 48, 72, 96, 120, and 144 hours post infection (hpi), 
cell-free supernatants were harvested by centrifugation at 2,000 rpm for 5 min. For the 
viral growth curves, the supernatants were serially diluted in triplicate and subjected to 
traditional plaque assays to measure infectious particles (Fig. 4A and 5A). For the 
measurement of extracellular viral genome copies by real-time PCR (Fig. 4B and 5B), 
200 μl of the clarified supernatant from each infection sample, spiked with salmon sperm 
DNA, was processed through a DNeasy column (QIAGEN) for DNA isolation. Isolated 
DNA was then subjected to real-time PCR in triplicate using SYBR® Green mixture 
containing RRV Rta/Orf50 primers. For the measurement of intracellular viral genome 
copies by real-time PCR, an identical procedure was performed and the results are shown 
in Figures 4C and 5C. In order to account for cell death following viral replication in our 
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data analysis, intracellular viral genomes were also normalized to rhesus genomes using 
rhesus tubulin as an endogenous control (37) (Fig. 4D and 5D). 
We found that RRVR1/GFPcc, Revertant, RRV-GFPcc, and RRV-J all 
replicated to similar levels on rhesus fibroblasts. This was true as measured by plaques 
assays, as well as a viral genome assay quantitating intracellular and extracellular viral 
genomes. Since we observed no significant difference in replicative kinetics between 
RRVR1/GFPcc and the other three viruses in RhF that support lytic RRV infection, we  
conclude that R1 does not impact RRV de novo lytic infection and replication. 
 
Figure 4. Viral growth curves of RRVΔR1/GFPcc in rhesus fibroblasts at 1 MOI. 
Equivalent numbers of RhF cells were infected with RRVΔR1/GFPcc, RRV-GFPcc 
(wild-type with GFP insertion), RRV-J (wild-type without GFP insertion), or Revertant 
(rRRV-2.3.1) at a MOI of 1. Cell-free supernatants and cell pellets were harvested at 
indicated points post-infection. A) Infectious virus particles from supernatants were 
quantitated by traditional plaque assay. B) Extracellular viral genomes from the same 
samples as in A) were quantitated by real-time PCR assay. C) Intracellular viral genomes 
extracted from infected cell pellets were quantitated by real-time PCR. D) Same as in C) 
except that the viral genomes were normalized to rhesus β-tubulin. In all panels, results 
are the averages of duplicate or triplicate samples. Error bars represent standard 
deviations. 
122 
 
 
 
Figure 5. Viral growth curves of RRVΔR1/GFPcc in rhesus fibroblasts at 5 MOI. 
Equivalent numbers of RhF cells were infected with RRVΔR1/GFPcc, RRV-GFPcc 
(wild-type with GFP insertion), RRV-J (wild-type without GFP insertion), or Revertant 
(rRRV-2.3.1) at a MOI of 5. Cell-free supernatants and cell pellets were harvested at 
indicated points post-infection. A) Infectious virus particles from supernatants were 
quantitated by traditional plaque assay. B) Extracellular viral genomes from the same 
samples as in A) were quantitated by real-time PCR assay. C) Intracellular viral genomes 
extracted from infected cell pellets were quantitated by real-time PCR. D) Same as in C) 
except that the viral genomes were normalized to rhesus β-tubulin. In all panels, results 
are the averages of duplicate or triplicate samples. Error bars represent standard 
deviations. 
 
Disruption of the RRV R1 gene leads to an enhanced establishment of latency and 
lower levels of spontaneous reactivation in B cells. 
We next investigated whether R1 played any role in the latent phase of the RRV 
lifecycle. We have previously reported that RRV establishes latency in the B cell line 
BJAB (13, 37). We infected BJAB cells with RRVΔR1/GFPcc or RRV-GFPcc (MOI = 
0.5) as previously described (15, 37). Seven days post-infection, infected BJAB cells 
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were sorted by flow cytometry for the presence of green fluorescence. After sorting, 
equivalent numbers of GFP-positive cells from both RRVΔR1/GFPcc-infected and RRV-
GFP-infected BJAB cells were used for further experimentation to assess the 
maintenance of viral latency. From here onwards, the infected BJAB cells were split 
equally on the same days and GFP-positive cells were continuously monitored by flow 
cytometry (Fig. 6) and fluorescence microscopy (Fig. 7) as we previously described (37). 
The RRVΔR1/GFPcc-infected BJAB sample showed a less rapid loss of GFP-positive 
cells on days 7, 14, 21, and 28 post-sorting as determined by fluorescence microscopy 
and flow cytometry (Figure 6). Figure 7 shows the relative GFP-positive cells on days 7, 
14, 21, and 28 post-sorting as determined visually by fluorescence microscopy, 
respectively. To confirm that the higher number of GFP-positive cells in 
RRVΔR1/GFPcc-infected BJAB cells was a true reflection of a higher percentage of 
BJAB cells harboring the virus (or intracellular viral genomes), we performed 
quantitative real-time PCR to calculate RRV genome copy numbers normalized to human 
GAPDH copy number. RRVΔR1/GFPcc-infected BJAB cells displayed significantly 
higher intracellular viral genomes compared with RRV-GFPcc infected BJAB cells (Fig. 
8A).  
We also examined the role of R1 in RRV reactivation. In brief, GFP-positive 
RRVΔR1/GFPcc or RRV-GFPcc-infected BJAB cells were isolating by flow sorting and 
equivalent numbers of cells were subjected to reactivation through various means 
including the phorbol ester 12-O-tetradecanoyl phorbol 13 acetate (TPA) (13, 20), the 
HDAC inhibitors sodium butyrate (NaB) (13, 20) and trichostatin A (TSA) (13), or by 
etopic Rta expression (13, 38). A KSHV Rta baculovirus was used because  we have 
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previously reported that KSHV Rta can activate RRV promoters and vice versa (9). TPA 
activates the PKC and ERK signaling pathways leading to Rta activation, whereas NaB 
and TSA activate Rta and other promoters by inhibiting their silencing via deacetylation. 
In the absence of artificial induction of viral reactivation, we observed that 
RRVΔR1/GFPcc-infected BJAB cells released less RRV genomes (i.e. was more latent) 
than RRV-GFPcc, suggesting that R1 expression enhances spontaneous RRV reactivation 
(Fig. 8B). Next we investigated the effect of chemical or Rta-mediated induction of 
reactivation of the RRVΔR1/GFPcc or RRV-GFPcc-infected latent BJAB cells. 
Interestingly, induction using a cocktail of TPA (25 ng/ml), NaB (0.1 mM), and TSA 
(100 nM) or by infection with a baculovirus expressing KSHV Rta/Orf50 (38) resulted in 
approximately equivalent level of reactivation from both RRVΔR1/GFPcc and RRV-
GFPcc-infected latent BJAB cells. RRV reactivation was very robust by chemical 
induction with the TPA/NaB/TSA cocktail and led to almost complete cell death after 24 
h. RRV reactivation stimulated by KSHV Rta overexpression was a slower process and 
yielded similar levels of extracellular genomes at 96 h compared to chemical induction at 
24 h but the extracellular RRV genomes accumulated to much higher levels up to 168 h 
post-induction. Our data suggest that R1 activates signaling pathways that are required 
for spontaneous viral reactivation from latency and that these pathways are similar to 
those activated by chemical and Rta induction.  
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Figure 6. Flow cytometry analysis of RRVΔR1/GFPcc and RRV-GFPcc infected 
BJAB cells. Flow cytometry analysis was performed to measure the percentage of GFP-
positive cells in RRVΔR1/GFPcc or RRV-GFPcc infected BJAB cells immediately after 
sorting (day 0 post-sorting) and 7, 14, 21, and 28 days post-sorting. The percentages of 
GFP-positive cells at the indicated time points are shown.  
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Figure 7. Representative images of RRVΔR1/GFPcc and RRV-GFPcc infected 
BJAB cells. Brightfield and GFP fluorescence images of RRV-infected GFP-positive 
BJAB B cells are shown on days 7, 14, 21, and 28 post-sorting. 
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Figure 8. RRVΔR1/GFPcc and RRV-GFPcc latent infection and lytic reactivation in 
B lymphocytes. A) Intracellular viral genomes of RRVΔR1/GFPcc (■) and RRV-GFPcc 
(□) infected BJAB cells on days 7, 14, 21, and 28 post-sorting. Intracellular genomes 
extracted from infected cell pellets were quantitated by real-time PCR to determine viral 
genome copy number. The viral genomes were normalized to human GAPDH. Results 
are the averages of triplicate samples. Error bars represent standard deviations. B) 
Extracellular viral genomes were quantitated by real-time PCR assay. RRV-infected B 
cells were subjected to chemical induction with a mix of TPA (25 ng/ml), NaB (0.1 mM), 
and TSA (100 nM) for 24 h or KSHV Rta/Orf50-containing baculoviral infection for 96 h 
or 168 h. DNA from extracellular virus present in the cell supernatant was isolated and 
subjected to real time quantitative PCR analysis to determine viral genome copy 
numbers.  
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DISCUSSION 
 KSHV cannot establish a robust and persistent infection in mice or rhesus 
macaques (16, 29) and hence, RRV serves as a unique model to study KSHV 
pathogenesis in vivo. By utilizing an overlapping set of cosmids developed by Bilello et 
al. (4), we generated a R1-deleted virus (RRVR1/GFPcc) and an isogenic revertant 
virus. We confirmed proper placement of the exogenous GFP cassette into the R1 ORF 
and the integrity of RRVR1/GFPcc by diagnostic PCR, restriction digests and Southern 
blot analysis. The viral genome of recombinant RRVR1/GFPcc appeared to be identical 
to that of the wild-type RRV H26-95, except for the insertion of the GFP expression 
cassette. We also generated a rescue virus in which the GFP expression cassette was 
removed by traditional homologous recombination between the RRVR1/GFPcc genome 
and ah28A/H cosmid. The revertant virus showed no genetic difference from the 
parental RRV H26-95 virus by restriction digest and Southern blot analysis. 
 Characterization of the recombinant RRVR1/GFPcc and revertant viruses in 
RhF demonstrated that these viruses were replication competent and replicated on RhF 
with growth kinetics (PFU and viral genome titers) that were similar to those of the wild-
type control viruses at single-step growth (5 MOI) or multiple-step growth (1 MOI). 
Disruption of the R1 gene resulted in a mutant virus more capable of establishing and 
maintaining latency in BJAB cells. This suggests that R1 fine-tunes the activity of RRV 
during these phases of the viral lifecycle. Since our data imply that R1 modulates latent 
infection and spontaneous reactivation, one may speculate that R1 should have a similar 
effect during de novo lytic replication. One possibility for not observing this could be due 
to cell-type specificity and a difference in the kinases expressed between B cells versus 
129 
fibroblasts. R1 has thirteen tyrosine residues in its cytoplasmic tail which may interact 
with multiple kinases and demonstrate specific interactions with different kinases in 
different cells.  
 Whereas RRVR1/GFPcc-infected BJAB cells released less virions as measured 
by extracellular viral genomes than RRV-GFPcc-infected BJAB cells (indicative of a 
defect in reactivation), both wild-type and RRVR1/GFPcc viruses were able to produce 
similar levels of viral particles upon reactivation induced by a TPA/NaB/TSA chemical 
cocktail or ectopic Rta overexpression. This suggests that the R1 signaling functions are 
in the same pathway (and upstream) of the signaling events activated by TPA, NaB, and 
TSA. In agreement with this model, Lagunoff et al. reported blockage of lytic replication 
by K1 ITAM mutants that could be overcome by TPA treatment, thus suggesting that 
TPA-mediated signaling pathways could substitute for the loss of K1 signaling (23). 
Another interesting observation from our study is that KSHV Rta/Orf50 was able to 
reactivate RRV from latency, which implies that KSHV Rta can functionally complement 
or substitute for RRV Rta as we previously described using reporter assays (9).  
An alternative interpretation of the data is that as a glycoprotein, R1 may function 
to optimize efficient maturation and/or regress of the virus particle in B cells. This could 
also account for the observed enrichment of intracellular viral genomes and reduction of 
extracellular viral genomes. Future directions include electron microscopy to determine 
the number, subcellular distribution, and morphology of viral particles within 
RRVΔR1/GFPcc and RRV-GFPcc infected cells. These two scenarios may co-exist and 
not be mutually exclusive.  
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An opposing model posits that R1 functions to inhibit viral gene expression and 
subsequent virus production. In this model, GFP expression would imply spontaneous 
reactivation (without complete lytic replication) instead of latency. In this scenario, 
higher intracellular genomes would be the result of increased spontaneous reactivation 
without complete lytic replication and cell lysis. Although a portion of the viral 
population may reactivate, the presence of R1 in the viral genome may suppress complete 
viral replication and lytic replication. In this scenario, R1 contained in the wild-type 
RRV-GFPcc virus might down-modulate GFP expression driven by the CMV promoter, 
thus accounting for our observation of fewer GFP-positive cells. In the absence of R1 in 
RRVΔR1/GFPcc-infected BJAB, the regulation into the latency program may not be as 
tight. Thus, there would be more GFP-positive cells and more intracellular viral genomes 
representing a higher percentage of reactivating cells. This model would also predict less 
intracellular genomes in the wild-type RRV-GFPcc than RRVΔR1/GFPcc as we 
observed in Figure 8A, although the fact that we do see less extracellular genomes 
released in Figure 8B in the uninduced condition would be inconsistent with and argue 
against this alternative model.  
To examine whether R1 can suppress viral gene expression, we will isolate total 
mRNA from RRVΔR1/GFPcc or RRV-GFPcc infected BJAB cells to the RRV QPCR 
array developed by the Dittmer lab as previously described (17, 37). This would enable 
us to profile the transcripts that are differentially regulated by RRV in the presence or 
absence of R1 and determine whether R1 predominantly represses the transcription of the 
majority of RRV messages. An alternative approach to testing this model is to repeat the 
latency assay using real time PCR to measure intracellular viral genomes over the course 
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of the infection, but without flow sorting for GFP-positive cells after infection. This 
would avoid any bias in enriching cell populations that undergo spontaneous reactivation 
(GFP-positive) at the expense of excluding cells that are latently infected (GFP-negative). 
In addition to its role in viral persistence in vitro, R1 may function as an 
immunoregulatory protein in vivo. KSHV K1 has been shown to downregulate BCR 
surface expression (25). As BCR activation and downstream signaling events may yield 
to terminal differentiation and apoptosis, K1 modulation of BCR signal transduction may 
provide a long-term survival advantage in vivo. Indeed, K1 expression has been shown to 
protect cells from Fas-mediated apoptosis (34, 35). Furthermore, the PI3K/Akt pathway 
activated by K1 is pro-survival and controls Fas-mediated apoptosis (34, 36), R1 also 
activates B-cell signaling pathways (8) and can also activate the Akt pathway 
(unpublished). R1 may exhibit a similar phenotype to K1. 
In the context of SIV co-infection, experimental infection with wild-type RRV 
resulted in B cell hyperplasia, persistent lymphadenopathy, and persistent infection in 
macaques (19, 27, 39). It will be interesting to assess whether rhesus macaques infected 
with RRVR1/GFPcc (compared to RRV-GFPcc) would develop a similar phenotype. In 
the case of the related gammaherpesvirus HVS, deletion of the left-hand terminal 
membrane protein, STP, resulted in a mutant virus fully competent in replication but 
defective in growth transformation of primary T lymphocytes in vitro and pathogenesis in 
vivo (18). Because R1 is the positional homolog of STP and deregulates similar signal 
transduction in B-cells (8), RRVR1/GFPcc may have a similar phenotype in vivo, 
perhaps in the context of the development of B-cell hyperplasia.  
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 In conclusion, we have generated a recombinant RRV virus designated 
RRVR1/GFPcc, in which the R1 ORF has been disrupted by the insertion of a GFP 
expression cassette. This R1 deletion virus exhibited increased persistence in our B cell 
culture model, but had no effect on replication upon de novo infection of rhesus 
fibroblasts.  
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ABSTRACT 
Rhesus monkey rhadinovirus (RRV) is a γ-herpesvirus that is closely related to 
human Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8). RRV is the closest relative 
to KSHV that has a fully sequenced genome and serves as an in vitro and an in vivo model 
system for KSHV. The latency-associated nuclear antigen (LANA) protein of both KSHV 
and RRV plays key roles in the establishment and maintenance of these herpesviruses. We 
have constructed a RRV recombinant virus (RRVΔLANA/GFP) in which the RRV LANA 
open-reading frame has been disrupted with a GFP expression cassette generated by 
homologous recombination. Integrity of the recombinant virus was confirmed by diagnostic 
PCR, restriction digest, Southern blot analysis, and whole-genome sequencing. We compared 
single-step and multi-step replication kinetics of RRVΔLANA/GFP, RRV-GFP, wild-type 
(WT) RRV H26-95, and a revertant virus using traditional plaque assays as well as real-time 
QPCR based genome quantification assays. The RRVΔLANA/GFP recombinant virus 
exhibited significantly higher lytic replicative properties compared to RRV-GFP, WT RRV, 
or the revertant virus. This was observed upon de novo infection and in the absence of 
chemical inducers such as phorbol esters. In addition, by employing a quantitative real-time 
PCR-based viral array, we are the first to report differences in global viral gene expression 
between WT and recombinant viruses. The RRVΔLANA/GFP virus displayed increased lytic 
gene transcription at all timepoints post-infection compared to RRV-GFP. Moreover, we 
have also examined several cellular genes that are known to be repressed by KSHV LANA 
and report that these genes are de-repressed during de novo lytic infection with the 
RRVΔLANA/GFP virus compared to RRV-GFP. Finally, we also demonstrate that the 
RRVΔLANA/GFP virus fails to establish latency in B cells, as measured by the loss of GFP-
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positive cells and intracellular viral genomes. Our future goal is to evaluate the 
RRVΔLANA/GFP as a vaccine candidate in rhesus macaques. 
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INTRODUCTION 
Kaposi sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8, is a 
member of the γ2 -herpesviridae subfamily. This virus has been implicated as the etiological 
agent of Kaposi sarcoma (10) and lymphoproliferative diseases of B cell origin, namely, 
primary effusion lymphoma (PEL) (9) and the plasmablastic variant of multicentric 
Castleman disease (MCD) (29, 79).  
A detailed understanding of KSHV replication and pathogenesis is important for 
understanding the biology of the diseases that are associated with this virus. However, in vivo 
studies of KSHV are limited due to the inability of KSHV to persistently infect mice or 
rhesus macaques (24, 69). Furthermore, difficulties are encountered when trying to study 
KSHV replication in vitro (68). Although several groups have described the use of 
endothelial cells to investigate de novo KSHV replication (20, 45, 68, 73), the virus replicates 
lytically only for a limited number of rounds before entering latency in these cells. Hence 
viral titers of KSHV are quite low in endothelial cells and plaques were rarely observed. 
Another system to generate lytic virus involves the treatment of KSHV-infected PEL cell 
lines with TPA or n-butyrate (57, 71). Here the problem is that only a small subset (25-30%) 
of latently infected PEL lymphocytes can be artificially reactivated with TPA (57, 71). Thus, 
the heterogeneous nature of the lytically and latently infected cell populations hampers the 
dissection of the function of individual viral genes in the context of the whole virus.  
We have used rhesus monkey rhadinovirus (RRV) to model KSHV pathogenesis in 
rhesus fibroblasts (RhF) (60). RRV was first identified by Desrosiers et al. in 1997 at the 
New England Primate Research Center (NEPRC) as a γ2-herpesvirus of rhesus macaques 
(Macaca mulatta) (16). This isolate was designated H26-95. Additionally, Wong et al. at the 
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Oregon Regional Primate Research Center isolated a different strain of RRV (designated 
17577) from SIV-infected macaques (89). Sequence analysis revealed that the two RRV 
isolates are homologous to each other, though not identical. Importantly, both genomes 
exhibit co-linearity with the KSHV genome (2, 77) and all RRV genes have homologs in 
KSHV (2, 77). Wong et al. showed that in SIV-infected macaques, RRV induced B-cell 
hyperplasia resembling KSHV MCD (89) as well as non-Hodgkin lymphoma (61). Mansfield 
et al. reported that RRV also caused an arteriopathy in SIV-infected macaques (55).  
RRV presents several advantages for studying lytic replication. First, the RRV 
lifecycle can be modeled in vivo, in rhesus macaques. Second, rhesus fibroblasts (RhF) 
support one hundred percent lytic replication of RRV and allows for the production of high 
titers of virus (approximately 106 plaque forming units per ml) (59). Our group has 
demonstrated that the transcription program of RRV is similar to that of KSHV (18, 26). 
Several laboratories have used the RRV model to study viral gene products, including the 
viral interleukin-6 (vIL-6) homologue (38), Rta/Orf50, R8/RAP, R8.1 (18, 51), R1 (14, 15), 
R15 (47, 64), RRV Orf4 (56), and the RRV-encoded microRNAs (75). We previously 
reported the kinetics of gene expression with regard to immediate-early, early, and late genes 
during RRV lytic infection and have reported they are similar to those seen during KSHV 
reactivation (18, 26). We also generated a RRV-GFP recombinant virus and devised plaque 
assays and quantitative real time QPCR assays for the determination of viral titers (19). This 
validates the experimental methods used here.  
In KSHV, the latency-associated nuclear antigen (K-LANA) maintains latency by 
tethering the circularized viral episome to the mitotic host chromosomes, which allows the 
viral genome to co-segregate with the host genome to daughter cells during cellular 
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replication (6-8, 12, 13, 34, 39, 40, 42, 43, 66, 70, 81, 88, 90, 91). We have previously 
reported the identification and characterization of RRV LANA (R-LANA) (17). R-LANA 
shows homology to K-LANA except for the central variable-length internal acidic repeat 
domain, which is absent in R-LANA. The N- and C-terminal ends of R-LANA show high 
degree of sequence similarity to K-LANA, containing the same arrangement of chromosome-
binding domain, nuclear localization signal, proline/serine-rich and glutamine-rich regions. 
Similar to K-LANA, R-LANA exhibited a speckled nuclear localization (17). We have 
previously reported that R-LANA can bind the RRV viral genome and may tether the RRV 
genome to the host chromosome in a similar fashion as K-LANA (17).  
Genetically, both K-LANA and R-LANA are encoded by open reading frame (Orf) 
73 of their respective viruses. K-LANA is found in the tricistronic latency-associated 
cassette, which also includes Orf71/vFLIP and Orf72/vCyclin (23, 74, 83). Differential 
splicing of the tricistronic cassette results in a 1.7 kb bicistronic transcript containing Orf72 
and Orf71. Thus the expression of KSHV Orf71, Orf72, and Orf73 is coordinately driven by 
the common LANA promoter. Within the bicistronic transcript, there exists an internal 
ribosome entry site (IRES) in Orf72 for protein translation of Orf71. Although expressed at 
low levels, monocistronic Orf71 transcript was also detected during KSHV latency, and this 
transcript was upregulated during lytic reactivation, suggesting that there might be a cryptic 
promoter for Orf71 expression during the lytic cycle (32). In RRV, similarly arranged 
tricistronic (LANA, vCyclin, and vFLIP) and bicistronic (vCyclin and vFLIP) transcripts 
have been previously described by our group (18). In KSHV, LANA has also been shown to 
transactivate its own promoter (36, 37, 63, 80). Additionally, as a possible mechanism to 
ensure K-LANA expression during the lytic cycle, Rta (replication transcription activator) 
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was described to positively regulate K-LANA gene expression by recruiting RBP-Jκ to the 
LANA promoter (46). K-LANA, on the other hand, has been shown to inhibit Rta 
transactivation of downstream viral promoters by various mechanisms (reviewed in (85)).  
Our lab has previously demonstrated that R-LANA inhibits RRV Rta transactivation 
of lytic promoters (17). In order to examine the role of R-LANA protein in the RRV lifecycle 
we have disrupted the expression of R-LANA in the viral genome using homologous 
recombination. In this report we describe the construction of a RRVΔLANA/GFP knockout 
virus and compare the replication kinetics of RRVΔLANA/GFP, RRV-GFP, and wild-type 
(WT) RRV H26-95 at three different multiplicities of infection (0.1, 0.5, and 5) using 
traditional plaque assays as well as real-time PCR based genome quantification assays. We 
have also constructed a revertant virus (RRVREV) and find that it behaves similar to WT 
RRV.  
Previously, LANA knockout viruses have been published for KSHV and murine 
gammaherpesvirus 68 (MHV68) (27, 28, 48, 58). The KSHV LANA deletion virus showed a 
higher viral replication than wild-type in contrast to the MHV68 LANA-null virus which 
showed absolutely no difference in replication in vitro at high MOI, and a lower amount of 
replication than wild-type at very low MOIs (28, 48, 58). These experiments yielded 
important insights, but also raised new questions since these viruses behaved very differently 
from each other with respect to replication. RRV is the closest relative to KSHV that has a de 
novo infection system. We constructed a RRVΔLANA/GFP knockout virus and have 
examined RRV LANA's contribution to the lytic and latent cycle. We found that 
RRVΔLANA/GFP exhibits enhanced lytic replication similar to the KSHV LANA deletion 
virus. Additionally, this higher lytic replication is seen upon de novo infection and in the 
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absence of chemical inducers like TPA. Furthermore, we are the first to employ a 
quantitative real-time PCR-based RRV viral array to transcriptionally profile genome-wide 
viral gene expression during de novo infection with RRVΔLANA/GFP and RRV-GFP 
viruses. We also analyzed several cellular genes that were previously reported to be repressed 
by KSHV LANA alone and found that they were derepressed in RRVΔLANA/GFP infected 
cells compared to RRV-GFP infected cells. This suggests that R-LANA modulates 
transcription of these genes during lytic infection and in the context of the whole virus. 
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MATERIALS AND METHODS 
Cell culture 
Immortalized rhesus macaque skin fibroblasts (RhF) with puromycin resistance were 
described previously (18). Cells were maintained at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium-H (DMEM-H) with Gluta-max supplemented with 10% fetal 
bovine serum (FBS), penicillin, and streptomycin. BJAB cells, a human B-cell line that is 
KSHV negative and Epstein-Barr virus negative were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, penicillin, and streptomycin. 
Construction of the recombinant RRVΔLANA/GFP virus and the revertant RRVREV 
virus 
RRV isolate H26-95 (16) and RRV-GFP (19) were previously described.  To construct 
RRVΔLANA/GFP, a 3051-bp RRV LANA sequence of RRV H26-95 spanning nucleotides 
117207 to 121414 was PCR amplified with primers 5′-
CGCCGCGAATTCCGGTCAATGGAGAGCATCAGGTG-3′ and 5′-
CGCCGCAAGCTTCGCGCGCTCACATAGACCTATAC-3′. This amplicon was 
subsequently cloned into pSp72 (Promega) at EcoRI and HindIII restriction sites to create 
pSp72-R-LANA-flank (also called R-LANA-flank plasmid). Site-directed mutagenesis was 
performed to create a SacI site at nucleotide position 40 of the R-LANA ORF with primers 
5'-CAGGAACTTCGCAACCCGAGCTCCGATACTATGCCGGAAC-3' and 5'-
GTTCCGGCATAGTATCGGAGCTCGGGTTGCGAAGTTCCTG-3'. The resulting plasmid 
was designated pSp72-R-LANA-flank-new SacI. The EGFP expression cassette driven by 
the CMV IE promoter with the SV40 polyadenylation signal was PCR amplified from a 
148 
 
pEGFP-N1 (Clontech) plasmid in which the multiple cloning site was removed by digesting 
with BamHI and BglII and religating the ends together. The EGFP-N1 cassette primers used 
were 5′- CAAAAAGAGCTCGTAATCAATTACGGGGTCAT -3′ and 5′- 
CAAAAAGAGCTCACCACAACTAGAATGCAGTG -3′. The resulting SacI tagged CMV-
GFP-pA amplicon was ligated into pSP72-R-LANA-flank-new SacI to form 
pSp72ΔLANA/GFP (also called R-LANA-flank+GFP plasmid). This plasmid was linearized 
by EcoRI digestion and then transfected into RhF by Amaxa Nucleofection system as 
described by the manufacturer. Forty-eight hours post-nucleofection, RhF were infected with 
RRV H26-95 virus at a low MOI. A single GFP-positive virus was isolated and purified by 
limiting dilution and plaque assay five times. To generate a revertant virus, RhF were 
nucleofected with EcoRI-linearized pSp72-R-LANA-flank plasmid and subsequently 
infected with RRVΔLANA/GFP at a low MOI. Clear, GFP-negative plaques were isolated 
and the revertant virus was further separated from RRVΔLANA/GFP by three rounds of 
plaque purification. This revertant virus was designated RRVREV.  
Viral DNA of RRV-H26-95, RRVΔLANA/GFP, or RRVREV was used as a template for PCR 
analysis with the following primers: R-LANA flanking primers: 5’- 
CGCCGCGAATTCCGGTCAATGGAGAGCATCAGGTG-3’ and 5’-
CGCCGCAAGCTTCGCGCGCTCACATAGACCTATAC-3’, R-LANA primers: 5’-
GAGTTGGAATTC TTAGTGCTGAATTGGCAG-3’ and 5’-
CGGCAATCTAGATTAGTGCTGAATTGGCAGTCCTCTGTCCATGCGCACTATGC-3’.  
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Southern hybridization 
Virus was harvested from virus-infected RhF by centrifugation at 17,000 rpm for 3 h. The 
virus pellet was resuspended in PBS, treated with sarkosyl and subsequently with proteinase 
K at 60°C for 1 h. Viral DNA was extracted by phenol-chloroform method. For Southern blot 
analysis, 1μg of the viral DNA was digested with NheI for hybridization with the RRV 
LANA probe or digested with SacI for hybridization with the GFP probe. Digestion 
fragments of viral genomic DNA were subjected to electrophoresis through 1% low-melt 
agarose (NuSieve) and transferred overnight to a nylon membrane (Hybond N+) by capillary 
action. Following UV cross-linking, membranes were prehybridized in QuikHyb solution at 
65°C for 15 min. Probes were generated from a 330-bp RRV LANA fragment restriction 
digested by KpnI and FspI (R-LANA ORF nucleotide position 985 through 1315) and a 154-
bp GFP fragment (nucleotide position 362 through 515 from the ATG start codon of EGFP-
N1 plasmid) derived from PCR by random prime method using 32P labeled dCTP (Roche). 
Probes were denatured at 95°C for 3 min and added to QuikHyb prehybe solution 
(Stratagene). Hybridization was carried out for 1 h at 65°C. Probe solution was removed and 
membranes were washed twice for 15 min with 2× SSC 0.1% SDS at room temperature and 
once for 30 min at 60°C with 0.1× SSC 0.1% SDS. Membranes were exposed overnight on 
an X-ray film.  
Illumina/Solexa sequencing  
Supernatant of RRV-infected RhF was filtered, concentrated by ultracentrifugation, and 
loaded on a Sepharose CL-4B column (Sigma) to isolate RRV virions.  RRV genomic DNA 
was released by sarkosyl and proteinase K (Qiagen) treatment, and purified by phenol-
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chloroform extraction. The viral DNA was further purified using Wizard® SV Genomic 
DNA Purification System (Promega) as per manufacturer’s instructions. Four micrograms of 
RRVΔLANA DNA were submitted to UNC-CH Genome Analysis Facility and sequenced by 
the Illumina/Solexa 1G Genome Analyzer using the Illumina DNA sample Prep Kit (FC-102-
1001), Standard Cluster Generation Kit (FC-103-1001), and 18-cyle Illumina Sequencing Kit 
(FC-104-1001). This sample was sheared to 200-300bp length using a Bioruptor.  Library 
preparation then followed standard Illumina protocols for a GA2 sequencer (Illumina, San 
Diego CA). The Illumina GA2 sequencer was run with 36 cycles using the standard flow 
cell. Raw Illumina GA2 sequence image data was phased and filtered for quality using 
default GERALD parameters for unaligned reads (analysis: NONE, Use Bases: 35). 
Sequence reads were aligned to the RRV genome using the emboss function fuzznuc (72) 
and CLC Genomics Workbench V2.0.4 (CLC bio Inc.) under Mac OS X 10.5.5. Further 
analysis was conducted using R (GNU general public license (1)). For junction search, raw 
sequence data were first converted into a blast database using formatdb and then the 
predicted junction fragments 5’-
ATGTCCCCTGCAGGAACTTCGCAACCCGAGCT_CGTAATCAATTACGGGGTCATT
AGTTCAT and 5’-
TTTTTTCACTGCATTCTAGTTGTGGTGAGCT_CCGATACTATGCCGGAACGATGTT
GCCG (underscore marks the junction) were searched against the Illumina read database. 
Quantitative real-time PCR for viral load and cellular gene expression analysis 
For each sample, 10 μg of salmon sperm carrier DNA was added to 200 μl of clarified 
supernatant from infected cells and was processed through the DNeasy Kit (QIAGEN, 
Valencia, CA) as per the manufacturer’s protocol. To quantify viral DNA, SYBR® Green 
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Real-time PCR in 384-well format was performed using the ABI PRISM® 7900 Sequence 
Detection System (Applied Biosystems Inc: Foster City, CA). To generate a standard curve 
for cycle thresholds versus genomic copy numbers, the pcDNA3-RRVOrf50 plasmid was 
serially diluted to known concentrations in the range of 101 to 106 plasmid molecules/μl. 
Each PCR mixture (15 μl) contained 4 μl of viral or standard DNA, 1 μl of Orf50 primer set 
(final working concentration at 3.33 μM), 7.5 μl of SYBR Green 2X PCR mix (Applied 
Biosystems), and 2.5 μl of DNase- and RNase- free water (Sigma) in a total volume of 15 μl. 
Primers for amplification of an 81-bp amplicon internal to the Orf50 sequence were 5′-
GTGGAAAGCGGTGTCACAGA-3′ and 5′-TGCGGCGGCCAAAAT-3′. PCR conditions 
were as follows: 95°C for 15 min, followed by 95°C for 15 s, 60°C for 1 min repeated for 40 
cycles.  Similar reactions were assembled to assess cellular gene expression. The sequences 
for real-time PCR primers for the specific cellular genes shown in Table 1 including -actin 
(housekeeping control) are provided in Table 2. 
Plaque assays 
RhF monolayers in 12-well plates were achieved by plating 2 × 105 cells per well 2 days 
before starting the assay. Ten-fold dilutions of virus-infected cell supernatants were made in 
DMEM-H supplemented with 2% fetal bovine serum (FBS). Each sample dilution was 
performed in triplicate. Two hundred microliters of each dilution was placed in each well of 
12-well dishes and incubated at 37°C with redistribution of inoculum every 15 min. 
Importantly, for all infections, we incubated the virus with the cells for exactly two hours, 
after which the inoculum was aspirated and an overlay of methylcellulose was added to each 
well. The overlay media consisted of (per well): 1 ml 2×DMEM, 1 ml 1.5% methyl-cellulose 
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(Sigma M0512), and 40 μl FBS (2%). Cells were then incubated 7 days at 37°C and 5% CO2. 
Overlay media was then aspirated and cells were stained with 0.8% crystal violet (Sigma 
C3886) in a 50% ethanol staining solution for 1 h. Plaques were counted under 10X 
magnification.  
RRV real-time PCR genome array
The RRV quantitative real-time reverse transcription-PCR genome array was previously 
described (26). Samples were prepared for the viral array as follows: Virus was used to infect 
RhF at 0.5 MOI. The infected RhF were centrifuged and snap-frozen at −80oC at 12, 24, 48, 
72, 96, 120, and 144 hours post-infection. RNA from RRV-infected RhF was isolated using 
RNAzol (Tel-Test Inc.) as previously described (25, 26). Poly A mRNA was prepared using 
dT-beads (QIAGEN) and reverse-transcribed using Superscript II reverse transcriptase (Life 
Technologies) according to the manufacturer's recommendations. Five hundred nanograms of 
RNA were reverse-transcribed using ABI cDNA archive kit and random hexanucleotide 
primers (Applied Biosystems, Inc). The reaction mixture was sequentially incubated at 42°C 
for 45 min, 52°C for 30 min, and 70°C for 10 min. The RT reaction was quenched by heating 
to 95°C for 5 min and then subject to 0.5 U RNaseH (Invitrogen) treatment at 37°C for an 
additional 30 min. Afterwards, the cDNA pool was diluted 25-fold with diethyl 
pyrocarbonate-treated, distilled H2O and stored at -80°C. For quantitative real-time PCR, 2.5 
μl of primer mix was combined with 7.5 μl SYBR Green 2X PCR mix (Applied Biosystems) 
and 5 μl cDNA and subjected to real-time QPCR on an MJR Opticon2 cycler using standard 
cycling conditions. 
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RRV infection of BJAB cells 
2 × 105 BJAB cells were spinoculated in flat-bottom 12-well plates with 1.5 ml of diluted 
viral stock in complete RPMI medium in the presence of 4 µg/ml of polybrene as previously 
described (86). The cells were washed once with complete RPMI medium and then allowed 
to grow and expand in complete RPMI medium.  
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RESULTS 
Generation of a RRVLANA/GFP recombinant virus. 
Our lab has previously published the generation of a RRV recombinant virus 
expressing GFP (RRV-GFP) using homologous recombination (19). We used a similar 
homologous recombination approach to construct a RRVLANA/GFP recombinant virus by 
inserting a GFP expression cassette into the R-LANA ORF to disrupt R-LANA transcription 
and translation.  A 3051 bp RRV LANA sequence of RRV H26-95 spanning nucleotides 
117207 to 121414 was PCR amplified and subcloned into the plasmid pSp72 to create 
pSp72-R-LANA-flank. We then mutagenized a unique SacI restriction site in the R-LANA 
ORF in the pSp72-R-LANA-flank plasmid at nucleotide position 40 of the R-LANA ORF to 
generate pSp72-R-LANA-flank-new SacI. The GFP expression cassette was subcloned into 
this SacI site in an opposite direction to the R-LANA ORF to yield the plasmid 
pSp72ΔLANA/GFP. Next, the pSp72ΔLANA/GFP plasmid was linearized with EcoRI, and 
RhF were nucleofected with the linearized pSp72ΔLANA/GFP plasmid, followed by RRV 
infection at a low multiplicity of infection (Fig. 1A). Single GFP-positive viruses were 
plaque purified for five rounds and one such isolate, named RRVΔLANA/GFP, was chosen 
for further study. Using a similar procedure, we subsequently generated a rescue virus by 
nucleofection of RhF with EcoRI-linearized pSp72-R-LANA-flank plasmid, followed by 
infection with RRVΔLANA/GFP at a low multiplicity of infection (Fig. 1B). Clear, GFP-
negative plaques were isolated and separated from GFP-positive RRVΔLANA/GFP by 
plaque purification.  One such revertant virus, designated RRVREV, was chosen for further 
study. 
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Figure 1 (previous page). A schematic representation of the construction of the 
RRVΔLANA/GFP and RRVREV recombinant viruses. A) Construction of the 
RRVΔLANA/GFP virus. An EGFP expression cassette driven by a CMV promoter was 
inserted into the N-terminus of R-LANA (Orf73) to disrupt the R-LANA ORF. This EGFP 
cassette was cloned into a plasmid containing the coding sequence of R-LANA and flanking 
ORFs (Orf71 to Orf74). The plasmid (pSp72ΔLANA/GFP) was linearized and transfected 
into RhF, and then subjected to RRV infection at a low multiplicity of infection (MOI). 
Single GFP-expressing viral plaques were purified for five rounds and one such isolate, 
designated RRVΔLANA/GFP, was chosen for further study. B) Construction of a revertant 
RRVREV virus. A plasmid containing the coding sequence of R-LANA flanked by Orf71 and 
Orf74 (pSp72-R-LANA-flank) was linearized and transfected into RhF. Transfected cells 
were infected with RRVΔLANA/GFP at a low MOI. GFP-negative viral plaques were 
purified. One such isolate was designated RRVREV and chosen for further study. LF denotes 
left flank; RF, right flank. 
 
We have confirmed the correct insertion of the GFP cassette into RRVΔLANA/GFP 
by diagnostic PCR with two different sets of primers targeting full length R-LANA ORF and 
its flanking regions, respectively (Fig. 2A, B, C). Cell pellets of RhF infected with 
RRVΔLANA/GFP were subjected to total DNA isolation on DNeasy columns (Qiagen). 
Approximately 500 nanograms of total DNA per infected sample were subjected to standard 
PCR. The R-LANA-flank plasmid (also called pSp72-R-LANA-flank plasmid in Fig. 1B), or 
parental H26-95 viral DNA, was used as the PCR template as a negative control for GFP 
insertion. The R-LANA-flank+GFP plasmid (also called pSp72ΔLANA/GFP in Fig. 1A) 
served as the PCR template for the positive control. The R-LANA primers and R-LANA 
flanking primers amplified from the R-LANA-flank+GFP plasmid template showed the 
expected fragment sizes of 2950 bp and 5800 bp, respectively (Fig. 2B & 2C). 
The removal of the GFP sequence in rescue virus RRVREV was likewise confirmed by 
diagnostic PCR (Fig. 2D, 2E, 2F). Total DNA was isolated from RRVREV-infected RhF 
pellets and subjected to standard PCR. The R-LANA-flank plasmid DNA or H26-95 viral 
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DNA was used as a control to show the expected amplicon sizes of intact R-LANA (Fig. 2). 
The PCR products of RRVREV viral DNA show the correct size of 1350 bp for wild-type R-
LANA ORF with the full length R-LANA primer set (Fig. 2E), and 4200 bp for wild-type R-
LANA flank sequence with the R-LANA flank primer (Fig. 2F).  
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Figure 2 (previous page). PCR analysis of recombinant viruses. A) A schematic 
representation of PCR diagnosis of RRVΔLANA/GFP virus. Primers (arrows) for either the 
full length R-LANA ORF (lower bracket) or the R-LANA flanking ORF (upper bracket). B) 
Templates used in the PCR reactions are labeled on top of each lane. NTC denotes non-
template control and M denotes marker. With the R-LANA primer set, the expected size for 
R-LANA (~1350 bp) was seen in R-LANA-flank plasmid (i.e. pSp72-R-LANA-flank 
plasmid in Fig. 1B) and RRV H26-95 viral DNA. The RRVΔLANA/GFP lane and R-LANA-
flank+GFP (i.e. pSp72ΔLANA/GFP in Fig. 1A) plasmid lane show the expected size (~2950 
bp) for EGFP cassette (~1600 bp) insertion. C) With the R-LANA flanking primer set, an 
expected size of ~4200 bp was seen with the R-LANA-flank plasmid and RRV H26-95 viral 
DNA. The RRVΔLANA/GFP lane and R-LANA-flank+GFP plasmid lane show the expected 
size (~5800 bp) for EGFP cassette insertion. D) A schematic representation of PCR diagnosis 
of RRVREV. Primers (arrows) for either the full length R-LANA ORF (lower bracket) or the 
R-LANA flanking ORF (upper bracket). E) With the full length R-LANA primer set, the 
PCR product of RRVREV shows the correct size for R-LANA ORF, similar to the amplicon 
size (~1350 bp) of positive template controls (R-LANA-flank plasmid and RRV H26-95 viral 
DNA). F) PCR using the R-LANA flank primer set displays an expected amplicon size 
(~4200 bp) for the RRVREV template as indicated by the same amplified fragment size when 
wild-type R-LANA-flank plasmid or viral DNA H26-95 was used as the template.  
 
To rule out aberrant insertion of the exogenous GFP cassette into the rest of the viral 
genome, diagnostic Southern blot analysis following restriction digest was performed. We 
have provided a graphical scheme of the restriction digestion and Southern blotting in Fig. 
3A. Virion DNA from wild-type RRV H26-95, RRVΔLANA/GFP, and RRVREV 
recombinant viruses grown on RhF was isolated and digested with NheI. The digested DNA 
fragments were resolved on two separate agarose gels by electrophoresis and the gels were 
transferred and crosslinked to nitrocellulose membrane. Southern blots were performed using 
a radiolabeled probe complementary to either the R-LANA or the GFP sequence (Fig. 3A). 
The R-LANA specific probe hybridized to a predicted 2.4 kb fragment in RRVΔLANA/GFP 
and a predicted 6.5 kb fragment in RRV H26-95 and RRVΔLANA REV digested with NheI 
(Fig. 3B). The GFP-specific probe used in the Southern blot revealed the expected 
hybridization fragment size of 5.6 kb for NheI digested RRVΔLANA/GFP virion DNA (Fig. 
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3C). As expected, the probe did not hybridize to the wild-type H26-95 or the rescue virus 
DNA. A third Southern blot was performed using the GFP probe (Fig. 3D). Since the GFP 
cassette in RRVΔLANA/GFP was inserted into the virus at a newly created SacI site, 
restriction digestion with SacI should release a 1.6 kb fragment corresponding to the size of 
the exogenous GFP sequence from this recombinant virus. In the Southern blot shown in Fig. 
3D, this fragment was detected by the GFP probe in SacI-digested virion DNA of 
RRVΔLANA/GFP but was absent in the SacI-digested H26-95 and RRVREV genomic DNA, 
as expected. Ethidium bromide stained gels of SacI single-digested and SacI/EcoRI double-
digested RRV H26-95 and RRVΔLANA/GFP viral DNA are shown in Fig. 4. 
 
Figure 3 (next page). Restriction digest and Southern blot analysis of recombinant 
viruses. A) A schematic illustration showing the strategy for NheI or SacI restriction enzyme 
digestion and Southern blot analysis of RRVΔLANA/GFP, wild-type H26-95, and RRVREV 
genomic DNA. R-LANA probe was generated from digestion of a plasmid encoding R-
LANA, and the GFP probe was generated from a PCR product of the pEGFP-N1 plasmid. B) 
The R-LANA probe hybridized to a 2.4 kb fragment in RRVΔLANA/GFP digested with 
NheI, and a 6.5 kb fragment in RRV H26-95 and RRVREV digested with NheI. C) The GFP 
probe hybridized to a 5.6 kb fragment of NheI digested RRVΔLANA/GFP genomic DNA. 
The GFP probe did not hybridize to the wild-type H26-95 or RRVREV DNA, as expected. D) 
Restriction digestion with SacI released a 1.6 kb fragment corresponding to the size of the 
exogenous GFP sequence from RRVΔLANA/GFP genomic DNA, but no fragment was 
detected in the wild-type or revertant viral DNA.  
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Whole genome sequencing of the RRVΔLANA/GFP recombinant virus. 
The results from these traditional molecular analyses suggest that the 
RRVΔLANA/GFP recombinant virus is genetically identical to the wild-type RRV H26-95 
genome, except for the insertion of the GFP expression cassette in the R-LANA ORF. To 
further ensure complete genetic integrity at the nucleotide level, we performed genome-wide 
sequencing of RRVΔLANA/GFP virus using the recently developed Illumina/Solexa 
sequencing technology. It was crucial to obtain highly pure and abundant viral DNA for such 
a purpose. Approximately 5 × 108 RhF were subjected to RRVΔLANA/GFP infection and 
virus was amplified until complete cytopathic effect was observed. Cell-free supernatant of 
RRV-infected RhF was filtered, ultracentrifuged, and subjected to virion purification on a 
  
Figure 4. Restriction digestion analysis of recombinant RRVΔLANA/GFP and 
parental H26-95 genomes. The ethidium bromide-stained agarose gel images were taken 
with Kodak Gel Logic 200 Imaging system. The image was shown in this figure with 
reverse contrast. A) Viral genomes were restriction digested with SacI, which released a 
unique 1.6 kb fragment in RRVΔLANA/GFP (marked with an arrow head). B) Viral 
genomes were double-digested with EcoRI and SacI. The expected DNA fragments unique 
for RRVΔLANA/GFP viral DNA were marked with asterisks (*). H26-95 contains only one 
unique restriction fragment and it was marked with <. M denotes marker. 
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sepharose column. RRV genomic DNA was released by sarkosyl and proteinase K treatment, 
and purified by phenol-chloroform extraction. Further purification of genomic DNA was 
performed using Wizard® SV Genomic DNA Purification System (Promega). Four 
micrograms of RRVΔLANA DNA were submitted to the UNC-CH Genome Analysis 
Facility. We obtained full coverage of the RRVΔLANA/GFP viral genome when the parental 
RRV H25-95 (AF210726) excluding the 3’ terminal repeat was used as the reference 
sequence. We used stringent alignment parameters. Only reads of 35 nucleotides were used. 
We obtained 8,179,932 raw reads. 1,451,388 reads matched the AF210726 RRV strain H25-
95 sequence excluding any gaps and allowing for at most one mismatch. Maximum coverage 
was 876 fold excluding the terminal repeats. The detailed coverage distribution is shown in 
Fig. 5A. Importantly, RRVΔLANA/GFP contained no deletions or rearrangements (average 
coverage per base pair >100). The RRVΔLANA/GFP genome is identical to the reference 
H26-95 sequence except at the disrupted R-LANA ORF. A few single nucleotide 
polymorphisms (SNPs) were present that were also polymorphic in the other RRV 17577 
strain and may in fact represent sequencing errors in the initial reference sequence. Correct 
insertion of the GFP cassette into the R-LANA ORF was verified by comparing the 
sequenced fragments with the predicted LANA-GFP junctional sequences (Fig. 5B and 5C). 
Importantly, 476 illumina reads matched the 5’ junction without gaps or mismatch and 500 
reads matched the 3’ junction sequences without gaps or mismatch. This demonstrates that 
the recombinant virus had the desired structure and no inadvertent secondary mutations. 
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Figure 5. Illumina/Solexa whole viral genome sequencing. A) Coverage of 
RRVΔLANA/GFP genome by Solexa sequencing reads.  Solexa generates 35bp DNA 
reads. These were aligned to the RRV H26-95 genome using the reference sequence. The 
arrows on top represent individual RRV ORFs and the numbers represent nucleotide 
coordinates. The graph below shows the number of reads at each nucleotide position on a 
linear scale from 0 to 876. Peaks indicate regions of high coverage; valleys indicate 
regions of low coverage. Complete coverage of the whole RRV H26-95 genome was 
achieved. Maximum coverage was 876 fold. B) Correct insertion of the GFP cassette into 
the R-LANA ORF was verified by comparing all Solexa fragments with the predicted 
RRV LANA-GFP junctional sequence. We found 476 Solexa reads that matched the 5’ 
LANA-GFP junctional sequence. Shown is the distribution (density) of BLAST scores 
log(blast E value) for this comparison. Lower values (< -10) indicate sequence reads that 
matched the junction sequence perfectly, without any gap or even a single mismatch. C) 
We found 500 Solexa reads that matched the 5’ LANA-GFP junctional sequence. Shown 
is the distribution (density) of BLAST scores log(blast E value) for this comparison. 
Again, the majority of reads matched perfectly (lowest log(blast E value)). If there was an 
inadvertent single nucleotide insertion at this site, we would expect the majority (i.e. the 
peak of the density distribution) not to be associated with the lowest log(blast E value), 
but with a higher one, indicative of a mismatch. 
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Absence of R-LANA leads to more lytic replication during de novo infection. 
As we have previously reported (19), RRV infection of RhF provides a lytic system 
to study de novo viral replication. We wanted to examine the role of R-LANA in lytic 
replication in the context of the whole virus. Infection with RRVΔLANA/GFP, the parental 
H26-95 virus, revertant virus RRVREV, and RRV-GFP viruses was performed at 0.5 MOI 
(Fig. 6), 0.1 MOI (Fig. 7), or 5 MOI (Fig. 8) in duplicate on confluent monolayers of RhF. 
These three different MOIs were chosen in order to assess whether R-LANA may have 
variegating effects on lytic viral replication based on multiple-step (0.1 and 0.5 MOI) versus 
single-step (5 MOI) infection conditions. RRV-GFP virus (19) contains a CMV immediately-
early promoter-driven GFP cassette in a non-coding intergenic region of RRV between ORFs 
18 and 19. RRV-GFP virus was used to control for any undesirable GFP-related effects on 
RRVΔLANA/GFP viral replication. After an inoculation period of two hours for optimal 
adsorption, the supernatants from the infected cells were aspirated and replaced with DMEM 
containing 2% FBS to allow infections to proceed. At 0, 24, 48, 72, 96, 120, and 144 hours 
post infection (hpi), cell-free supernatants were harvested by centrifugation at 2,000 rpm for 
5 min. For the viral growth curves, the supernatants were serially diluted in triplicate and 
subjected to traditional plaque assays to measure infectious particles (Fig. 6A, 7A, and 8A). 
For real-time PCR to measure extracellular viral genome copies (Fig. 6B, 7B, and 8B), 200 
μl of the clarified supernatant for each infection sample, spiked with salmon sperm DNA was 
processed through a DNeasy column (QIAGEN) for DNA isolation. Two hundred microliters 
of the eluate were collected, 4 μl of which was then subjected to real-time PCR in triplicate 
using SYBR® Green mixture containing RRV Orf50 primers. To obtain absolute 
quantification, a standard curve for Orf50 was generated for each real-time PCR run. For 
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QPCR intracellular viral assays, the infected cells were harvested by trypsinization.  Each 
infected cell pellet was resuspended in 200 μl of PBS and the total DNA content was 
column-purified by the DNeasy kit (QIAGEN) and eluted in 200 μl of elution buffer. Four 
microliters of the eluate was then subjected to real-time QPCR in triplicate. The results are 
shown in Figures 6C, 7C, and 8C. In order to account for cell death following viral 
replication in our data analysis, intracellular viral genomes were also normalized to rhesus 
genomes using rhesus tubulin as an endogenous control (Figs. 6D, 7D, and 8D).  
The results at all three MOIs show that RRVΔLANA/GFP exhibited significantly 
faster growth kinetics by replicating to higher titers compared to the other three viruses. This 
enhanced growth property was more pronounced during earlier timepoints. At later 
timepoints the levels of RRVΔLANA/GFP viral genomic DNA and RRVΔLANA/GFP 
infectious particles reached a plateau, while DNA synthesis of the parental H26-95 virus and 
revertant virus RRVREV, and RRV-GFP continued. This was likely due to the depletion of 
viable cells available for replication for RRVΔLANA/GFP virus during later timepoints after 
the virus had replicated through the monolayer of RhF at earlier timepoints. Expectedly, the 
rescue virus RRVREV, displayed nearly identical growth kinetics as wild-type RRV by plaque 
assay and genome quantitation assay. As revealed by comparing the growth curves of RRV-
GFP virus with the wild-type and revertant viruses, the presence of GFP slightly decreased 
virus replication at both 0.1 and 0.5 MOI. This is likely due to the cytotoxic effects of GFP 
expression on the infected RhF. Thus, true assessment of the role of R-LANA on lytic viral 
replication should be made by comparing the viral growth curves of RRVΔLANA/GFP with 
that of the RRV-GFP recombinant virus. The RRVΔLANA/GFP virus showed a greater than 
10 fold higher level of replication than the RRV-GFP virus at early timepoints. Additionally, 
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the RRVΔLANA/GFP virus produced more viral genomes and functional virions than the 
RRV-GFP virus at all timepoints at both 0.1 and 0.5 MOI. At the single-step MOI of 5, the 
more rampant viral replication by RRVΔLANA/GFP was maintained during early infection 
up to 72 hpi and then plateaued due to the depletion of viable cells required for replication. 
 
Figure 6. Viral growth curves of RRVΔLANA/GFP in rhesus fibroblasts at 0.5 MOI. 
Equivalent numbers of RhF cells were infected with RRVΔLANA/GFP (◊), wild-type H26-
95 (□), RRVREV (∆), or RRV-GFP (O) at a MOI of 0.5. Cell-free supernatants and cell pellets 
were harvested at indicated points post-infection. A) Infectious virus particles from 
supernatants were quantitated by traditional plaque assay. B) Extracellular viral genomes 
from the same samples as in A) were quantitated by real-time PCR assay. In this real-time 
PCR-based assay, a RRV Orf50/Rta copy number standard curve was used to generate the 
viral genome copy number. C) Intracellular viral genomes extracted from infected cell pellets 
were quantitated by real-time PCR using a RRV Orf50 standard curve to generate the viral 
genome copy number. D) The viral genomes were normalized to rhesus β-tubulin copy 
numbers. The same samples as in C) were subjected to real-time PCR with RRV Orf50 
primers as described in panel C, and rhesus β-tubulin primers to absolutely quantitate rhesus 
β-tubulin copy numbers using a rhesus β-tubulin standard curve. During real-time QPCR, the 
amount of product at each cycle is quantified and the cycle threshold (Ct) at which the 
product signal crossed a user-defined threshold is recorded.  In this figure, dCt is 
mathematically defined as CtRta-Cttubulin, the signal difference between the viral gene Orf50 
and the cellular gene rhesus β-tubulin in a sample. The y-axis (2 –(CtRta-Cttubulin)) thus reflects the 
fold difference, or relative abundance, of RRV viral genomes compared with the cellular 
genomes. In all panels, results are the averages of duplicate or triplicate samples. Error bars 
represent standard deviations.  
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Figure 7. Viral growth curves of RRVΔLANA/GFP in rhesus fibroblasts at 0.1 MOI. 
Equivalent numbers of RhF cells were infected with RRVΔLANA/GFP (◊), wild-type 
H26-95 (□), RRVREV (∆), or RRV-GFP (O) at a MOI of 0.1. Cell-free supernatants and 
cell pellet were harvested at indicated points postinfection. A) Infectious virus particles 
from supernatants were quantitated by traditional plaque assay. B) Extracellular viral 
genomes from the same samples as in A) were quantitated by real-time PCR assay. In this 
real-time PCR-based assay, a RRV Orf50 copy number standard curve was used to 
generate the viral genome copy number. C) Intracellular viral genomes extracted from 
infected cell pellets were quantitated by real-time PCR using a RRV Orf50 standard curve 
to generate the viral genome copy number. D) The viral genomes were normalized to 
rhesus β-tubulin copy numbers. The same samples as in C) were subjected to real-time 
PCR with RRV Orf50 primers as described in panel C, and rhesus β-tubulin primers to 
absolutely quantitate rhesus β-tubulin copy numbers using a rhesus β-tubulin standard 
curve. In all panels, results are the averages of duplicate or triplicate samples. Error bars 
represent standard deviations.  
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Figure 8. Viral growth curves of RRVΔLANA/GFP in rhesus fibroblasts at 5 MOI. 
Equivalent numbers of RhF cells were infected with RRVΔLANA/GFP (◊), wild-type 
H26-95 (□), RRVREV (∆), or RRV-GFP (O) at a MOI of 5. Cell-free supernatants and cell 
pellet were harvested at indicated points postinfection. A) Infectious virus particles from 
supernatants were quantitated by traditional plaque assay. B) Extracellular viral genomes 
from the same samples as in A) were quantitated by real-time PCR assay. In this real-time 
PCR-based assay, a RRV Orf50 copy number standard curve was used to generate the 
viral genome copy number. C) Intracellular viral genomes extracted from infected cell 
pellets were quantitated by real-time PCR using a RRV Orf50 standard curve to generate 
the viral genome copy number. D) The viral genomes were normalized to rhesus β-tubulin 
copy numbers. The same samples as in C) were subjected to real-time PCR with RRV 
Orf50 primers as described in panel C, and rhesus β-tubulin primers to absolutely 
quantitate rhesus β-tubulin copy numbers using a rhesus β-tubulin standard curve. In all 
panels, results are the averages of duplicate or triplicate samples. Error bars represent 
standard deviations.  
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Absence of R-LANA results in the enhanced transcriptional expression of many RRV 
genes. 
         Based on our growth curve experiments (Figs. 6, 7, and 8), RRVΔLANA/GFP virus 
displayed more lytic viral replication than H26-95, RRV-GFP, and RRVREV viruses. We 
were therefore interested to determine whether the overall pattern of RRV viral gene 
expression was altered during de novo infection. We used the RRV real-time quantitative 
PCR viral array our lab previously reported (26) to profile the gene expression of all 84 RRV 
ORFs following de novo infection of RhF at 0.5 MOI. A heat map representation of real-time 
QPCR data normalized to rhesus tubulin (dCT) from viral infection timepoints at 0, 12, 24, 
48, 72, 96, 120, and 144 hpi was generated. The dCT values were subjected to hierarchical 
clustering using the standard Euclidian correlation method. Beginning at 24 hpi, the 
RRVΔLANA/GFP infected cells displayed upregulation of the majority of viral genes of 
immediate-early (IE), early (E), and late (L) classes compared to RRV-GFP infected cells 
(Fig. 9A). The upregulated RRV IE genes included Orf50/Rta. Furthermore, almost all of the 
RRV early genes (ORFs R1, 43, 6, 29a, 17, R9-1, 27, 24, 45, 55, R8, 74, 8, and 49) were 
robustly upregulated in the RRVΔLANA/GFP infected cells compared to RRV-GFP infected 
cells. Examples of upregulated late transcripts in the RRVΔLANA/GFP infected cells are 
ORFs 25/MCP, 28/gp150, 29b (packaging protein), 32 (transport protein), 53/gN, R9-3/vIRF, 
65/SCIP, 67, 67.5, 69, 75/vFGARAT, 23 (egress protein), and 9/polymerase. Unlike the 
immediate-early and early genes, the extent of late gene upregulation in the 
RRVΔLANA/GFP infected cells was not as robust. Indeed, amongst the late genes listed 
above, only Orf65/SCIP and Orf69 exhibited highly differential expression in the 
RRVΔLANA/GFP infected cells compared to the RRV-GFP infected cells. The remainder of 
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the late transcript levels were only modestly increased in the RRVΔLANA/GFP infected 
cells. Notably, infection with RRVΔLANA/GFP resulted in increased expression of all RRV 
Rta-responsive genes. These include R8, Orf8/gB, Orf57/MTA, whose expression we 
previously reported to be induced by RRV Orf50 transient expression using luciferase 
reporter constructs (18). Transcription of the RRV homologues of KSHV Rta-responsive 
viral genes (Orf6/ssDBP, R1, Orf9/DNApol, Orf74/vGPCR, and Orf45) were also found to 
be preferentially elevated in the RRVΔLANA/GFP infected cells compared to RRV-GFP 
infected cells. Taken together, these data suggest that RRV Rta function may be unchecked 
in the absence of R-LANA expression, and that R-LANA has an enormous impact on the 
expression of many RRV viral genes. Only a few RRV genes did not show much R-LANA 
dependency in their expression profiles, these included Orf38 and OrfR9-3/vIRF. 
Importantly, genetic disruption of R-LANA did not inhibit the transcription of the adjacent 
Orf71 and Orf72 genes. Orf72 gene expression was upregulated in the RRVΔLANA/GFP 
virus, suggesting that unimpeded Rta expression further enhances the R-LANA promoter for 
this transcript. Orf71 was also increased in the RRVΔLANA/GFP infected cells but less 
dramatically than Orf72. This result might be due to the predominant effect of the cryptic 
promoter for monocistronic Orf71 transcript driving Orf71 expression in an Rta-independent 
fashion during lytic replication as previously described (32). Our array also contained 
negative controls including primers for KSHV genes (Orf73/LANA, Orf50/Rta, Orf57/MTA, 
K1, Orf74/vGPCR), human GAPDH, human actin, and murine apoB genes. As expected, the 
expression of any KSHV, human or mouse transcripts was undetectable in RRV infected 
rhesus fibroblasts.  
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Figure 9. Viral gene profiling of RRVΔLANA/GFP and RRV-GFP infected rhesus 
fibroblasts. A) A heat map representation of real-time QPCR data normalized to rhesus 
tubulin (dCT) of infected cells taken at the following timepoints: 0, 12, 24, 48, 72, 96, 120, 
and 144 hpi. The dCT values were hierarchically clustered using standard Euclidian 
correlation method. Blue indicates low, white represents intermediate/median, and red 
represents the highest level of viral mRNA detected relative to rhesus tubulin. B) Quality 
control of RRV QPCR primers for all of the ORFs. There was no significant correlation 
between the magnitude of the log(SD) and the mean CT, demonstrating that except for three 
outliers, changes in RRV gene expression did not depend on the overall levels of any 
particular viral mRNA. C) Distribution of RRV ORFs showing differential transcript 
abundance between samples. We determined for each individual gene in the array whether its 
relative abundance at each time point differed between wild-type and mutant. The 
significance of the difference is expressed by the p-value of the F statistic. mRNAs that 
differed significantly in their transcription pattern yield a low p-value. We then plotted the 
density, i.e. the distribution of p values for all mRNAs in the array. Individual dots just above 
the x-axis indicate individual mRNAs. The peak at a low p-value indicates that the majority 
of mRNAs have differential expression between the wild-type RRV-GFP and mutant 
RRVΔLANA/GFP viruses. Orf4 has a p-value of 0.076 and is a watershed to differentiate 
ORFs that exhibit statistically significant differences (peak group left to Orf4) from those 
that do not (right to Orf4). Orfs 28 and 56 are the only genes within the peak group with 
p>0.05. D) A great concern in array analysis is the problem of multiple comparisons. Given 
172 
 
enough comparisons; one would expect some ORFs to show a statistically significant 
difference by chance alone. These are called false positives. The expected number of false 
positives (rate) can be calculated based on the total number of genes in the array and the p-
values of the individual comparisons. Shown in this panel is a plot of the expected rate of 
false positive against the number of RRV ORFs considered showing individually statistically 
significant differences in mRNA levels between wild-type and mutant viruses. Based on the 
p-value distribution in panel C one would expect less than 1 (<0.02) false positive within the 
top 71 differentially regulated genes, i.e. those that differed more significantly between wild-
type and mutant than Orf 4 (indicated in panel D). 
 
 The QPCR primers amplified their respective targets efficiently and independent of 
the overall levels of any particular viral messages. This is visualized by plotting the log(SD) 
against the mean raw CT values (Fig. 9B). No correlation was evident. Except for three 
outliers with mean CT > 35 all data were within the linear range of the assay. 
 To quantitatively assess whether there was a difference in the transcription profile 
between the mutant and wild-type viruses, we calculated the difference ddCT in mRNA 
levels for every mRNA at every time point, which is equivalent to taking the ratio of absolute 
mRNA levels between RRVΔLANA/GFP and RRV-GFP viruses. Next, we fitted a linear 
regression curve to the ddCT over time and calculated the p-value using the F statistic (30) to 
determine whether there was a linear trend over time. For any mRNA with no differences 
between the mutant and wild-type virus, ddCT would be the same at each timepoint and there 
would be no significant correlation. This is evidenced by tubulin, which has a p-value of 0.76 
(Fig. 9C). Note that this statistic is based on n = 16 data points. A few viral genes showed 
intermediate dependencies, but the majority of viral mRNAs (n = 72) exhibited a significant 
linear trend with a mean p≤ 0.02. We used q-value calculations (82) to adjust for multiple 
comparisons (Fig. 9D).  This demonstrated that within our total set of 84 genes, we would 
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expect at most 4 genes to show this trend by chance alone. As we observed 72 genes, this 
analysis establishes that there is a significant difference between wild-type and recombinant 
virus mRNA levels and that almost all mRNA transcripts of the RRVΔLANA/GFP were 
transcribed at higher levels at earlier times than the wild-type virus. 
R-LANA modulates the transcription of cellular genes.  
  We also examined several cellular genes that are known to be repressed by KSHV 
LANA in the context of lytic infection with the RRVΔLANA/GFP and RRV-GFP viruses. In 
brief, RhF were infected with either virus (1 MOI) for 48 hours. Total RNA was isolated 
from infected RhF and one microgram of the RNA was reverse-transcribed using the 
Promega reverse transcription system and Oligo(dT) primers. The cDNA was then subjected 
to real time PCR using standard cycling conditions with primers specific to genes that were 
previously cited to be repressed by LANA (Table 1). The real time PCR primers are shown 
in Table 2. In real time PCR, higher Ct values correlate with lower abundance of the 
examined RNA and vice versa. A dCt value is defined as the Ct value of each listed gene 
minus the Ct value of the endogenous control, rhesus β-tubulin. A negative dCt value 
indicates a higher expression level of the specific gene compared to the control rhesus β-
tubulin gene. The Ct value for each gene (including β-actin) was normalized to the Ct value 
of rhesus β-tubulin from the same sample to generate dCt (dCt=Ctgene of interest-Ctβ-tubulin) values 
for mock, RRVΔLANA/GFP and RRV-GFP infected cells (Table 1). A ddCt value is defined 
as the dCt value of each listed gene from an infected sample minus the dCt value of the same 
gene from a mock infected sample. Negative values of ddCt indicate higher expression of 
genes in infected compared to mock infected samples. The ddCt values were calculated for 
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RRVΔLANA/GFP compared to mock-infection, and for RRV-GFP compared to mock 
infection, respectively. The fold activation of the specific gene in RRVΔLANA/GFP infected 
cells compared to RRV-GFP infected cells was subsequently deduced and is shown in Table 
1. Previous reports have shown that KSHV LANA can repress nuclear receptor coactivator 3 
(NCOA3), cAMP responsive element binding protein-like 1 (CREBL1), CCAAT-box 
binding transcription factor, G1/S-specific cyclin-D2 (CCND2), and forkhead box protein 
G1B (FKHL1/FOXG1B) when expressed in isolation in B cells or endothelial cells (3, 4, 52). 
We found that these genes are derepressed i.e. activated during de novo lytic infection of RhF 
with the RRVΔLANA/GFP virus compared to RRV-GFP (Table 1). The β-actin gene serves 
as a control since its expression did not change in cells infected with either 
RRVΔLANA/GFP or RRV-GFP. Specifically, An et al. showed that the transcriptional 
factors NCOA3, CREBL1, and CCAAT-box binding transcription factor were down-
regulated between 2 and 4.9 fold when LANA expression was induced by doxycycline in 
BJAB/Tet-On/LANA cells (3). Our data using the RRVΔLANA/GFP virus suggests that R-
LANA might also repress the transactivation of cellular and/or viral genes that are dependent 
on these transcription factors. Since NCOA3 has an intrinsic histone acetyltransferase (HAT) 
activity (11), one might also speculate that LANA suppression of NCOA3 gene expression 
could lead to histone remodeling in order to silence genes that are normally activated by 
NCOA3. Moreover, Shamay et al. previously demonstrated that expression of KSHV LANA 
in TIME endothelial cells resulted in a strong repression of FKHL1/FOXG1B (17 fold) and 
CCND2 (4.6 fold) gene expression (78). Such repression was due to LANA recruitment of 
the methyltransferase Dnmt3a and could be reversed using a methyltransferase inhibitor (78). 
Our finding that the RRVΔLANA/GFP virus infected cells display higher activation of 
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FKHL1/FOXG1B and CCND2 gene expression than the RRV-GFP infected cells suggests 
that R-LANA does indeed repress FKHL1/FOXG1B and CCND2 gene expression even in 
the context of the whole virus. This finding also suggests an epigenetic mechanism for R-
LANA mediated silencing of cellular genes, and further corroborates LANA’s role in 
suppressing gene transcription (78).  
Table 1. Cellular genes that are activated (derepressed) in RRVΔLANA/GFP infected 
RhF compared to RRV-GFP infected RhF. 
 
Table 2. Real-time QPCR primers for rhesus cellular genes. 
GENE NAME FORWARD PRIMER REVERSE PRIMER 
NCOA3 GGGGATGGTGAGCTGTGACT  TGACATCCAAAATGGTCAGCA  
CREBL1 TGAGGTGGGGGTGTTC  GAGCTCTATATTCCGAAAAGG  
CCAAT-box 
binding TF  
TTTCAAGTCCTTTCACCCCAG  GCAAGGCTGTTTTTTACCCC  
CCND2  ATTGGCTATGATGGTGACAT  CTCTTAAAAGGCAGCTGACTA  
FKHL1/FOXG1B  AAGAAAGTTGTTTCAGTTGGC  TTCAATTGAATGGGCAGT  
β-actin  CCTTCCATCGTCCACCGCAAA
TGCTTCTAGGC  
GTCAAGAAAGGGTGTAACGCA
ACTAAGTCACA  
 
R-LANA is important for establishment of latency in BJAB cells. 
We determined whether R-LANA also modulates the establishment and maintenance 
of RRV in B cells. To address this question, we infected BJAB B cells with 
RRVΔLANA/GFP or RRV-GFP (MOI = 0.5) as previously described (19). Seven days post-
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infection, infected BJAB cells were sorted by flow cytometry for the presence of green 
fluorescence. RRVΔLANA/GFP showed higher infectivity of BJAB cells than RRV-GFP on 
day 0 pre-sorting (data not shown). After sorting, we used equivalent numbers of GFP-
positive cells from both RRVΔLANA/GFP-infected and RRV-GFP-infected BJAB cells for 
further experimentation (Fig. 10A, upper panels). From here onwards, BJAB cells were split 
every two days and GFP-positive cells were continuously monitored by fluorescence 
microscopy and flow cytometry. The RRVΔLANA/GFP-infected BJAB sample showed a 
rapid loss of GFP-positive cells on days 7 and 14 post-sorting as determined by fluorescence 
microscopy and flow cytometry. Fig. 10A (lower panels) and Fig. 10B show the relative 
GFP-positive cells on day 14 post-sorting as determined quantitatively by flow sorting and 
visually by fluorescent microscopy, respectively. To confirm that the dramatic decrease in 
GFP-positive cells in RRVΔLANA/GFP-infected BJAB cells was due to the loss of RRV 
particles (or intracellular viral genomes), we performed quantitative real-time PCR to 
calculate RRV genome copy number. RRVΔLANA/GFP-infected BJAB cells displayed 
significantly lower intracellular viral genomes compared with RRV-GFP infected BJAB cells 
(Fig. 10C). 
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Figure 10 (previous page). RRVΔLANA/GFP and RRV-GFP infection of B 
lymphocytes. The KSHV-negative PEL cell line, BJAB, was infected with 
RRVΔLANA/GFP or RRV-GFP virus at 0.5 MOI by spinoculation. Seven days post-
infection, infected BJAB cells were sorted by flow cytometry for the presence of green 
fluorescence. A) Flow cytometry analysis of GFP- positive BJAB cells infected with 
RRVΔLANA/GFP or RRV-GFP virus immediately after sorting (day 0 post-sorting) and 14 
days post-sorting. The percentages of GFP-positive cells at the indicated time points are 
shown below the graphs. B) Representative images of RRVΔLANA/GFP and RRV-GFP 
infected BJAB cells on day 14 post-sorting. Brightfield and GFP fluorescence images of 
RRV-infected GFP-positive B cells are shown. C) Intracellular viral genomes of 
RRVΔLANA/GFP (■) and RRV-GFP (□) infected BJAB cells on day 7 and day 14 post-
sorting. Intracellular genomes extracted from infected cell pellets were quantitated by real-
time PCR using a RRV Orf50 standard curve to generate the viral genome copy number. The 
viral genomes were normalized to human GAPDH copy numbers, which were generated 
using a human GAPDH standard curve. Results are the averages of triplicate samples. Error 
bars represent standard deviations.  
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DISCUSSION 
KSHV LANA (K-LANA) has been extensively studied in regard to its molecular 
functions in regulating cell cycle, apoptosis, immune evasion, as well as viral latency 
(reviewed in (22, 85)). By comparison, relatively little is known about R-LANA. Given our 
previous finding that R-LANA can inhibit RRV Rta-mediated transactivation of a sub-set of 
lytic viral genes (17), we hypothesized that a R-LANA deletion mutant virus would display 
dysregulated transcription compared to wild-type RRV. Here we report the use of 
homologous recombination to generate RRVΔLANA/GFP and a revertant RRVREV 
recombinant virus to gain insight into the replication kinetics of the R-LANA knockout virus. 
We found that RRVΔLANA/GFP displayed increased lytic activity when the R-LANA ORF 
was functionally disrupted by insertion of a GFP expression cassette. By generating viral 
growth curves using traditional plaque assays as well as QPCR viral load assays, we 
demonstrated increased production of both viral genomes by real-time QPCR, and infectious 
virion particles by plaque assay, in RRVΔLANA/GFP infected RhF compared to wild-type 
and RRV-GFP infected RhF. Furthermore, whole-genome profiling of RRV transcripts 
provided an unbiased scrutiny of all RRV lytic gene expression that was altered by the 
functionally disrupted R-LANA, suggesting that the observed increase in RRV lytic activity 
was caused by global upregulation of RRV mRNA transcripts. Because Orf50/Rta is 
necessary and sufficient for initiation and orchestration of the lytic viral transcriptional 
cascade, we speculate that the lytic behavior of RRVΔLANA/GFP in our permissive RhF 
tissue culture system was largely due to unhampered Rta transactivation activity when R-
LANA expression was lost. Thus, R-LANA plays a pivotal role in suppressing lytic 
replication during de novo infection.  
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Several possible mechanisms could explain how R-LANA might inhibit Rta 
transactivation of Rta-responsive genes. The most obvious explanation is chromatin 
remodeling, as R-LANA has been implicated in recruiting histone deacetylases (HDACs) 
(17) , the result of which may lead to histone modification of Rta-responsive viral promoters. 
Such a mechanism has also been proposed for K-LANA by physical interaction with RBP-Jκ 
and other cellular proteins (21, 46, 53, 54). Additionally, Lu et al. have reported that Orf50 
transcription is specifically repressed by KSHV LANA during viral latency (53). In dually 
infected PELs, K-LANA has been shown to suppress EBV viral genes by regulating the 
mSin3 corepressor complex (44), although K-LANA was also reported to activate EBV or 
HIV viral genes (31, 35) as well as cellular genes (5, 41, 84). The transcriptional activation 
and repression activities have been mapped to the amino and carboxyl termini of K-LANA, 
respectively (62, 76, 87). In addition to recruiting HDACs for transcription repression, as we 
previously published (17), R-LANA might sequester histone acetyltransferases (HATs) from 
Rta or Rta-dependent viral promoters. Our finding that R-LANA decreased the gene 
expression of the histone acetyltransferase, NCOA3, suggests that R-LANA might also 
repress HAT-mediated transcription.  
In KSHV, both LANA and Rta have been shown to bind CREB-binding protein 
(CBP), which has HAT activity and can activate transcription (33, 49, 50). Other possibilities 
by which R-LANA could inhibit Rta function include affecting Rta protein levels and 
modification of Rta post-translationally in order to downregulate Rta transactivation 
function. Our preliminary data have excluded these two possibilities (unpublished data). 
Interestingly, a significant number of RRV genes that were upregulated in the 
RRVΔLANA/GFP infected cells compared to the RRV-GFP infected cells have not been 
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previously identified as being Rta-responsive in either the KSHV or RRV viral systems. 
KSHV LANA has been shown to act as a transcriptional repressor on some cellular 
promoters such as those that are dependent on CBP or E2F transactivation (49, 50, 65, 67). It 
is therefore plausible that R-LANA acts as a direct transcriptional repressor of a sub-set of 
viral genes, independent of its inhibition of Rta transactivation.  
 The characterization of a KSHVLANA virus in the context of lytic replication was 
recently published (48). The investigators reported that deletion of KSHV LANA resulted in 
the increased production of KSHV infectious virions after TPA and sodium butyrate 
treatment of KSHVLANA infected cells, as well as enhanced transcription of four Rta-
responsive lytic genes including MTA, Orf59, vIL-6, Orf-K8.1 (48). The expression of these 
homologous genes in RRV was also increased by RRVΔLANA/GFP de novo infection of 
RhF, and increased production of infectious RRV virions was also observed with 
RRVΔLANA/GFP infection compared to RRV-GFP infection. Importantly, this differential 
pattern of gene expression was seen in the absence of exogenous artificial inducers such as 
TPA and butyrate (48). 
Furthermore, our study showed for the first time that LANA modulates transcription 
of cellular genes during lytic infection and in the context of the whole virus. Cellular genes 
such as NCOA3, cAMP responsive element binding protein-like 1, CCAAT-box binding 
transcription factor, CCND2, and FKHL1/FOXG1B, which were previously reported to be 
repressed by KSHV LANA in either B cells or endothelial cells (3, 4, 52), were found to be 
derepressed in cells infected with RRVΔLANA/GFP compared to RRV-GFP. 
182 
 
Unlike KSHV and RRV, deletion of LANA from MHV68 showed absolutely no 
difference in replication in vitro at high MOI, and the MHV68LANA virus displayed 
reduced viral titers compared to wild-type virus at very low MOIs upon de novo infection of 
primary murine embryonic fibroblasts or NIH3T3 fibroblasts (27, 28, 48, 58). This 
paradoxical observation could be attributed to the different cell lines being investigated, 
mouse versus primate cells. On the other hand, the discrepancies here may reflect that the 
KSHV LANA protein may be functionally more similar to its primate homologue, RRV 
LANA, than the murine MHV68 LANA homolog.  
Finally, RRVΔLANA/GFP was inefficient in establishing latency in infected BJAB 
cells. This was similar to what was observed with the KSHV LANA deletion mutant BAC36-
ΔLNA, which failed to establish a latent infection in transfected human 293 cells (90). A 
future goal of our study is to investigate RRVΔLANA/GFP infection in rhesus macaques to 
determine its behavior in vivo. In the case of the MHV68 LANA deletion virus, previous 
reports suggest that the loss of LANA resulted in a compromised ability of the virus to 
replicate in the lungs and establish latency in the spleen of infected mice (28, 58). Given the 
biological properties of the RRVΔLANA/GFP recombinant virus, we hypothesize that such a 
virus would make a good candidate vaccine, which will protect against challenge with wild-
type RRV-GFP virus. This is because the highly lytic nature of this virus results in the 
dysregulated expression of multiple lytic viral genes, which should expose the virus to the 
host innate and adaptive arms of the immune system to a greater extent than WT RRV-GFP. 
Hence, the host should be able to mount a robust immune response against the 
RRVΔLANA/GFP virus, which may help protect the host from subsequent challenge with 
wild-type RRV. Furthermore, the inability of this virus to establish latency in dividing cells 
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means that unlike wild-type RRV-GFP and other herpesviruses, this virus should be lost from 
proliferating cells since R-LANA is not expressed.  
We are currently evaluating the RRVΔLANA/GFP as a vaccine candidate in rhesus 
macaques in collaboration with Dr. Ronald Desrosiers at Harvard Medical School. We will 
determine the biological characteristics of the RRVΔLANA/GFP recombinant virus in terms 
of its persistence, viral load levels in the blood, anti-viral antibodies present in the 
RRVΔLANA/GFP infected rhesus macaques and to use it as a vaccine to protect against 
challenge with WT RRV. 
In conclusion, we have created a RRVΔLANA/GFP that is more lytic than RRV-
GFP, wild-type RRV H26-95, or a revertant RRVREV virus. This recombinant virus displays 
higher viral loads in rhesus fibroblasts as well as increased expression of a multitude of RRV 
viral genes during lytic replication in rhesus fibroblasts. Additionally, cellular genes that are 
normally repressed by LANA are derepressed in RRVΔLANA/GFP infected cells compared 
to RRV-GFP infected cells. Furthermore, the RRVΔLANA/GFP recombinant virus also fails 
to successfully establish latent infection in B lymphocytes.  
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General Conclusions 
 KSHV is etiologically associated with three human neoplastic diseases, namely 
KS (8), PEL (6), and MCD (22, 40). KS is a vascular malignancy of endothelial origin, 
whereas PEL and MCD are lymphoproliferative disorders of B cell origin (8). KSHV 
encodes a plethora of transforming/tumorigenic proteins and cellular homologs that 
perturb normal cellular signaling pathways. The cellular functions affected by KSHV 
include cell growth and proliferation, cell death, innate and adaptive immunity. The ideal 
outcome for the virus is efficient viral replication and persistent infection of the host to 
benefit its own survivorship.  
KSHV lifecycle exhibits lytic and latent phases of infection. During a lytic 
infection, the virus replicates its linear viral genomes and expresses more than 80 
transcripts in a highly orchestrated temporal order, resulting in the production and release 
of infectious particles. In latency, the KSHV viral genome is circularized and exists as an 
extra-chromosomal episome. The latent virus only expresses a very small subset of latent 
transcripts (e.g. LANA) in the infected cells and produces no functional or infectious 
viral particles. Despite different roles in the viral lifecycle, both latent and lytic proteins 
of KSHV can be tumorigenic/oncogenic: the lytic viral proteins may mediate paracrine 
secretion of growth and angiogenic factors essential for tumor growth and development. 
The latent viral proteins may enhance the survival and proliferation of the infected cells. 
 The KSHV K1 and LANA proteins, which are the subjects of this dissertation, 
have been implicated in tumorigenesis and oncogenesis. The K1 ORF is located at the far 
left end of the KSHV genome (25), and is the positional equivalent of RRV R1 and HVS 
STP. It is therefore not surprising K1 and R1 can functionally substitute STP to 
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immortalize T lymphocytes (11, 15). Although K1 has been shown to perturb BCR cell 
signaling (15, 28, 42) and inhibit apoptosis in B cells (42) and have oncogenic properties 
(e.g. transformation of rodent fibroblasts (15) and induction of tumor formation in mice 
(15)), the mechanism of action contributing to these phenotypes is largely not known. 
Our lab and others have shown that while K1 gene expression could be detected in 
latently infected cells, it was induced to a higher level during lytic replication and thus 
K1 behaved like an early gene (7, 10, 24, 26, 39). We therefore sought to understand the 
role of K1 during various aspects of the lifecycle, i.e. latency, de novo lytic replication, 
and lytic reactivation, using RRV as a model system.  
The LANA oncoprotein can suppress the activity of the tumor suppressors p53 
(20) and Rb (36), and promote cell cycle progression by sequestering GSK-3β that leads 
to subsequent activation of CCND1 and Myc (3, 21). In addition, LANA is critical for the 
maintenance of the viral genomes in infected cells (13, 37, 44) and can inhibit Rta 
transactivation of viral promoters and thus the release of viral progeny (29). One would 
therefore speculate that depletion of LANA will result in a virus that is even more highly 
lytic but fails to establish and/or maintain latency. Because there is no cure or vaccine for 
KSHV as well as other rhadinovirus infections, we generated a LANA knockout virus in 
RRV and characterized its biological properties in vitro. A future goal is to explore its 
vaccine potential in vivo using a rhesus macaque model system.  
The research work I performed under the supervision of Dr. Blossom Damania 
has generated new questions and hypotheses. Addressing the unresolved puzzles will 
stimulate further research and provide new insights into the oncogenic pathways usurped 
by KSHV as well as the basic virology of KSHV and other rhadinoviruses. My work also 
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provides further rationales for targeting K1 and its binding partners, especially Hsp90, to 
treat KSHV-associated lymphomas and for the use of a LANA knockout virus as a 
vaccine to prevent rhadinovirus infection and/or tumor development. The conclusions for 
the chapters will be reiterated below, with future directions and specific remarks 
wherever relevant and applicable.  
The role of Hsp90 and Hsp40 in K1 expression and function 
Despite the known signal transduction pathway and functions of K1, relatively 
little is known about how K1 protein expression and function are modulated. Using TAP, 
we identified Hsp90β and the ER-associated Hsp40/Erdj3 protein as the cellular partners 
of K1. This was corroborated by co-immunoprecipitations that confirmed these protein-
protein interactions. We have further shown that K1’s interaction with Hsp90β (but not 
Hsp40/Erdj3) is dependent on the presence of ATP and perhaps ATP hydrolysis by 
Hsp90β. To test specifically whether Hsp90 ATPase activity is essential for its interaction 
with K1, it will be worthwhile to test if Hsp90 inhibitors can also disrupt or abrogate the 
interaction between K1 and Hsp90.  
Hsp90 has been show to regulate subcellular trafficking and function of viral 
proteins in KSHV and other herpesviruses (4, 18, 23). Our finding that K1 is a viral client 
protein of Hsp90 and the ER-associated Hsp40/Hsp70 system is novel and intriguing, 
because it implies that the protein expression of the K1 viral oncogene can be 
manipulated with existing Hsp90 inhibitors as well as siRNA/small hairpin RNAs 
targeting Hsp90 and/or Hsp40/Erdj3 chaperones. By performing confocal 
immunofluorescence assays, we showed that K1 interacts and colocalizes with Hsp90 and 
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Hsp40/Erdj3 in KSHV-positive PEL B cell lines. K1 and Hsp90 expression can also be 
detected in PEL tumors in our immunohistochemical study. Thus, our data validate 
Hsp90 as an important therapeutic target for treating KSHV-associated lymphomas.  
Using the Hsp90 inhibitor geldanamycin (GA), we showed that Hsp90 ATPase 
activity and chaperoning function are required for optimal expression of K1. GA inhibits 
all the known Hsp90 homologs. Thus, it is possible that Hsp90 homologs other than 
Hsp90α and Hsp90β may also associate with K1 and modulate its expression and 
function. Future work addressing this possibility may elucidate if a general Hsp90 
inhibitor or an isoform-specific Hsp90 is more preferable to target K1-driven pathways. 
The use of an isoform-specific Hsp90 inhibitor may cause fewer side effects than a 
general Hsp90 inhibitor in vivo. Similar to GA treatment, genetic knockdown of either 
Hsp90β or Hsp40/Erdj3 using siRNA also dramatically reduced K1 protein expression. 
Interestingly, we did not see much effect of K1 on the expression of levels of Hsp90 or 
Hsp40. It is plausible that instead of regulating the protein expression of Hsp90/ER-
associated Hsp40, K1 modulates the chaperoning function of Hsp90 and/or ER-
associated Hsp70 (that requires Erdj3 as a co-chaperone for optimal chaperoning 
activity). Future experiments testing K1’s effect on the ATPase activity of Hsp90 and 
ER-associated Hsp70 will address this possibility. 
While depletion of both endogenous Hsp90β and ER-associated Hsp40 negated 
the ability of K1 to prevent Fas-mediated apoptosis, depletion of only Hsp90β or Hsp40 
by itself had no effect. One explanation is that knockdown of both Hsp90β and Hsp40 
reduced K1 expression levels more robustly than single knockdowns of these proteins. A 
second possibility is that there are two different pools of K1 whose expression and/or 
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function are regulated by Hsp90β and Hsp40. K1 has been shown to be expressed on the 
plasma membrane as well as in the ER (30). Since Hsp90β is predominantly cytosolic 
and Hsp40/Erdj3 is ER-associated, one may speculate that these different pools of K1 are 
topologically distinct (Fig. 1). Hence, knockdown of the ER-restricted chaperone may 
reduce K1 levels in the ER, but not affect cytosolic or cell surface levels of K1, and vice 
versa. A simple experiment to test this in the future is to repeat the Hsp40/Erdj3 and 
Hsp90 knockdown experiments and perform immunofluorescence assays for K1-Hsp90 
and K1-Hsp40/Erdj3 colocalization and also fluorescently label the ER or endosome 
compartment with an ER-tracker (e.g. glibenclamide that binds to ER-specific 
sulphonylurea receptors of ATP-sensitive K+ channels) or endosome marker (e.g. EEA1 
and CD71/transferring receptor). Alternatively, we can perform the individual 
knockdown experiments and then fractionate the 293-K1 cells to obtain the cytosolic, ER, 
and membrane fractions and repeat the co-immunoprecipitation assays for K1-Hsp90 and 
K1-Erdj3. If the K1-Hsp90 and K1-Erdj3 complexes are topologically exclusive, we may 
only see the former complex predominantly in the cytosolic/endosome compartment and 
the latter in the ER compartment, respectively, by IFA or co-IP. With the control siRNAs 
transfected, we will detect K1-Erdj3 complex localized predominantly in the ER, and the 
majority of K1-Hsp90 complex in other compartments (e.g. plasma membrane, 
endosome, or cytosol). With Hsp90 siRNA transfection, we will detect mostly K1-Erdj3 
complex in the ER, whereas with Erdj3 siRNAtransfection, K1-Hsp90 complex in other 
subcellular compartments. It will be interesting to see whether knockdown of Hsp90 will 
result in the enrichment of the Hsp40 colocalizing and interacting with K1 and vice versa. 
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Such a result may explain why single knockdown of Hsp90 or Erdj3 did not induce 
caspase-3 activation or cell death in 293-K1 cells relative to 293-Vec cells. 
 
Figure 1. A working model for the interaction of K1 with Hsp90 and ER-associated 
Hsp40. K1-interacting complexes may be topologically distinct as shown. N: N-terminal 
domain of K1; C: C-terminal domain of K1. 
 
Targeting Hsp90 and K1 as a therapeutic approach to PEL and other KSHV-
associated malignancies 
Our data showed that inhibition of Hsp90 activity by 17-AAG and 17-DMAG at 
low concentrations resulted in cell growth inhibition and cell-cycle arrest at G0/G1 phase. 
Furthermore, preliminary data (not shown) demonstrate that stable knockdown of K1 in 
BCBL-1 cells by shRNA also suppressed PEL cell proliferation. These data suggest the 
relevance of targeting Hsp90 and K1 as a potential therapeutic to PEL. To determine if 
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Hsp90 is also efficacious against KSHV-derived tumorigenic endothelial cells in the 
future, we will measure the IC50 and/or LC50 of Hsp90 inhibitors in long term-infected 
telomere-immortalized human umbilical vein endothelial (TIVE) cells that stably harbor 
KSHV. A key future direction is to test if Hsp90 inhibitor or stable knockdown of Hsp90 
or K1 by shRNA can prevent the formation and/or progression of PEL-like or KS-like 
tumors in mouse models. Our lab as well as the Dittmer lab have established long term-
infected TIVE cells (LTC)-severe combined immunodeficient (SCID) and PEL-SCID 
mouse xenograft models that have been shown to reflect KS and PEL tumorigenesis, 
respectively (5, 10, 35, 45).  
We also speculate that there are several other KSHV proteins that utilize 
molecular chaperones to modulate their expression and function. Future experiments 
generating TAP-tagged molecular chaperones such as Hsp90 and Erdj3 and performing 
tandem affinity purification in reactivated KSHV-positive PEL or tumorigenic 
endothelial cell lines may identify additional KSHV proteins that interact with them. 
Similar experiments may also be performed in RRV-infected RhF lysates to identify 
RRV proteins that bind Hsps. All of the above experiments may provide even further 
insights and rationale for using inhibitors against molecular chaperones for KSHV-
derived cancer therapy. 
Investigation of the role of K1 in the viral lifecycle using RRV R1 as a model 
The KSHV K1 protein has been shown to transform cells, inhibit apoptosis, and 
perturb cellular signaling pathways in B cells and endothelial cells (reviewed in (47)), yet 
its role in the KSHV lifecycle has not been well studied. K1 is expressed at low levels 
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during latency (7, 10, 17, 25, 38) and is upregulated during lytic infection (24, 26, 31, 39) 
where it demonstrates early kinetics. The role of K1 during latency versus lytic 
replication may depend on the level of K1 expression. Chandriani and Ganem recently 
reported using a very sensitive, limiting dilution-based assay that K1 RNA was present at 
low levels in latently infected cells in a context-dependent fashion (7).  
Using overexpression systems, two laboratories previously studied the role of K1 
on reactivation in B cells, albeit with conflicting data: Lee et al. observed in the KSHV-
positive BCBL-1 cells that K1 overexpression resulted in the suppression of lytic 
reactivation by TPA treatment (31), whereas Lagunoff et al. showed in KSHV-negative 
BJAB B cells that K1 overexpression augmented lytic reactivation upon KSHV Rta 
overexpression (27). Notably, Lagunoff et al. also found that introduction of a K1 
dominant negative mutant into BCBL-1 cells, followed by KSHV Rta-mediated induction 
of lytic replication, diminished lytic gene expression by up to 80% (27). These inhibitory 
effects could be overcome by TPA (27). Thus, these two publications reported 
contradictory results. 
To this day, the role of K1 during lytic de novo infection/reactivation and latency 
still remains unclear. Similar to the situation of K1, while R1 appears to be the positional 
and functional homolog of K1, R1’s role in RRV lifecycle has not been sufficiently 
addressed. By utilizing an overlapping set of cosmids developed by Bilello et al. (2), we 
generated a R1 functional knockout virus (RRVΔR1/GFPcc) of RRV and examined its 
replicative properties. Our findings should shed light onto the role of R1 and K1 in 
KSHV and RRV biology. 
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 RRVΔR1/GFPcc and the revertant virus replicated on RhF with growth kinetics 
that were similar to those of the wild-type control viruses at single-step growth or 
multiple-step growth. However, disruption of R1 resulted in a mutant virus less capable 
of establishing and maintaining latency as well as reactivating in BJAB cells. This 
suggests that R1 fine-tunes the lytic activity of RRV during these phases of the viral 
lifecycle. Since our data imply that R1 modulates latent infection and lytic reactivation, 
one may speculate that R1 should have some effect during de novo lytic replication. One 
possibility for not observing this could be due to cell-type specificity. While K1 
expression has been detected in KSHV-associated tumors, and K1 function and signaling 
have been demonstrated in B and endothelial cells, R1 function has only been described 
in B cells. Thus, rhesus fibroblasts might not represent the natural cell type in which R1 
signals or functions. The SH2 binding motifs in R1 might be specific for SH2-binding 
proteins in lymphocytes and/or endothelial cells only. Alternatively, since RhF is a highly 
lytic system that supports efficient RRV infection, our experimental setup might not be 
sensitive enough to detect minor suppressive effects of R1 on de novo replication under a 
high background of lytic replication. Hence, we are currently in the process of 
performing viral infections at very low MOIs (e.g. 0.01) which may potentially address 
this question.  
We are also comparing the replicative kinetics or RRVΔR1/GFPcc, Revertant, 
RRV-GFPcc, and RRV-J in immortalized human umbilical vein endothelial cells 
(HUVEC) that support de novo lytic infection to a lesser extent than RhF. Our 
preliminary data (not shown) revealed that RRVΔR1/GFPcc in HUVEC resulted in 
slightly less infectious particles and viral genomes when compared to the other three 
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viruses at 0.1 MOI. Interestingly, no difference was seen in all four viruses at higher 
MOIs (1 and 5). This suggests that R1 might modestly enhance lytic infection of HUVEC 
at low MOIs. However, these experiments were only performed once and will need to be 
repeated. 
In our B cell model, while RRVΔR1/GFPcc-infected BJAB cells released less 
virions than RRV-GFPcc-infected BJAB cells, the former were able to produce similar 
levels of viral particles upon more robust reactivation induced by TPA/NaB/TSA cocktail 
or KSHV Rta/Orf50 transactivation activity. Thus, R1 signaling might be complemented 
by some of the signaling events activated by TPA, NaB, and TSA, or by Rta-mediated 
transactivation of viral and/or cellular promoters. In agreement with our finding, 
Lagunoff et al. reported blockage of lytic replication by K1 ITAM mutants that could be 
overcome by TPA treatment, thus suggesting that TPA-mediated signaling pathways 
could substitute for the loss of K1 signaling (27). An interesting observation from this 
study is that KSHV Rta/Orf50 was able to reactivate RRV from latency, which implies 
that KSHV Rta can functionally complement or substitute RRV Rta. This finding echoes 
our previous observation that the Rta of RRV and murine gammaherpesvirus-68 (MHV-
68) can functionally substitute for their KSHV homolog.  
An alternative and valid interpretation of the data is that as a glycoprotein, R1 (or 
K1) may function to optimize efficient maturation and/or egress of the virus particles 
from B cells. This could also account for the observed enrichment of intracellular viral 
genomes in the RRVΔR1/GFPcc infected B cells, and reduction of extracellular viral 
genomes in the supernatant in the RRVΔR1/GFPcc infected B cells compared to RRV-
GFPcc infected B cells. To rule out this possibility, electron microscopy to examine and 
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compare the number, subcellular distribution, and morphology of viral particles within 
RRVΔR1/GFPcc and RRV-GFPcc infected BJAB cells will be performed in the future.  
To address the mechanism by which R1 affects the viral lifecycle, we may 
determine whether R1 may affect viral genes and assess whether those viral genes are 
Rta-responsive in the near future. We will subject isolated viral RNA from 
RRVΔR1/GFPcc or RRV-GFPcc infected BJAB cells to the RRV quantitative real-time 
PCR array developed by the Dittmer lab as previously described (14, 48), in order to 
assess the transcriptional profile of all RRV viral genes. We are in the progress of 
generating BJAB cell lines stably and latently infected with RRVΔR1/GFPcc or RRV-
GFPcc for the RRV viral array.  
In addition to its role in latency maintenance or lytic reactivation in vitro, R1 may 
function as an immunoregulatory protein in vivo. KSHV K1 has been shown to 
downregulate the BCR surface expression (30) that may otherwise lead to apoptosis. 
Thus K1 modulation of BCR signal transduction may provide a long-term survival 
advantage in vivo. Indeed, K1 expression has been shown to protect cells from Fas-
mediated apoptosis (42, 46). Like K1, R1 activates B-cell signaling pathways (9). We 
have preliminary data supporting that R1also increases the phosphorylation of Akt 
(S473), FKHR and Bad involved in the PI3K/Akt pathway (data not shown) (1, 42, 46). 
Since the same PI3K/Akt pathway activated by K1 is pro-survival and controls Fas-
mediated apoptosis (41, 43), R1 may exhibit a similar phenotype to K1 in vitro. Future 
experiments comparing the ability of RRV∆R1/GFPcc or control RRV-GFPcc to inhibit 
apoptosis upon Fas-induction will address whether R1 can also protect cells from 
apoptosis in the context of the whole virus during lytic replication and latency. 
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It will be interesting to assess whether rhesus macaques co-infected with SIV and 
RRVΔR1/GFPcc (or RRV-GFPcc) would develop B cell hyperplasia and persistent 
lymphadenopathy (16, 33, 49). Because R1 is the positional homolog of STP that has 
been shown to be critical for transformation in vivo (15) and R1 deregulates signal 
transduction in B-cells (9), RRVΔR1/GFPcc may be defective in inducing B cell 
hyperplasia in rhesus macaques. 
In conclusion, we have generated a recombinant RRV designated 
RRVR1/GFPcc, in which the R1 ORF has been disrupted by a GFP expression cassette. 
This R1 deletion virus displayed suppressed lytic activity in our B cell model for latency 
and reactivation, but had no significant effect on replication during de novo infection on 
rhesus fibroblasts at MOIs of 1 and 5. By determining the functional role of R1 in the 
RRV lifecycle, we may shed light on the role of K1 in KSHV lifecycle. This knowledge 
may guide future therapeutic strategy against rhadinovirus infection as well as KSHV 
infection and KSHV-associated malignancies. 
 
The role of RRV LANA in the context of the whole-virus infection 
The various functions of KSHV LANA (K-LANA) have been extensively studied 
(reviewed in (13, 44, 47)). By comparison, relatively little is known about R-LANA. 
Given our previous finding that R-LANA can inhibit RRV Rta-mediated transactivation 
of a subset of lytic viral genes (12), we hypothesized that a R-LANA knockout virus 
would be more lytic and display dysregulated transcription compared to the wild-type 
RRV. In order to gain insight into the role of LANA in RRV infection and replication, we 
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generated RRVΔLANA/GFP and a revertant virus (RRVREV). We found that 
RRVΔLANA/GFP displayed increased lytic activity in RhF. Disruption of R-LANA also 
resulted in a global upregulation of RRV mRNA transcripts as assayed by a QPCR RRV 
array. Because Rta is necessary and sufficient for initiating and orchestrating the lytic 
viral transcriptional cascade, we speculate that the lytic behavior of RRVΔLANA/GFP in 
our permissive RhF tissue culture system was largely due to unhampered Rta 
transactivation activity when R-LANA was no longer expressed. Altogether, our data 
suggest that R-LANA suppresses lytic replication during de novo infection in RhF. For 
future studies, it will be important to test if R-LANA has similar effects on HUVEC that 
also supports lytic replication. An established role of LANA in viral persistence in 
endothelial cells may prove important for KS development. 
RRVΔLANA/GFP exhibited elevated lytic activity in both viral production as 
well as global gene transcription that can be explained by unrestrained Rta transactivation 
activity. Several possible mechanisms could explain how R-LANA might inhibit Rta 
transactivation of Rta-responsive genes in the wild-type virus. The most obvious 
explanation is chromatin remodeling, as R-LANA has been implicated in recruiting 
histone deacetylases (HDACs) (12) , the result of which may lead to histone modification 
of Rta-responsive viral promoters. Additionally, Lu et al. have reported that Rta 
transcription is specifically repressed by KSHV LANA during viral latency (32). In 
addition to recruiting HDACs for transcription repression (12), R-LANA might sequester 
histone acetyltransferases (HATs) from Rta or Rta-dependent viral promoters. Our 
finding that R-LANA decreased the gene expression of the HAT, NCOA3, suggests that 
R-LANA might also repress HAT-mediated transcription. Other possibilities by which R-
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LANA could inhibit Rta function include affecting Rta protein levels and modification of 
Rta post-translationally in order to downregulate Rta transactivation function. Our 
preliminary data have excluded these two possibilities (unpublished data). Interestingly, a 
significant number of RRV genes that were upregulated in the RRVΔLANA/GFP 
infected cells compared to the RRV-GFP infected cells have not been previously 
identified as being Rta-responsive in either the KSHV or RRV viral systems. It is 
plausible that R-LANA acts as a direct transcriptional repressor of a sub-set of viral 
genes, independent of its inhibition of Rta transactivation.  
Furthermore, several cellular genes reported to be repressed by KSHV LANA in 
either B cells or endothelial cells were found to be derepressed in cells infected with 
RRVΔLANA/GFP compared to RRV-GFP. A future experiment will be to identify all 
cellular transcripts whose expression is altered by the presence of R-LANA during de 
novo lytic infection in the context of the whole virus. Specifically, we will subject mRNA 
isolated from RRVΔLANA/GFP vs. RRV-GFP infected RhF to Agilent Rhesus Macaque 
Gene Expression Microarray to profile cellular gene expression.  
Finally, RRVΔLANA/GFP also failed to efficiently establish and maintain 
latency in BJAB cells. This was similar to what was observed with the KSHV LANA 
deletion mutant BAC36-ΔLNA in 293 cells (50).  
 
RRVΔLANA/GFP as a vaccine candidate against rhadinovirus infection 
A future goal of our study is to investigate RRVΔLANA/GFP infection in rhesus 
macaques to determine its behavior in vivo. Given the biological properties of the 
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RRVΔLANA/GFP recombinant virus, we hypothesize that such a virus would make a 
good candidate vaccine, which will protect against challenge with wild-type RRV-GFP 
virus. This is because the highly lytic nature of this virus resulted in the dysregulated 
expression of multiple lytic viral genes, which should expose the virus to the host innate 
and adaptive arms of the immune system to a greater extent than the wild-type RRV-GFP 
virus. Hence, we hypothesize that the host should be able to mount a robust immune 
response against the RRVΔLANA/GFP virus, which may help protect the host from 
subsequent challenge with wild-type RRV. Furthermore, the inability of this virus to 
establish latency in dividing cells means that unlike the wild-type RRV-GFP and other 
herpesviruses, this virus should be lost from proliferating cells since R-LANA is not 
expressed. It is possible that although R-LANA is required for the establishment of 
latency in dividing cells, it is not required for the establishment of latency in non-dividing 
cells, in which case low amounts of the RRVΔLANA/GFP virus may still be detected in 
non-dividing cells (e.g. macrophages and dendritic cells that can support KSHV 
infection). We will determine if this is the case when we isolate macrophages and 
dendritic cells from blood for viral DNA analysis. If RRVΔLANA/GFP can persist in 
these non-dividing presenting immune cells, booster vaccinations may not be needed as 
there will be persistently high immune responses to confer long-term protection.  
A critical criterion for vaccines is safety. Importantly, RRVΔLANA/GFP virus 
could not achieve long-term latency in infected B cells that serve as the natural reservoir 
for rhadinoviruses. This should minimize the time and likelihood for the recombinant 
virus to transform infected B cells into lymphomatous cells. The presumably rampant 
clearance of this highly lytic virus should also discourage full-blown viral dissemination 
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as well as prolonged systemic symptoms in the host. Because both KSHV and RRV 
encode a number of cellular homologs, a legitimate concern is that RRVΔLANA/GFP 
genome may recombine with or integrate into the host cell genome. Another concern is 
that while herpesviruses have relatively stable DNA genomes, RRVΔLANA/GFP may 
still slowly mutate to lose its high lytic activity and revert back to the wild-type 
phenotype. With these potential problems in mind, we are currently evaluating the 
RRVΔLANA/GFP as a vaccine candidate in rhesus macaques in collaboration with Dr. 
Ronald Desrosiers at Harvard Medical School. We will determine the biological 
characteristics of the RRVΔLANA/GFP recombinant virus in terms of its persistence, 
viral load levels in the oral cavity and blood, anti-viral antibodies, and complete blood 
counts (CBC) present in the RRVΔLANA/GFP infected rhesus macaques (Table 1). We 
will also perform subsequent experiments to use it as a vaccine to protect against 
subsequent challenge with the wild-type RRV (Table 2). 
In conclusion, we have created a RRVΔLANA/GFP that is more lytic than RRV-
GFP, wild-type RRV H26-95, or a revertant RRVREV virus. This recombinant virus 
displays higher viral loads in rhesus fibroblasts as well as increased expression of a 
multitude of RRV viral genes during lytic replication in rhesus fibroblasts. Additionally, 
cellular genes that are normally repressed by LANA are derepressed in 
RRVΔLANA/GFP infected cells compared to RRV-GFP infected cells. Furthermore, the 
RRVΔLANA/GFP recombinant virus also fails to successfully establish latent infection 
in B lymphocytes. These unique properties prompt us to investigate the vaccine potential 
of RRVΔLANA/GFP in the future by utilization of a rhesus macaque model system. 
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Table 1: Biological characterization of the RRVΔLANA/GFP recombinant virus 
 
Table 2: Vaccination with RRVΔLANA/GFP virus and challenge with WT RRV 
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